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ABSTRACT
MICELLES AND LIPID NANOPARTICLES: CATALYSIS AND BIOMEDICAL
APPLICATION

Faisal Ibrahim
August 12, 2021

RNA-based therapeutics is a rapidly expanding field due to its enormous potential
for treatment of diseases through knockdown of genes or expression of therapeutic
proteins. However, due to the overall negative-charge of an RNA molecule, RNA-based
therapeutics must rely on delivery systems to overcome the various biological barriers for
ultimate release of an RNA payload into the cytosol. Over the past three decades, the
development of lipid-based RNA delivery systems, especially lipid nanoparticles (LNPs),
have been comprehensively studied due to their unique properties. LNPs represent the
most widely used delivery systems for RNA-based therapeutics, as evidenced by the
clinical approvals of three LNP-RNA formulations: patisiran (ONPATTRO®), and
BNT162b2 and mRNA-1273, which are LNP-encapsulated mRNA-based vaccines for
prevention of COVID-19. Cationic lipids are also considered suitable candidates for RNAi
therapeutics delivery. To this end, the present thesis work centers on examining liposome
formulations of oxime ether (OELs) containing hydroxylated head groups in animal studies
to validate their suitability as in vivo RNA carriers.
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This thesis work also examines the effects of adding a boron-containing lipid to OEL4based formulations. Conjugation chemistry, particularly oximation, is a critical component
for the development of these lipids. Oximation involves the reaction of an aminooxy group
with a carbonyl group of an aldehyde or ketone to form an oxime ether. The versatility of
oximation is highlighted and exploited in this thesis. In addition, as part of my initial
studies on micelles, the synthesis and synthetic applications of a novel, environmentally
benign surfactant developed to form micelles containing polar cores is also described.
This thesis is divided into two parts. Part I focuses on the synthesis and applications
of PS-750-M, a surfactant developed to enable organic synthesis transformations in water.
Accordingly, Chapter 1 reviews the historical development of micellar catalytic processes.
Chapter 2 details the synthesis of the surfactant PS-750-M and its application in
Suzuki-Miyaura couplings of unactivated quinoline systems. PS-750-M contains a prolinebased linker between its hydrophobic and hydrophilic regions that imparts polarity to the
micellar core, which is presumed to play a significant metal-coordinating role in the
micellar Suzuki-Miyaura coupling reactions. PS-750-M functions as a green solvent that
mimics toxic dipolar-aprotic solvents, such as DMF, DMAc, NMP, and 1, 4-dioxane. The
micellar reaction medium derived from PS-750-M is demonstrated to be recyclable.
Part II focuses on the use of hydroxylated oxime ether lipids (OELs) as delivery
agents for RNAi therapeutics. We first explore the in vivo utility of OELs. We found that
OEL4 liposomes formulated using 3 mol% DSPE-PEG350 accumulate in tumors at highest
efficiency as compared to other formulations and exhibited significant increases in tumor
to liver ratios, indicative of improved delivery selectivity. The PEGylated liposomes also
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showed a statistically significant luciferase signal reduction in tumors as compared to an
untreated mice control group.
Chapter 3 reviews the structural features of cationic lipids in siRNA/DNA therapy
and contrasts it with novel features of cationic OELs. A modified synthesis of OELs that
proceeds in 7 steps in overall 13% yield, constituting a 4-fold improvement over the
previously reported synthesis, is also presented. The formulation and results of in vitro and
in vivo transfection studies using OEL4 are presented in Chapter 4. Our studies show that
the surface modification of OEL4 was essential for tumor accumulation in mice bearing
human lung cancer xenografts. The surface-modified OEL4 formulations were developed
by inclusion of distearoylphosphatidylethanolamine (DSPE) bound to varying lengths of
poly(ethylene glycol) (PEG) polymer. The results of in vivo studies on mice bearing human
lung cancer (A549-luc2) determined the optimal OEL4 formulation for delivery of an RNA
payload to be the formulation OEL4:DOPE:DSPE-PEG350 (48.5:48.5:3). Chapter 5
discusses the synthesis of boron-containing lipids and preliminary results of boron-assisted
RNA transfection studies using both oxime ether- and boron lipid-derived formulations.
The results of in vitro transfection studies using oxime ether- and boron lipid-derived
formulations established that inclusion of the novel boronic acid-containing cationic lipid
DMDBH to an OEL4 lipoplex formulation enhances the gene silencing of capability of
OEL4 by about 20%. The action of DMDBH in this regard remains unknown; however,
nmr studies of OEL4 and DMDBH suggest dimerization of DMDBH and OEL4, which
could increase the strength of the interaction with RNA and increase lipoplex stability.
Chapter 6 presents detailed experimental procedures of the chemistry and biology
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described in Chapters 2, 3, 4 and 5. Supporting spectroscopic data of synthesized
compounds are also included in Chapter 6.
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CHAPTER 1
INTRODUCTION TO MICELLAR CATALYSIS

1.1. Background
Mostly, organic reactions conducted in the academic laboratories as well as in
industry require organic solvents as reaction media. These organic solvents play critical
role in dissolving or dispersing, especially polar and unipolar organic substrates, reagents,
and catalysts. Generally in the industrial setting, the production of complex compounds
requires large quantities of solvent during their synthesis and purification. These organic
solvents mostly generate enormous waste that are toxic and harmful to human life and the
environment. In separate publications, Shaughnessy and DeVasher1 and also Sydnes2
reported that over 80% organic waste in chemical industries is attributed to the use of
organic solvents, posing serious hazard to both human health and environment. In spite of
this, organic solvents are still being used, although todays environmental consciousness
imposes the use of water as a solvent by both industrial and academic chemists.3 Water is
safe, benign, environmentally friendly, inexpensive and economical compared with
organic solvents. However, the use organic solvent as a reaction medium is not vastly
practiced for mainly two reasons. First, most organic materials are insoluble in water and,
as a result, water does not function as reaction media. The second reason is that water can
decompose or deactivate many reactive substrates, reagents, and catalysts.
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In efforts to reduce or eliminate generation of hazardous substances, many eco-friendly
green solvents or sustainable reaction media have been developed.4 In this regard,
sustainable green technologies including the fluorous and aqueous media, supercritical
CO2, and ionic liquids have been employed in many useful transformations.5-7 Considering
the matrices of greenness for any process, Jessop and co-workers3 state that despite
fascinating properties and advantages of ionic liquids, it cannot be considered as fully green
alternatives to organic solvents. Other proposed strategies include solvent-free conditions
and mechanochemistry.8,9 Clearly, as an ubiquitous, inexpensive, economical, safe, nontoxic, and sustainable, water is certainly the most safe and green solvent with very low
environment footprints. In nature, water as a solvent has been used to carry out all kinds of
biochemical transformations regardless of the solubility of the substrates. Therefore, it is
worthwhile to mimic the natural strategy to perform chemical transformations in water. In
natural biochemical processes, the environmental factor (E factor) value is zero, which
means it is not considered a waste in chemical transformations. E factor is a numerical
measure of the amount of waste in manufacturing processes (expressed in kg waste/kg
product), introduced by Sheldon in 2007.10 In recent years, the E Factor is turning out to be
the new norm in the production line of pharmaceuticals, oil and bulk chemicals. Recently,
using water as a reaction medium, Kobayashi and co-workers showed the synthetic
potential of aqueous heterogeneous catalysis.11 Authors have demonstrated how a new
Cu(II) catalyst (see nonracemic ligand L, Scheme 1.1) leads to asymmetric conjugate
additions of the PhMe2 Si nucleophile to enones, enoates, unsaturated nitriles, and nitro
olefins obtaining 80-98% enantioselectivity of resulting products. However, product
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isolation and the amounts of organic solvent(s) required for workup and product
purification is a major drawback of this technology.
WG
+

R

PhMe2Si-BPin

cat. LCu(acac)2
H2O, rt, 24-48 h

WG = ketone, ester
NO2, CN

L=

SiPhMe2

WG

R

(ee’s typically 80-98%)

N
OH

N
HO

(insoluble!)
Scheme 1.1. Asymmetric 1,4-additions of SiPhMe2 in water at room temperature.

As decribed by Sheldon, another merit for using water as a reaction medium is that the
catalyst remains in the reactor and can be re-used,12 minimizing the amount of organic
solvent needed for catalyst separation.
The use of water as solvent in organic chemistry dates to early 80s when propene and 1butene were converted into the corresponding one carbon longer aldehydes using rhodium
catalysts modified with sulfonate-containing phosphine ligands by the Ruhrchemie–
Rhône-Poulenc hydroformylation process.13 Water through strong hydrogen bonds give
rise to the hydrophobic effect, resulting in segregation of apolar species rather than provide
single molecule solvation. Hydrophobic effect has been understood to impact the progress
of a reaction between poorly water-soluble substrates. Breslow and coworkers14 found that
the Diels–Alder cycloaddition reaction in water is faster than in organic protic and aprotic
solvents, an observation that excluded simple polarity or H-bonding effects on catalysis. In
recent years, aqueous phase reaction has become a major subject of green chemistry, as
described in some reviews on the progress of aqueous phase reactions.4,15-17 In 2005,
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Sharpless first proposed the “on-water” reaction,18 which required vigorous stirring
because the reaction was carried out on oil-water interface. In contrast, the dissolution of
the hydrophilic substrate in aqueous solution is a requirement in ‘in-water’ reactions.
However, most organic species have poor solubility in water, making it a limited process.
Inspired by nature,19 micellar catalysis was established as an attractive substitute to
dissolve lipophilic species in the aqueous system. The hydrophobic pockets formed in
water by enzymes or cell membranes serve as vessels for lipophilic species to promote
chemical reactions during the evolution of life.20-27 Analogous to enzymes or cell
membranes, surfactants also comprise hydrophilic and hydrophobic fractions. Thus it can
also self-assemble into nano-sized micelles in water. The micellar core provides an avenue
to dissolve organic species, wheras the hydrophilic portion serves as the reaction medium
surrounding the water. Enhancement of reactivity is also achieved through micellar
catalysis by accommodating the reaction components into “nanoreactor”. This allows the
chemical transformations to be executed under the mild reaction conditions.
Eleanor and Fendler first used surfactants in aqueous reactions via the formation of
micelles in the 70s, which were considered to solubilize hydrophobic substances.28 In
general, the shape and the size of these micelles are crucial for the the success of the desired
reaction. Therefore, the reaction was regulated by micellar structure. One can also tune the
self assembly of amphiphiles by modifying portions of the surfactant structure, such as the
length of the hydrophobic chain and the charge of the head group.29,30 For the effective
dissolution of catalysts and substances to participate in the reaction, the sizes of these
micelles typically range from 10 to 100 nm.
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Lipshutz and co-workers proposed the “nano-to-nano” effects when metal
nanoparticles (NPs) were used as catalysts.31 However, Paprocki, et al. demonstrated that
some reactions like the Passerini reaction can progress effortlessly in an aqueous surfactant
system without any catalysts,32 making the use of the term “micellar catalysis” in these
reactions a controversial one. Regardless of this however, the fact that micelles change the
rate of these reactions without being expended during the course of the reaction, the simple
use of catalysis is justified.26
In the past two decades, studies on micellar catalysis are gaining prominence in the
synthetic organic chemistry. It involves using water as solvent in organic reactions
including transition-metal-based cross-couplings.33 Micellar catalysis is practiced not only
because of the excellent catalytic performance, but also the practicability of various organic
processes. Examples of organic chemistry in water have been highlighted in several
reviews. A review on transition-metal-based cross-couplings by Chao-Jun Li on “metalmediated C–C bond formations in aqueous media34 is one of such relevant reviews.
Nonetheless, from the summary of earlier work and reviews by Li’s group,35 yet micellar
technology has not seen significant applications to key cross-coupling reactions, including
those catalyzed by palladium. Even though there are research materials and books on
surfactant technology,36 there is room for improved application in synthesis. The available
commercial surfactants currently used have been recognized not to be sufficient to perform
thousands of reactions; hence, substantial efforts have been made to produce specially
designed surfactants in the past five years. However, the logical choice of these surfactants
for different types of reactions still requires attention. In this account, our goal is to study
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novel catalytic systems that enables the use of water as a solvent for a wide range of
reactions of organic materials.

1.2 Structure and properties of micelles
One of the simplest methods to achieve catalysis in water is the use of surfactants under
micellar conditions since surfactants (surface active agents) are inexpensive, benign, and
easily accessible. Sorrenti,37 recently pointed out that micellar environments are not just a
soapy version of homogeneous catalysis, but micelles behave more as nanoreactors
characterized by exceptional features. Surfactants are mostly derived from petroleum
feedstock. Recently, biosurfactants, (synthesized from natural resources through yeast,
bacteria and plant transformation) where the amphiphilic molecule possesses biological
functionalities, have emerged. Examples of such surfactants (Figure 1.1) can be seen in
glycolipids, lipopeptides, phospholipids, fatty acids, and neutral lipids most of which are
anionic or neutral. The hydrophilic parts of the molecule are based on carbohydrates, amino
acids, cyclic peptides, phosphates, carboxylic acids or alcohols while the hydrophobic
portion are made up of long-chain fatty acids, hydroxy fatty acids or α-alkyl-β-hydroxy
fatty acids.
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Figure 1.1. Commonly used nonionic and ionic surfactants.38-41
The polar external surface of the aggregate is surrounded by water and their behavior and
properties are different from water molecules in the bulk. The type of aggregate formed is
determined by the following (i) the molecular structure of the amphiphile, (ii) the
proportion between hydrophilic and hydrophobic parts, (iii) the geometry of the molecule
and (iv) the experimental conditions in which they are used such as temperature, pH and
ionic strength. Concentration play critical role in the shape and nature of the aggregate
formed. Aggregates could initially form spherical micelles, but increase in concentration
can result in ellipsoidal micelles, rods, hexagonal liquid crystal phase (LC, hexagonal
arrangement of long cylinders), lamellar LC phase and, eventually, reverse phases are
possible. Microemulsions are achieved in the presence of large amounts of substrates,
usually liquids, to favor their close contact with water and the surfactant. Enhancement of
catalytic activity and selectivity has been observed under these conditions.
First generation surfactant PTS (polyoxyethanyl α-tocopheryl sebacate) (Figure 1.2),
which forms ca. 22−25 nm micelles, has shown potential for Suzuki Miyaura couplings to
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be run in nanomicelles.42,43 PTS is an unsymmetrical diester and, therefore, contains three
components: a dicarboxylic acid (Sebacic acid in this case), a lipophilic portion in vitamin
E (or α-Tocopherol), and a hydrophilic subsection based on PEG-600 (which consists of a
distribution of oxyethanyl units centered at 13 in number). PSS,44-46 (Figure 1.2) which is
very similar to PTS, has a polycyclic hydrocarbon characteristic of the cholesterol mimic,
β-Sitosterol. Nonionic surfactants include Triton® X-100,38 BRIJ® 30,39 and polysorbates,40
(e.g., TWEEN® 80). Example of anionic surfactant is sodium dodecyl sulfate (SDS;
technically a detergent),41 while cationic surfactant cetyltrimethylammonium bromide
(CTAB) is also frequently used. The use of ionic surfactants has been highlighted in
Shaughnessy’s paper on Pd-catalyzed couplings in aqueous media1 although product
isolation is noted as potentially challenging.
Sebacic
acid O

O H
n

O
A

PEG

4

O

Sebacic
acid

B

O

O

O
O

H

H

O

4

O

O H
n
PEG

H

α-Tocopherol

H
β-sitosterol

Figure 1.2. (A) Structure of the nonionic amphiphile PTS (1, n = ca. 13), (B) Structure of
the Nonionic Amphiphile PSS (1, n = ca. 13).
Micelles consist of two different regions with opposing affinity towards water. They are
amphiphiles with colloidal structures and particle diameters of between 5 to 100 nm. The
micellar core consists of hydrophobic fragments of amphiphilic molecules, whereas its
shell comprises hydrophilic fragments of micellar molecules. Micellar amphiphilic
molecules exist separately in aqueous medium at low concentrations and they aggregate if
their concentration is increased. But aggregation of micellar molecules happens only within
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a limited concentration interval called the critical micelle concentration (CMC). The
critical micelle concentration is the concentration of a monomer of micellar amphiphile at
which aggregation begins and micelles appear. The critical micellization temperature is the
temperature at which aggregates appear and below which micellar molecules exist as
monomers.
Micellar catalysis has been used in cross-coupling reactions to replace toxic aprotic organic
solvents such as DMF, DMAc, NMP, etc with even improved yields. In 2015 Lipshutz and
co-workers reported nucleophilic aromatic substitutions (SNAr) of oxygen, nitrogen and
sulfur-based nucleophiles in water, with low E-factors and under mild conditions, using a
“benign-by-design” nonionic surfactant, TPGS-750-M47,48 (Figure 1.3).
TPGS-750-M

Sebacic
acid
O
O

O
O

O

O
17

PEG-750

α-Tocopherol

Figure 1.3. Structure of TPGS-750-M.
These reactions are usually heavily dependent on dipolar-aprotic solvents such DMF,
DMAc, NMP, etc. Being one of the important reactions in organic chemistry, SNAr is used
in synthetic schemes in making some important FDA-approved molecules such as
ziprasidone,49-51

pioglitazone,52-56 levofloxacin,57,58 febuxostat,59 moxifloxacin,60-63

itraconazole,64 pazopanib,65,66 timolol,67,68 olanzapine,69,70 and rosiglitazone.71,72 However,
these reactions are primarily conducted in organic media with more than half of the cases
using toxic aprotic solvents such as DMF, DMAc, NMP, etc.73 These solvents cause serious
negative health impact on the liver, kidney, spleen, thymus, and brain and cause
developmental toxicity/fetal death such as miscarriage or stillbirth.74-76 However, as
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concluded by Orlando Acevedo and William L. Jorgensen, SNAr reactions involving ionic
nucleophiles are more favorable in aprotic-polar solvents, making the use of micellar media
somewhat redundant. The nucleophilic ions may have strong interactions with water,
impeding the reaction progress.77 Reactions with ionic nucleophiles also require elevated
reaction temperature78-80 and may involve transition metal catalysts.81
Depending on the surfactants employed, micelles can be either charged or neutral,
encompassing a wide range of size and polar properties. Usually, polar surfactants are
oligomers of ethylene oxide while the neutral ones are usually based on precisely defined
apolar portions. Micelles are believed to behave like enzymes, isolating species from the
bulk solvent. Micelles also at times improve solubilization of organic reagents in water,
favoring compartmentalization of reagents with enhancement of the local concentration
and reactivity, influencing the chemo-, regio- and stereoselectivities. Beyond these positive
features, micellar catalysis comes with some limitations. One such limitation is associated
with the amounts of substrates that can be incorporated into the micelles. Usually, high
concentration of substrates can be loaded into the micelles than in conventional organic
solvents, as a result, the higher selectivities often observed in micellar catalysis. It is worth
noting that the concentration of the substrate within the micellar core may be higher than
the overall typical concentration of substrates for catalysis in the entire micellar medium,
which is usually 10−1–10−3 M, since the solubilization of the organic reagents occurs
predominantly within micelles and not in the entire volume of the liquid phase. Typically,
the concentrations of surfactant used are much higher than the c.m.c. and micro-emulsion
conditions are present. Substrate loading under this condition can be much higher than
previously described. The main advantages of micelles is the distribution of organic species
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between bulk water and micelles depending on the charge and polarity of these species.
Apolar substrates, within the micelles, experiences a higher concentration in the
supramolecular aggregates some orders of magnitudes higher than that calculated
considering the entire volume of solution. This is a consequence of the hydrophobic effect.
Moreover, charged micelles tend to concentrate species of opposite charge on their surface.
Therefore, in cationic micelles the surface local pH is slightly more basic than in the bulk
solution, and the reverse is true for anionic micelles. Similarly, water insoluble charged
metal species can be concentrated and dissolved in micellar media due to ionic interactions
with micelles of opposite charge.
After reaction completion, extraction of products from this aqueous process possess a bit
of a challenge in the perspective of the greenness of this technology. This leads to a
biphasic product extraction and recycling of the catalyst. Although the success of catalyst
recycling is almost exclusively dependent on whether the catalyst remains enclosed in the
micellar aggregates during reaction workup. In some instances, the product is insoluble in
the reaction media, it precipitates and can easily be filtered out. This was clearly illustrated
by Handa et al.82 in a Suzuki–Miyaura cross-coupling reaction of heterocyclic partners 1
and 2 with a designer ligand, HandaPhos, by simple filtration with aqueous surfactant and
water washes, the product 3 was isolated in 93% yield.
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Figure 1.4. Catalyst and medium recycling in a micellar catalytic process. Adapted from
Handa et al.64
1.3 Conclusions
Micellar catalysis has shown some promising features, right from its inception, in terms of
both the manipulation of chemical reactions and the operational procedures. In pursuits for
sustainability in the field of organic synthesis, benign micellar catalysis has emerged as
sustainable technology to ultimately preclude noxious organic solvents, remove/lower the
harsh thermal demand, and enable ease of purification. In the ongoing effort for green and
sustainable chemistry, this work served as a stimulus for future scientific research in
finding alternatives to noxious organic solvents.
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CHAPTER 2
SUZUKI-MIYAURA COUPLINGS OF UNACTIVATED (ISO)QUINOLINES IN
WATER
2.1. Introduction
An environmentally benign proline-based surfactant PS-750-M has been developed
for general, clean, and sustainable Suzuki-Miyaura cross-couplings of 2-and 4-quinoline
and isoquinoline systems. This transformation was achieved with the use of π-allyl Pd
catalyst in aqueous nanomicelles of PS-750-M (Figure 2.2). The designer surfactant PS750-M is used exclusively without any toxic organic solvent under mild reaction
conditions. The aqueous reaction medium containing nanomicelles can be recycled and
efficiently re-used without any purification. PS-750-M was designed primarily to mimic
toxic dipolar-aprotic organic solvents such as DMF, DMAc, NMP, 1,4-dioxane. These
solvents are commonly used in catalytic organic reactions including palladium-catalyzed
Suzuki-Miyaura cross-couplings. In general, dipolar-aprotic solvents provide an ideal
environment for cross-coupling, so a successful transformation with an aqueous solution
of PS-750-M would open the avenue to explore more reactions.
2.2. Background
The micellar reaction has recently resurfaced as a worthwhile substitute to noxious organic
solvents in synthetic organic chemistry. This reemergence has recently been focused on
nonionic rather than ionic micellar media, with typical anionic(e.g., SDS) and especially
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cationic (e.g., CTAB) media receiving relatively little attention83 compared to preceding
years,84 possibly due to the greater generality which has progressively been ascribed to
nonionic systems.85 Furthermore, since nonionic surfactants do not have a polar head
group, they may be compatible with enzymes or biocatalysts, while the medium containing
ionic surfactants may result in denaturing the enzyme.83,86,87 Brij, Triton, Tween, and other
nonionic surfactants (Figure 2.1) which are usually cheap and commonly accessible, are
employed in aqueous reactions. Feng, et al. reported a radical hydroxysulfonylation
coupling reaction using oxygen as the oxidant in a nonionic micellar medium88 (Table 2.1).
O

O

H

O

ca. 4

Brij-30

Brij-35

OH
n-C8H17

O

O

xO

O H
y

O

O

O

w

O
Tween 20 (w + x + y+ z = 20)

OH
ca. 23

OH

O

ca. 20

Brij-58

O

O

H
ca. 10

OH

O

Triton X-100

ca. 20

Brij-78

Figure 2.1. Representatative of commercially available nonionic surfactants.
These authors have established that Brij L4 was the most suitable surfactant (Table 2.1,
entry 3-9) because it's cheaper, although TPGS or Tergitol has shown similar activities. In
their study, Brij L4 did not only enhance the reactivity but also the selectivity was enhanced
in micellar medium, which was ascribed to the good property to dissolve oxygen and the
distribution of raw materials. They also revealed that both surfactant and substrates
concentration were closely related to the yield (Table 2.1, entry 10-12). Satisfactory yield
could be achieved when substrates concentration increase to maximum 0.2M.
Regioselective N-alkylation reaction (Scheme 2.1) carried out successfully under a mild
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O H
z

condition in Tween 20 aqueous solution88,89 was another example. One other advantage of
nonionic micellar medium is the prospect of being compatible with a variety of additives.
This was demonstrated by Cai and coworkers in their recent work.90
Table 2.1. Optimization for olefin hydroxysulfenylationa88

SH
Surfactant/H2O
1a

Entry

a

OH
S

O2 or air

+
Cl

1a/2a

S

+

Cl

Cl

2a

3a

Surfactant/Solvent

4a

Conc.

Yield (%)b

1c

1:1

H2 O

0.5M

3a
4a
Trace 91

2c

1:1

2 wt % Brij L4/H2O

0.2M

28

52

3c

2:1

2 wt % Brij L4/H2O

0.2M

56

30

4

2:1

2 wt%Brij L23/H2O

0.2M

55

7

5

2:1

2 wt% Brij C20/H2O

0.2M

35

20

6

2:1

2 wt% Brij O20/H2O

0.2M

71

5

7

2:1

2 wt% TPGS-750M/H2O

0.2M

80

3

8

2:1

2wt%Tergitol/H2O

0.2M

78

4

9

2:1

2 wt % SDS/H2O

0.2M

Trace 70

10

2:1

2 wt % Brij L4/H2O

0.3M

57

33

11

2:1

2 wt % Brij L4/H2O

0.2M

80

5

12

2:1

2 wt % Brij L4/H2O

0.1M

77

Trace

13d

2:1

2 wt % Brij L4/H2O

0.2M

0

84

Reaction conditions: 4-chlorothiophenol (0.25 mmol), ethene-1,1-diyldibenzene (0.125 or 0.25 mmol),
O2 balloon, RT, 4h; b GC-MS yield with naphthalene as internal standard; c under air; d under argon.
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They developed a Triton X-100 assisted, visible-light photoredox catalysis arylation
reactions where Eosin B was used as the photocatalyst in the Triton X-100 aqueous solution
to facilitate the smooth progress of the reaction in an aqueous medium at room temperature
(Table 2.2).
O
NH

Br

i-Pr2NEt (2 equiv)

Br

+

Tween 20/water (2% w/w)
3 h, rt

2 equiv

O
Br

N-alkylated product
1

2

O

+

N

NH
Br
O-alkylated product

3

4

Conversion was determined by HPLC peak areas at 214 nm for 2-pyridone and the regio-isomer products in
the reaction mixture. N-/O-alkylation ratio was determined by comparing integrations of characteristic
protons for product 3 and 4 in 1H NMR spectrum of the concentrated reaction mixture.

Scheme 2.1. N-Alkylation of 2-pyridone.
Table 2.2. Photocatalytic arylation of furan in watera88-90
NH2

O
+

2 wt% surfactant/H2O
20 W CFL, rt

Cl
1a

O

photocatalyst
t-BuONO (2 equiv)
Cl

2a

3a

Entry

Photocatalyst (mol%)

Surfactant/Solvent

Yield(%)b

1

Eosin Y (1)

Triton X-100

64

2

Eosin B (1)

Triton X-100

83

3

Rose Bengal (1)

Triton X-100

55

4

Rhodamine B (1)

Triton X-100

42

5

Rhodamine 6G (1)

Triton X-100

67

6

Ru(bpy)3Cl2•6H2O (1)

Triton X-100

67

7

Eosin Y (1)

Triton X-100

65

8

Eosin B (2)

Triton X-100

83

9

None

Triton X-100

19

16

10

Eosin B (1)

Brij L23

80

11

Eosin B (1)

Tween 80

62

12

Eosin B (1)

Span 80

21

13

Eosin B (1)

CTMAB

37

14

Eosin B (1)

SDS

Trace

15

Eosin B (1)

None

34

16c

Eosin B (1)

Triton X-100

12

a

Unless otherwise noted, the reaction conditions are as follows: 1a (0.5 mmol), 2a (5 mmol), t-BuONO (1
mmol), photocatalyst (1 mol%), 2 wt% surfactant in water (2 mL), irradiation withn a white LED lamp
(20 W) at rt for 2 h. TX100 is short for Triton X-100. b Isolated yield of pure product based on 1a. c The
experiment was carried out in the dark.

In recent years, Suzuki-Miyaura cross-coupling reactions in non-ionic micellar media have
taken a central stage in both academia and industry. Cross-coupling of Heteroaryls has
been the most recent target. Probably because heteroaryl rings are important structural
motifs mostly found in physiologically active compounds, such as natural products, drug
candidates, and clinically used drugs.91-98 These fragments are also versatile building
blocks for the production of various ligands99 in a range of transition-metal catalyzed
reactions such as cross-coupling reactions, C-H activation, asymmetric conjugate addition,
and asymmetric hydroboration. However, Suzuki-Miyaura cross-coupling reactions of
heteroaryl substrates, especially boronate esters, are particularly challenging because the
boronate esters may undergo proto-deborylation under standard Suzuki coupling
conditions and result in moderate yields.100-106 In this regard, the Suzuki-Miyaura crosscoupling chemistry of quinoline and isoquinoline systems in a nonionic micellar medium
of PS-750-M is a challenge worth undertaking. Sustainable cross-couplings of quinoline
and isoquinoline systems are under-developed.107-109 These fragments are highly valuable
in pharmaceuticals with antibacterial, antifungal, anticancer, antiviral, and anti17

inflammatory activities.110-115 In the design of a new surfactant to address the challenges of
performing various organic reactions in the micellar medium under mild conditions,
specific features must be incorporated to focus on specific issues. Reference is made to the
biological cell membrane. The biological cell membrane has a thin polar membrane made
of two layers of lipid molecules having a hydrophilic phosphate head and a hydrophobic
tail, which form the cell membranes of almost all organisms and viruses. The surface
chemistry of these membranes can be altered by specific head groups and tails in these
biological systems of cells. Like the biological cell membrane, micelles can be designed to
have a specific amphiphile structure to address catalytic activity under mild reaction
conditions. Some of the great success stories of developing new micelles for catalytic
organic reactions in aqueous solutions have recently been reported.106-119 The catalyst-free
synthesis of α-acyloxycarboxamides reported by Ostaszewski and coworkers was an
apparent example, where the reagents were able to self-assemble into micelles.120 Caprylic
acid was used as the carboxylic source in this micelle-promoted reaction, which could selfassemble into micelles. The subtract scope of this technology was however limited, due to
the inability of most reagents to self-assemble into micelles. The proline-based surfactant
PS-750-M was designed to form micelles with polar interior with different binding sites
such as (i) the inner lipophilic region (ii) the proline linker, and (iii) the mPEG region.
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Figure 2.2. Structure of a proline-based surfactant PS-750-M.
The proximity and conformation of carbonyl groups of PS-750-M may promote surfactant–
substrate interactions during the dynamic exchange process typical of micelles. PS-750-M
is a nonionic surfactant derived from affordable and benign feedstocks like proline, lauric
acid, and mPEG. On a detailed assessment of the PS-750-M structure, a DMAc-like amidic
moiety is revealed which is in direct vicinity to the hydrocarbon chain. It is expected that
hydrocarbon chain hydrophobicity would strongly favor the described amide rotamer
within the micellar aggregates because the other rotamer would require that the
hydrocarbon chain be positioned outside the inner micellar core with higher polarity.
Similarly, the hydrophilic chain may also have some influence on the orientation of the
ester carbonyl in micellar assemblies. As part of the designed strategy, the proline ring
prevents rotation about its C–N bond and consequently holds the two polar carbonyl groups
nearby.
2.3. Synthesis of PS-750-M
PS-750-M was synthesized from readily available chemicals. L-proline (5.0 g, 43.4
mmol) was dissolved in methanol (60 mL). The mixture was stirred at 0 oC and thionyl
chloride (3.8 mL, 53.1 mmol) added. The reaction mixture was allowed to warm to room
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temperature and stirred for 12 h. Subsequently, the amide was accomplished with lauryl
chloride (13.7 mL, 59 mmol) and Et3N (15.2 mL, 118 mmol) in dichloromethane (100 mL).
Hydrolysis of the ester was achieved with LiOH.H2O (5.2 g, 123 mmol) and 2N HCl (100
mL) before reacting with the mPEG-750 (40.5 g, 54 mmol) in toluene (100 mL) with
catalytic TsOH (40 mg, 0.23 mmol) to yield the desired product at 82 %. The final product
was analyzed using MALDI-TOF which showed a characteristic mass of 1060.3683.
a

b

CO2H

N
H
L-Proline

N
H

HCl
95 % (6.5 g)

O
N

CO2Me

N

CO2Me
O

10

78 % (9.6 g)

Me
O n

c

d

O
O

N

(n = ca. 16)

O

CO2H
10

88 % (8.0 g)

PS-750-M 82 % (23.5 g)

Conditions:
a. L-proline (5.0 g, 43.4 mmol), SOCl2 (3.8 mL, 52.1 mmol), MeOH (60 mL), 0 oC – rt, 12 h
b. lauryl chloride (13.7 mL, 59 mmol), Et3N (15.2 mL, 118 mmol), CH2Cl2 (100 mL), 0 oC – rt, 12 h
c. (i). LiOH×H2O (5.2 g, 123 mmol) EtOH (25 mL)/H2O (25 mL), 10 h (ii). 2 N HCl (100 mL)
d. p-toluenesulfonic acid (40 mg), mPEG-750 (40.5 g, 54 mmol), toluene (100 mL), reflux, 14 h

Scheme 2.2. Synthesis of PS-750-M.
Modification of the hydrophobic head for the reaction is a critical strategy when using
mPEG-750 as the hydrophilic head in the synthesis of surfactant. To improve the ability
of the micelles to accommodate organic components the structure of PS-750-M was
designed to reflect that of a polar solvent, DMF, in the hydrophobic domain. First, PS-750M was found to be effective for SM couplings of polar (iso)quinolines fragments using πallyl Pd catalyst. PS-750-M was also employed in a variety of transformations, such as
sulfonylation of polyfluoroarenes,120,121 coupling of nitroalkanes with aryl bromides
20

catalyzed by Pd under mild condition,122 selective oxyhalogenation of alkynes,123 selective
monofluorination

of

indoles,124

Buchwald-Hartwig

amination,125

selective

Cbz

deprotection,126 carbene migratory insertions,127 functionalization of styrenes,128 and fast
amide couplings.129 It is worth stating that, PS-750-M has been commercialized by SigmaAldrich as evidently shown in Figure 2.3A and used by pharmaceutical industry. The
related work on Suzuki-Miyaura cross couplings in micelles of FI-750-M (PS-750-M) was
also featured on a front cover of ChemCatChem (Figure 2.3B).
A

B

Figure 2.3. PS-750-M as: (A) commercial product (B) front cover article.
Figure A was directly taken from Sigma-Aldrich website.
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2.4. Reaction optimization
To obtain the optimum reaction conditions for Suzuki couplings of (iso)quinoline
systems, rigorous optimization studies were performed. Variables like the nature of the
base, amphiphile, and catalyst were all studied. The necessity of these variables on the
catalytic transformation was revealed in the optimization studies. Based on our previous
transformation using the PS-750-M/water micellar system we developed,113-115 we began
our study with catalyst screening for a model reaction between 1 and 2 (Table 2.3) using
K3PO4 as a base in a 3 wt% aqueous solution of PS-750-M and examining various π-allyl
Pd precatalysts. π-allyl Pd complexes 4–7, 10 and 12 displayed moderate to good catalytic
activity (Table 2.3, entries 1-4, 7 and 9). Catalyst 8 and 11, however show little or no
activity (Table 2.3, entry 5 and 8). Even though, catalytic activity of π-allyl palladium
complexes 5, 7 and 10 with the model reaction, were found relatively effective (Table 2.3,
entries 2, 4 and 7), catalyst 9 (Table 2.3, entry 6) was however favored in terms of atomic
mass and cost of catalyst, despite the suspected instability of the PCy3 ligand in water. To
contextualize the transformation, background reactions with just Pd(OAc)2 and also with
i-PrNEt2 and Et3N show inhibition of the reaction (Table 2.3, entries 10–12). This was

indicative of the ligand-like behavior of 4-bromoquinoline.
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Table 2.3. Optimizations of micelle-assisted catalytic cross-coupling of 4bromoquinolinea
Br

B(OH)2
+

2.0 equiv. base
1 mL 3 wt% aq. PS-750-M
45 oC, Ar

N
1

3 mol % catalyst

2

N
3

Entry

Catalyst

Base

Yield (%)*

1
2
3
4
5
6
7
8
9
10
11
12

4
5
6
7
8
9
10
11
12
Pd(OAc)2
9
9

K3PO4•H2O
K3PO4•H2O
K3PO4•H2O
K3PO4•H2O
K3PO4•H2O
K3PO4•H2O
K3PO4•H2O
K3PO4•H2O
K3PO4•H2O
K3PO4•H2O
i-PrNEt2
NEt3

82 (87)#
90 (94)#
54 (56)#
91(93)#
Traces
100
94
13
84
38 (46)#
10
15

a

Conditions: 1 (52 mg, 0.25 mmol), 2 (52 mg, 0.3 mmol), [Pd] catalyst (3 mol%), base (0.5 mmol),
1.0 mL 3 wt% PS-750-M, 45 oC, argon atmosphere. *Yields based on GCMS using mesitylene as
internal standard. #Yields from second run of experiment. For details, see detailed optimization
results in chapter 6.

Although Pd(OAc)2 showed slight reactivity, this was not general as no conversion was
detected when isoquinoline was subjected to the system. Having established the ligand-like
behavior of 4-bromoquinoline, we turned our attention to the role of surfactant on the
catalytic reaction. Reactions with neat water and other surfactants were conducted (Table
2.4). To determine the role surfactant play in this catalytic reaction, we began by
subjecting reaction of 2-bromoquinoline 39 with 4-trifluoromethylphenyboronic acid 37 in
neat water (Table 2.4). The reaction only yielded 19% of the expected product 16 (Table
2.4, entry 1).
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Table 2.4. Role of surfactant
B(OH)2

9 3 mol %

+

N
39

N

2.0 equiv. K3PO4•H2O
3 wt% aq. surfactant
45 oC, Ar

F3C

Br

37

16

Entry

3 wt % aq. Surfactant in H2O

16 (%)‡

1
2
3
4
5

neat water*
PS-750-M
TPGS-750-M
NOK
SDS

19
88
75
67
45

CF3

Conditions: 2-bromoquinoline (0.25 mmol), 4-trifluoromethylphenyboronic acid, (0.3
mmol), 9 (3 mol %), K3PO4 (0.5 mmol), 1.0 mL 3 wt % aq. surfactant, 45 °C, argon
atmosphere. ‡Isolated yield. *water was degassed with argon prior to use. Note. Similar
trend was observed when naphthyl-2-boronic acid was used.

Screening of surfactants using different surfactants like TPGS-750-M, NOK, and SDS
were also (Figure 2.4) identified PS-750-M (3 wt %) as the preferred amphiphile in water
(Table 2.4, entry 2). TPGS-750-M and NOK however, show relatively moderate activity
(Table 2.4, entry 3 and 4) with SDS being the least effective surfactant (Table 2.4, entry
5).

MPEG
n~13

MeO

O
O

O
n

H

O
succinic acid

Me
NOK

H

b-sitosterol

n-C8H17

H
Me
Me

H

OSO3 Na

Me
SDS
Me

Me
Sebacic
acid
O

O

O
O

O

O
17

PEG-750

α-Tocopherol
TPGS-750-M

Figure 2.4. Surfactants investigated in this study.
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There are some similarities between TPGS-750-M and PS-750-M. The mPEG regions in
both surfactants are identical while the succinate linker in TPGS-750-M is similar to the
proline linker of PS-750-M. The succinate linker in TPGS-750-M has two carbonyls that
are two atoms apart from each other and less restricted compared to those found on the
proline ring of PS-750-M. Finally, the optimal reaction condition was for the catalytic
activity were 1 mL of 3 wt.% PS-750-M as a surfactant, K3PO4·H2O as a base, 2–3 mol%
of catalyst 9 (Figure 2.6), and 45 oC as reaction temperature. Although lower catalyst
loading (1 mol%) resulted in complete conversion, a longer reaction time was required.

Cy Cy
OMe
P
Pd
i-Pr
OMe
i-Pr

Me

Me

Me

Cy
Cy
Cl
P
Pd
Oi-Pr

OTf

4
BrettPhosPd(crotyl)OTf

i-Pr

i-PrO

i-Pr

OMe
i-Pr

8

Cy
Cy
Cl
P
Pd
OMe

OTf

i-Pr

MeO

5

6

7

RuPhosPd(crotyl)Cl

t-BuXPhosPd(allyl)OTf

SPhosPd(crotyl)Cl

Me

Me
t-Bu t-Bu
OMe
P
Pd
i-Pr

Me

t-Bu t-Bu
P
Pd

Me
OTf
Cl

Pd

Cy Cy
P
Pd
i-Pr

Me
O

Cy P
Cy Cy
i-Pr

t-BuBrettPhosPd(allyl)OTf

PPh2

Cl
Pd
t-Bu P
t-Bu t-Bu

i-Pr

9
Cy3PPd(crotyl)Cl

Pd

Me
i-Pr

Me

PPh2 Cl

10
XPhosPd(crotyl)Cl

11
XantPhosPd(crotyl)Cl

12
(t-Bu)3PPd(crotyl)Cl

Figure 2.5. Catalysts used in the study.
Substrate scope was then explored, after obtaining optimal reaction conditions, to establish
the generality of the reaction protocol. Substrate scope exploration started with 2- and 4quinoline fragments. Reaction reproducibility in terms of yield and reaction completion
time was accessed while varying the attached functional group and steric and electronic
parameters (Table 2.5). Chloroquinolines displayed low reactivity compared to the
corresponding bromides and triflates. Compared to quinolinyl bromide, iodide, and triflate,
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poor conversions were observed with quinolinyl tosylate. Remarkable generality was
found concerning the nature of quinolines and boron nucleophiles. Both 2- and 4bromoquinolines were reactive under established reaction protocol. No homocoupling of
either quinolines or aryl (heteroaryl) boronic acids was detected.
Table 2.5. Substrate scope for catalytic couplings of 2- and 4-bromoquinolinesa
[B]

X

9 3 mol %

+

2.0 equiv. K3PO4 H2O
1 mL 3 wt% aq. PS-750-M
45 oC, Ar

[B] = B(OH)2,
Bpin, BF3K, MIDA

X = Br, I OTf

CF3

Cl

F

N

N
14

N

3

13

X = Br, [B] = B(OH)2, 78%
X = Br, [B] = B(MIDA), 79%
X = OTf, [B] = B(OH)2, 80%

X = Br
[B] = B(OH)2, 73%

N

15

X = Br
[B] = B(OH)2, 68%

X = Br
[B] = B(OH)2, 84%
F

OMe
N

N

N

16

17

CF3

X = Br, [B] = B(OH)2, 88%
X = Br, [B] = B(MIDA), 88%
90%
X = Br, [B] = BF3K,

N

O

18

X = Br, I
[B] = B(OH)2, 68%

19
X = Br
[B] = B(OH)2, 86%
[B] = B(MIDA), 84%

X = Br, I
[B] = B(OH)2, 72%

F
N

N

20
C(O)Me
X = Br
[B] = B(OH)2, 77%

CF3

N

24

21

O

N

N

X = Br
[B] = B(OH)2,

O
84%

X = Br
[B] = B(MIDA), 85%*

MeO

O

N

26

27

X = Br, [B] = B(MIDA), 51%
X = Br, [B] = Bpin,
60%

X = Br
[B] = B(MIDA), 55%

MeO

OMe

N

29
X = Br
[B] = B(MIDA), 51%

X = Br, I
[B] = B(OH)2, 88%

S

N

N

N

N
N O

23

NO2

X = Br
[B] = B(OH)2, 93%

X = Br
[B] = B(OH)2, 72%

CF3

N

22

Cl

25

CF3
X = Br, [B] = B(OH)2, 82%
X = Br, [B] = B(MIDA), 81%
85%
X = Br, [B] = BF3K,

28

N

30

F

X = Br, [B] = B(MIDA), 63%
X = Br, [B] = Bpin,
65%

a

31

N

X = Br, [B] = B(MIDA), 75%*
X = Br, [B] = Bpin,
76%*

Conditions: Bromoquinoline (0.25 mmol), aryl (hetero) aryl-[B] (0.3 mmol), 9 (3 mol%),
K3PO4•H2O (0.5 mmol), 0.5–1.0 mL 3 wt% PS-750-M, 45 oC, argon atmosphere, 24–72 h. Unless
otherwise noted, yields are isolated. *Reaction temperature 65 oC.
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Both electron-deficient (13, 14, 16, 19, 20, 22-24, 30) and electron-rich (17, 18, 25, 27, 28,
31) substrates were all well tolerated under the catalytic condition, yielding a good-toexcellent coupling products. Quite refreshingly, the chloro functional group (15, 21) was
unaffected under reaction conditions, and no side reaction was observed. Acetyl (20) and
nitro (22) functional groups were all successfully employed under the standard condition
without difficulty, and no adverse effect on the catalytic process was observed. No aldoltype side-products were noticed when the acetyl functional group was employed under the
prevailing conditions. Heteroaromatic nucleophiles such as furan (18), thiophene (26),
benzofuran (27), and pyridine (29) demonstrated good reactivity. Remarkably, no
polythiophene side product was observed. A highly electron-rich coupling partner with
notable steric congestion (31) was also feasible with good reactivity. Other quinoline and
isoquinoline systems, outside the 2- and 4-quinolinyl systems, were compatible with the
established catalytic system. These systems were well tolerated with our method, and 32–
35 were obtained in good-to-excellent yield even at such a low scale (Table 2.6).
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Table 2.6. Catalytic reactivity with other quinoline and isoquinoline typesa
B(OH)2

Br

9 (3 mol %)

+

2.0 equiv. K3PO4 H2O
1 mL 3 wt% aq. PS-750-M
45 oC, Ar

CF3

CF3

F
N

N
N

N

NH2
32 83%

33 73%

35 84%#

34 78%

a

Conditions: Bromoquinoline (0.25 mmol), arylboronic acid (0.3 mmol), 9 (3 mol%), K3PO4·H2O
(0.5 mmol), 0.5–1.0 mL 3 wt% PS-750-M, 45 oC, argon atmosphere, 24–72 h.Unless otherwise
noted, yields
are isolated. #Aryl MIDA boronate ester was used instead of aryl boronic acid.

Table 2.7. Polarity switch and reactivitya–couplings of aryl bromide with
quinlineyl boronic acid/MIDA boronate ester
B(OH)2

Br

9 (3 mol %)

+

2.0 equiv. K3PO4 H2O
1 mL 3 wt% aq. PS-750-M
45 oC, Ar

Cl

CF3

N
N
15
[B] = B(OH)2, 75%

F
30
[B] = B(MIDA), 78%

N
33
[B] = B(OH)2, 88%

a

Conditions: Bromoquinoline (0.25 mmol), arylboronic acid (0.3 mmol), 9 (3 mol%), K3PO4·H2O
(0.5 mmol), 0.5–1.0 mL 3 wt% PS-750-M, 45 oC, argon atmosphere, 24–48 h. Unless otherwise
noted, yields are isolated.

The catalysis is greatly influenced by the nanomicelles of PS-750-M. A dynamic light
scattering (DLS) experiment disclosed the presence of micelles with ca. 107 nm average
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diameter (Scheme 2.3-a). The particle size significantly increased upon the addition of 2bromoquinoline (0.01 M) to the surfactant solution, which indicates that the micelles can
accommodate substrate (Scheme 2.3-b). Furthermore, to understand the long-term stability
of π-allyl Pd catalyst 9 in our micellar system, 9 was dissolved in a 3 wt% aqueous solution
of PS-750-M and kept at room temperature for 7 days. No difference in the catalytic activity
was observed in a direct comparison between fresh or aged catalysts. Conventionally, Pd
catalyst decomposition generates Pd black. However, no Pd black was observed. Further
analysis of the aged sample by cryo-TEM did not also reveal the presence of any Pd
nanoparticle or Pd black, instead, nano-micelles of PS-750-M were detected, indicative of
the high stability of 9 in PS-750-M (Scheme 2.3-c). Next, NMR spectroscopy (31P NMR)
analysis of 9, extracted from an aged aqueous solution of PS-750-M and also freshly
prepared catalyst solutions afforded identical results (Scheme 2.3-d). Therefore, this
catalyst is bench stable in PS-750-M solution and could be used as a nanomicellar catalytic
reagent cross-couplings, especially for (iso)quinoline systems.

Scheme 2.3a,b. DLS data of 3 wt % PS-750-M; c) cryo-TEM of solution of 9 (aged, 7
days) in PS-750-M; d) 31P NMR of 9 to reveal stability and substrate binding.
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About the observed partial catalysis with Pd(OAc)2 (Table 2.3, entry 10), and the
inhibition of the reaction by triethylamine (Table 2.3, entry 12), we conducted control
experiments to comprehend the nature of the catalysis.
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P NMR suggested that the

nitrogen of 4-bromoquinoline reversibly binds with the catalyst 9 and blocks the catalytic
site (Scheme 2.2-d). To circumvent this, mild heating was required for the transformations.
In the absence of the nitrogen atom, the catalytic transformation proceeded efficiently both
at room temperature and 45 oC, i. e., the reaction of 2-bromonaphthalenes (36) with aryl
boronic acid (37) to obtain 38 (Scheme 2.3). The same reaction was hindered with the
addition of 1.0 equivalent of quinoline, and the conversion was slowed even at 45 oC along
with homocoupling of boronic acid. Similarly, the introduction of triethylamine in the same
reaction slowed the catalysis indicating that non-nitrogenous base and mild heating are
prerequisites to achieving effective catalysis.

2.5. Gram-scale and medium recyclability
Next, the gram-scale reproducibility of the protocol and recyclability of the micellar
medium were also explored. First, in a reaction between 37 and 39, using 1.5 mol% catalyst
loading, 16 was obtained with 94% isolated yield (Scheme 2.4). Remarkably, compound
16 was obtained by just simple filtration without any extra purification, which allowed the
recovery of amphiphile and catalyst. The product was then washed with water and dryed
under reduced pressure. No residual surfactant was also detected in 16 after a simple water
wash.
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(when X = N)
13 40%
Pd(OAc)2 3 mol %
Cu(OAc)2 20 mol %
(as additive)
conditions

B(OH)2

Br
38 45%*

9 3 mol %

9 (3 mol %)

+

1.0 equiv quinoline
(as additive)
condition

X

CF3

1 X=N
36 X = H

Condition: 1 or 36 (0.25 mmol),
K3PO4 H2O (0.5 mmol),
1 mL 3 wt% aq. PS-750-M, 45 oC,
argon atmosphere, 24 h. *11%
homocoupling of boronic acid

CF3

no additive
conditions
37

38 97%
(when X = H)

9 3 mol %
Et3N (2.0 equiv)
condition
(no K3PO4 H2O)
38 54%
(when X = H)

37 (1.09 g, 5.76 mmol)

N

Br

conditions

39
(1.0 g, 4.8 mmol)

N
16 94%
(1.22 g)

CF3

Conditions: K3PO4×H2O (2.22g, 9.6mmol), 9 (35mg, 0.072mmol, 1.5mol %), 3wt % aq. PS-750-M,
argon, 48 h.

Scheme 2.4. Control experiments and gram-scale reaction.
Attempts at full recycling of the catalyst on small scale (Scheme 2.5), resulted in slow
conversions. However, a recycling study with partial palladium and full reaction medium
resulted in a very low E factor of 5.91301 with the recovery of solvent used in
chromatography, a clear demonstration of the greenness of the protocol. Reaction cycles,
from zeroth to the fourth cycle were all conducted at 0.25 mmol scale and 24 h reaction.
The reactions were conducted according to the standard protocol. The completion of the
reaction was monitored by TLC and GCMS as complete consumption of the starting
material.
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16 89%
N

Br

39

16 88%
9 (1.25 mol %)

conditions

+

K3PO4 H2O (1.2 equiv)
B(OH)2

first recycle

F3C
37

9 (1.25 mol %)
K3PO4 H2O
(1.2 equiv)

E Factor = 5.9
16 88%

16 86%
9 (1.25 mol%)

9 (1.25 mol%)

fourth recycle

K3PO4 H2O
(1.2 equiv)

16 85%

third recycle

K3PO4 H2O
(1.2 equiv)

second recycle

Conditions: 39 (52 mg, 0.25 mmol), 37 (57 mg, 0.3 mmol), 9 (3.6 mg, 3.0 mol %, 0.0075 mmol),
K3PO4·H2O (115 mg, 0.5 mmol), 1.0 mL 3 wt% PS-750-M, 45 oC, argon, 24 h

Scheme 2.5. Measure of greenness by E factor and recycle study.

2.6. Conclusions
In conclusion, the design strategy of PS-750-M to mimic hazardous amidic and ethereal
solvents like DMF has been successfully demonstrated. The development of a stable,
environmentally benign, and recyclable catalytic system of PS-750-M and p-allyl Pd
catalyst enables couplings of challenging quinoline and isoquinoline systems using
recyclable π-allyl Pd catalyst. The robustness of the stability of the reaction medium was
also established with sustained recycling for at least four reaction cycles. A wide scope of
(iso)quinoline systems was also verified, with the process being readily practical to gramscale. Largely, this technology offers a method that is noteworthy for (1) low catalyst
loading; (2) general applicability to a broad range of quinolines and isoquinolines; (3) very
mild conditions; and (4) use of a benign aqueous reaction medium that avoids organic
solvents, requires very little water and allows in-flask recycling of the surfactant, water,
and catalyst.
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PART II
OXIME ETHER LIPIDS FOR IN VIVO RNA DELIVERY

This part of my thesis focuses on the development of novel boron-containing lipids
to facilitate RNA transfection using cationic oxime ether lipids (OELs). The in vivo utility
of hydroxylated oxime ether lipids and modifications in formulation of one analog, OEL4,
to improve tumor accumulation in mice bearing human lung cancer xenographs are
presented in the ensuing chapters.

Details of OEL preparation, characterization,

formulation, and transfection activities under various conditions is discussed. Specifically,
Chapter 3 presents an overview of the structural features associated with cationic
transfection lipids to contrast the novel features of cationic OELs. A discussion on a new
synthesis of OELs is also detailed. Chapter 4 presents the formulation details and results
of in vitro and in vivo transfection studies using OEL4. Chapter 5 discusses the synthesis
of boron-containing lipids and the results of transfection studies using formulations derived
from both oxime ether and boron lipids. Chapter 6 presents detailed experimental
procedures of the chemistry and biology described in Chapters 2, 3, 4 and 5. NMR spectra
as well as other spectroscopic data of synthesized compounds are included in Chapter 6.
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CHAPTER 3
CATIONIC LIPID NANOPARTICLES IN NANOMEDICINE

3.1. Introduction
Cationic lipids are becoming increasingly relevant to the field of RNA-interference
(RNAi),131-135 particularly their use in delivery of RNAi to cells. RNAi is gaining a lot of
attention for application in medicine, pharmaceutical sciences, and biotechnology due to
its potential for managing diverse gene-related medical conditions including cancer,
autoimmune diseases, neuropathological conditions, and viral infections.136-140 Apart from
regulating gene expression, small, non-coding RNA molecules can mediate the RNAi
effect in various ways, most markedly by inducing native mRNA degradation in the
cytoplasm as a part of the RNA-induced silencing complex (RISC), which subsequently
turns down the expression of the encoded protein.141 Since the report of the RNAi effect in
1998,142 scientists have been extremely focused on the application potential of RNAi,
bearing in mind the possibility of silencing the expression of almost any gene in an
expeditious, potent, and specific fashion. siRNAs have been extensively studied for
biomedical applications as they are highly adaptable and, along with miRNAs, have
recently become standard experimental tools to validate gene functions.141 The outlook for
therapeutic uses of RNAi agents is even more fascinating.136-140 The potential of RNAi
therapy is being reinforced by extensive in vitro and in vivo data.143 But for the challenges
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that continue to derail the reliable and safe delivery of small interfering RNAs (siRNAs)
to the site of disease, RNAi would be a practical mechanism to manage diseases.144 One
critical challenge of RNAi therapy is achieving efficient and targeted RNA delivery. To
this end, systemic delivery of RNA drugs into cells is difficult due apparently to their high
molecular weights (e.g., 13-14 kDa for a typical siRNA molecule) and poly-anionic nature.
Furthermore, because RNA is easily degraded, naked RNA molecules are short-lived after
being systemically administered.137,143 There is also the critical issue of target specificity,
which may increase the risk of triggering immunogenic responses by RNA drugs.145,146 The
2019-2020 global health pandemic caused by the coronavirus SARS-CoV2, the virus
responsible for COVID-19, has placed a sharp focus on the relevance of RNAi and on
methods for delivery of RNA into cells.

Theoretically, RNAi therapy appears

straightforward, but it is difficult to achieve practically. Fundamentally, the major hurdle
in implementing RNAi therapy is achieving efficient, safe, and targeted delivery with no
or minimal immune response.147 For systemic delivery, a delivery system is required to
overcome some of the difficulties enumerated above. Nonviral vectors (e.g., cationic lipids)
have been more generally used in siRNA delivery than viral ones because viral carriers are
associated with a higher risk of triggering lethal immunogenic responses.148 Amongst all
delivery systems, lipid-based formulations such as cationic liposomes are currently the
most commonly used siRNA delivery system. Cationic liposomes can efficiently deliver
siRNA to, for example, the lung by intravenous injection of cationic liposome–siRNA
complexes, often termed lipoplexes. This is because electrostatic interactions between the
positively charged lipoplexes and negatively charged erythrocytes cause agglutination149
and the agglutinates contribute to high entrapment of the lipoplexes in the highly extended

35

lung capillaries.150 Nanocarriers made of lipids and/or phospholipids have been the focal
point in solving the RNA delivery challenge because of their various favorable properties,
such as good biocompatibility, biodegradability, and liposome track record in biomedical
uses. The cell membrane consists mainly of lipids and phospholipids and therefore lipidbased nanocarriers have a natural predisposition to interact well with cell membranes to
facilitate cellular uptake of RNA.151
A desirable RNA delivery carrier should be capable of the following properties:152
1. encapsulate RNA into a particle with a size small enough to enter cells;
2. protect RNA from degradation;
3. maintain the integrity and stability of RNA after its in vivo administration;
4. possess some functional moieties that facilitate escape of RNA lipoplexes from
endosomes into the cytoplasm;
5. release RNA into the cell in its active form; and
6. possess a targeting moiety to direct the delivery of RNA to a particular type of cell
for transfection and/or nuclear localization.
The importance of cationic lipids in RNA therapy cannot be overemphasized.
Cationic lipids are capable of binding with RNA by means of electrostatic interaction. The
resultant complexes serve as ‘trojan horses’ that sneak the nucleic acid into cells. Over
several decades, many cationic lipids have been synthesized and shown to be active in
transfecting cells in vitro, and some of them have performed well in vivo. These include
glycerol based cationic lipids, 153-158 carnitine based cationic lipids,159 cholesterol-based
polyamines,160-162 and lipopolyamines.163-165
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3.2. Lipid-based nanocarriers as delivery vectors
In the late 1980s, Felgner et al. published the first cationic lipid-based gene delivery
system (the lipid-mediated delivery was initially termed lipofection).153 The synthetic
cationic

lipid,

N-[1-(2,3-

dioleyloxy)propyl-N,N,N-trimethylammonium

chloride

(DOTMA) (Figure 3.1), has in the past several decades become the most studied and
popular of all nonviral gene delivery lipids. Felgner and co-workers reported that DOTMA,
with or without neutral lipids, could form liposomes under physiological conditions.153 The
cationic liposome vesicles were shown to interact spontaneously with anionic DNA to form
lipid–DNA complexes (i.e., lipoplexes). Further research in the early 1990s revealed that
these cationic liposomes interact with DNA through charge interactions with extensive
lipid rearrangement during complex formation. The resulting lipoplexes are substantially
different from starting liposomes.166,167
Cationic lipid–mediated gene transfer is aimed at delivering DNA to a desired cell
to be transcribed and translated into a desired protein/peptide. The process involves (1)
formation of a multivalent surface-charged liposome from the cationic lipid, (2) interaction
of the charged liposome with the negatively-charged phosphate backbone of the DNA via
electrostatic interactions, (3) formation of the lipoplex complex, (4) internalization of the
lipoplex through a vesicular pathway, mainly endocytosis, (5) disruption of the endosomal
membrane by lipoplex components, (6) endosomal escape of DNA from the lipoplex into
the cell cytoplasm, or (7) diffusion of endosomal phospholipids into the lipoplex for
interaction with the cationic lipids, causing the DNA to dissociate into the cytoplasm, (8)
nuclear entry of some of the DNA, and (9) transcription and translation to protein. The
intracellular delivery of plasmid DNA was found to be effective using lipoplexes.
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Lipoplexes are effective in binding to cells in vitro, but lack specific elements, such as
surface proteins for targeting or cell entry, that can complicate in vivo applications.168
Selective targeting of plasmid DNA to a particular tissue or organ is, however, possible as
the cationic lipids can be covalently fitted with peptides, proteins, glycoproteins, or
glycosylated lipids. Functionally effective lipoplex formulations are generally observed to
be minimally toxic in vitro.
The major hurdle in development of lipoplexes for in vivo gene delivery is the low
transfection associated with their use. Inefficient cellular responses are assumed to be
caused by intracellular degradation and/or problems associated with endosomal escape of
internalized lipoplexes.169,170 To circumvent these drawbacks, many new cationic lipids
were designed and tested. Simoes et al. demonstrated that “helper” lipids (usually neutral
in charge), such as dioleoylphosphatidylethanolamine (DOPE), cholesterol (Chol),
dioleoylphosphatidylcholine (DOPC),171,172 or pH-sensitive liposomes assisted with
endosomal release.173 Improving endosomal release of DNA can significantly improve
transgene expression.
Conventionally, cationic lipids consist of three fragments: a polar head region, a
hydrophobic region, and a linker region that joins the polar head to the hydrophobic tail
(Figure 3.1). The polar head interacts with the negatively charged nucleotide while the
hydrophobic region helps form a lipid bilayer that self-assembles into liposomal
architectures. Cationic lipids can be classified into four different categories base on the
structure of the polar heads: (1) quaternary ammonium salt lipids, (2) lipoamines, (3)
cationic lipids containing both quaternary ammonium salt and lipoamines, and (4)
amidinium salt lipids and miscellaneous cationic entities.
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DOTMA

N

O
O
linker domain
hydrophilic headgroup

hydrophobic domain

Figure 3.1. Representative cationic lipid (DOTMA) illustrating the structural
components: hydrophilic headgroup, linker domain, and hydrophobic domain.
3.3. Role of lipid head group modification on transfection efficiency
This section focuses on the evolutions in the headgroups of cationic lipids and how
they influence transfection efficiencies. So far, cationic lipids as non-viral delivery agents
have become a major research tool for transferring exogenous genetic material into host
cells. Several new cationic lipids have been synthesized since the seminal work by Felgner
and co-workers in 1987. These ‘second generation’ cationic lipids are currently the most
extensively used non-viral delivery agents.174-182 They contain linkers that range from the
highly stable ether linkages used in DOTMA to more degradable carbamate linkages, such
as found in DC-Chol (3β-[N-(N′,N′ dimethylaminoethane) carbamoyl]-cholesterol
hydrochloride).160,183 Differences in the hydrophobic regions, such as the use of more rigid
steroid hydrophobic domains (e.g. DC-Chol), also were studied.

160,183

However, the

greatest influence on transfection activity was achieved by alterations to the polar
headgroup region.

Hydrophilic headgroups generally possess a positive charge that

promotes the interaction between the lipid construct with negatively charged nucleic acids
through electrostatic attractions leading to the formation of complexes.
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3.3.1. Quaternary ammonium headgroup
Several cationic lipids with quaternary ammonium headgroups (such as DOTAP,
DDAB, CTAB) have subsequently been reported and found to be active in a different cell
lines (Figure 3.2).153,184-186 These positively charged groups are mainly quaternary
ammonium salts linked to a lipid moiety that are involved in sustaining a self-assembling
system with nucleotides and stimulating fusion with the cell membrane. Ren et al.187,188
postulated that the high transfection efficiency of DOTMA was due to the paired oleoyl
chains and proposed that in vitro transfection activity can be determined by the structure
of a lipoplex and effects on interactions, after IV administration, between lipoplex and
blood components.189 Increasingly over the decades, there has been significant growth in
the knowledge of the ability to create and improve nonviral vectors for the delivery of
genetic material. Ren et al. also proposed the attachment of glucose or galactose moiety to
enhance cell targeting, using the concept of receptor-mediated endocytosis.190 To improve
transfection efficiency, Sigma-Tau Industrie Farmaceutiche Riunite S.P.A introduced a
series of carnitine perfluorinated esters191 which were found to transfect efficiently in
several human cell lines in vitro.
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Figure 3.2. Chemical structures of cationic lipids with quaternary ammonium
headgroups.
Life Technologies intellectualized the use of natural biodegradable linkages as
building blocks of cationic lipids192 and proposed the ester DOTAP (Figure 3.2) as an
alternative to the established ether DOTMA.158 An ether linkage between the lipophilic
portion and lipid headgroup has frequently been observed to cause accumulation of cationic
lipid in fatty tissues after repeated transfections. DOTAP was shown to accumulate less in
tissues than DOTMA.
Life Technologies also described a family of polyquaternary ammonium salts such
as (N,N’,N’’,N’’’-hexamethyl, N,N’,N’’,N’’’-tetrapalmyl) spermine and (N,N’,N’’,N’’’tetramethyl, N,N’,N’’,N’’’-tetrapalmyl) spermine (Figure 3.3), which are co-formulated
with DOPE.193 These lipids demonstrated comparable transfection efficiency to DOTMA
with reduced cytotoxicity. Polyquaternary ammonium salts became the center of attention
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N

for different companies and universities. For example, the University of California
described a family related to DOTAP/DOTMA, with two quaternary ammonium salts, for
example, PolyGum/DOPE (Figure 3.2).194
N CH2(CH2)14CH3
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Figure 3.3. Chemical structures polyquaternary ammonium salt.

As compared to DOTAP/DOPE these compounds were shown to improve in vitro gene
transfer on NIH3T3 cells. Imar Pharmaceutical Corp. offered quaternary ammonium salt
N, N’-bis(hexadecyl aminocarbonyl methylene)-N,N’-bis-(trimethyl ammoniummethyl
aminocarbonyl methylene) ethylene diamine diiodide and derivatives that demonstrated
enhanced transfection activity in vitro as compared to LipofectinTM or DOTAP.195 Other
examples include using cholesterol as a hydrophobic anchor, such as in (3b)-[N-(N’,N’’-
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dimethyl-aminoethyl)carbamoyl]cholesterol (DC-Chol), 3-b-[N-(N,N’,N’-triethylamino
propane)-carbamoyl] cholesterol (TEPAC-Chol) and its analogues, which demonstrated
better transfection efficiency in MCF7, A549, U37MG, and HUH7 cell lines.196 Cationic
phospholipids complexed with DOPE or cholesterol were found to be an effective
transfection vector for in vitro as well as in vivo applications.198-198 Cationic substitution
with nitrogen or phosphorus on the polar group of this family of compounds confers a
significant increase in transfection efficiency in vitro against CFT1, K562, HT29, and Hela
cell line and in vivo.
Further study on the diester class of lipids (e.g., DOTAP) found that incorporation
of hydrophilic groups in the lipid headgroup, more specifically hydroxyl groups, is a crucial
parameter that improves the transfection efficiency of lipids with quaternary ammonium
headgroup. Consequently, both DOTMA and the diester variant DOTAP were modified by
substituting an N-methyl group with a hydroxyethyl group to give DORIE (1,2-dioleoyl-3dimethyl-hydroxyethyl ammonium bromide) and DORI (1,2-dioleoyloxypropyl-3dimethyl-hydroxyethyl ammonium chloride), respectively (Figure 3.4).

199,200

The

presence of the hydroxyl group in DORIE and DORI establishes a hydrogen-bonding
functionality in the hydrophilic domain. These functionalized cationic lipids are believed
to either interact more readily with cellular membranes via hydrogen bonding or by
facilitating a greater electrostatic association, leading to greater transfection activity than
either DOTMA or DOTAP. The integrity of bilayer structure and the stability of complexes
can be increased when the cationic lipids form an ion pair with nucleic acid or with the
phosphate moiety of DOPE (dioleyl phosphatidylethanolamine) via the headgroup
hydroxyl groups of DORI or DORIE participating in intermolecular hydrogen bonding.
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Incorporation of hydroxyalkyl chain capable of hydrogen bonding to neighbouring
headgroups could decrease the headgroup hydration, while it improved the compaction of
nucleic acid by several mechanisms. For example, DNA could form hydrogen bonds with
the lipid, and the hydroxyl group could enhance the membrane hydration.201
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Figure 3.4. Chemical structures of DORIE, DMRIE and DORI.

Banerjee et al.202 found that with an equimolar amount of cholesterol as a co-lipid,
transfection using a cationic lipid with two hydroxyethyl chains, DHDEAB (3.3b) [Figure
3.5], was 2-3-fold more efficient than that of DDAB, (didecyldimethylammonium
bromide) which bears two methyl groups instead of two hydroxyethyl groups. DHDEAB
also showed higher transfection efficiency when compared to the cationic lipid 3.3a
[Figure 3.5] that contained only a single hydroxyethyl group in its headgroup region.
Hydroxyisopropyl headgroup-based cationic lipids (3.3c) [Figure 3.5] showed comparable
transfection efficiencies to DHDEAB in COS-1 cells.203 A cationic glycolipid (3.3d)
[Figure 3.5] with four hydroxyl moieties in the headgroup regions was also observed to
have higher transfection efficiencies than that of DHDEAB when used in combination with
cholesterol as a co-lipid.204
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Figure 3.5. Chemical structures of quaternary cationic lipids with hydroxyl moieties.

The introduction of a second quaternary ammonium group adds to the modification
of headgroups which led to the formation of dimeric lipids (3.4) (Figure 3.6).

205-208

Rosenzweig et al.206 found that these quaternary ammonium salts (3.5a-3.7c) exhibited
well to excellent transfection activity in BHK cells. The dimer of N,N-dioleyl-N,Ndimethylammonium chloride (DODAC) joined by a hydrocarbon tether of six carbons in
length (TODMAC6, 3.7c) was shown to possess better transfection properties compared
to DODAC. On the surface, it seemed that the introduction of a second quaternary
ammonium group could increase the strength of interaction with DNA. However,
TODMAC3 (3.7b) with the hydrocarbon tether of three carbons in length exhibited lower
transfection efficiency compared to TODMAC6 (3.7c). This was postulated to be
consistent with steric effects that restrict the formation of ion pairs with anionic lipids.209
The transfection efficiency of dimeric lipids appears to be controlled by the length of the
spacer between the headgroup ions, which determines headgroup charge separation and
chain packing. The length of the spacer influenced the complexation of DNA and the
physicochemical features of derived lipoplexes (3.8a-c).210
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Figure 3.6. Chemical structures of dimeric lipids.
Although, multi-headed cationic lipids bearing three or four quaternary ammonium
headgroups have attracted much attention,

211-216

they have been rarely used for gene

delivery in vivo. This class of cationic lipids possessed important biological functions due
to their unique physical and chemical properties, such as, the low micellar sizes and
aggregation numbers, the high CMCs (critical micellar concentration) and degrees of
counterion dissociation.211 The higher solubility in water and greater positive charge
density per molecule of these multi-headed cationic lipids enable them to interact better
with bacterial cell surfaces, enhancing their antibacterial activity.212 The greater positive
charge density per molecule of these multi-headed cationic lipids makes them potent
candidates for effective gene transfection activity compared to their single-headed
counterparts.217
Generally, as noted above, modifications to the quaternary ammonium headgroups
of cationic lipids fell into two main categories: introduction of hydroxyl groups and
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multiplicating the quaternary ammonium groups. The complexation and the release of
DNA/RNA is strongly affected by these modifications. The membrane-forming properties,
and the surface hydration of the lipoplexes formed from these lipids are also affected
leading to further influencing the efficiency of gene transfection.
3.3.2. Cationic lipids containing amine headgroups (lipoamines)
A new headgroup approach for design of transfection lipids, different from Felgner’s
quaternary ammonium salt-based headgroup approach, was proposed by Behr in 1989.218,
219

This approach exploits the property of the naturally nucleus-occurring polyamine

spermine, which condenses DNA during cell division. Unlike lipids with quaternary
ammonium headgroups, some lipids possessing primary, secondary, or tertiary amino
headgroups have better buffering function. The first cationic lipid of this class,
dioctadecylamidoglycylspermine (DOGS or TransfectamTM), was prepared by attaching
a lipophilic anchor to spermine (Figure 3.7).218, 219 DOGS increased transfection efficacy
as compared to quaternary ammonium salts by up to 50%. Lipopolyamines condense DNA
efficiently without the use of a helper lipid, in contrast to the quaternary ammonium salts,
to achieve significantly higher levels of transgene expression in vitro and in vivo.220
Subsequently, tertiary amines were introduced instead of quaternary ammonium salts to
lower the side effects associated with protein kinase C inhibition. The tertiary amine of
lipoamine DC–Chol was linked through a spacer to a cholesteryloxy-carbonyl lipid (Figure
3.7).160 The commercially available DC-Chol (3β-[N-(N′,N′-dimethylaminoethane)
carbamoyl]-cholesterol hydrochloride, (3.9c, Figure 3.8) with a tertiary amine headgroup
linked to cholesterol160 was first reported in 1991 by Gao et al.
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Figure 3.7. Chemical structures of lipoamines used for gene delivery.
The synthesis and transfection potential of the primary amine analogue (3β-[N(aminoethane)carbamoyl]cholesterol (AC-Chol, 3.9a), secondary amine derivative (3β-[N(N′-methylaminoethane) carbamoyl]cholesterol (MC-Chol, 3.9b), and the quaternary
ammonium salt 3β-[N-(N′,N′,N′-trimethylaminoethane)carbamoyl]cholesterol iodide (TCChol, 3.9d) was subsequently reported by Kearns et al. who found that AC-Chol and MCChol were the most effective mediators of cell transfection in studies on stimulating higher
β-galactosidase activities and had lower toxicities in comparison to tertiary and quaternary
ammonium counterparts.221
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Figure 3.8. Chemical structures of cationic lipids with cholesterol moieties combined
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Generally, tertiary amine 3.9e with a cholesteryl group as a hydrophobic tail gave a higher
transfection activity than the quaternary ammonium counterpart 3.9f. 222 Cationic lipids
with the amino headgroup and the hydrophobic tails separated by a significantly greater
distance (six or twelve carbon atom spacers) have been demonstrated to show favorable
transfection characteristics in selected human cancer lines.223, 224 Compared with primary
amino headgroups, the transfection activity of cationic lipids with tertiary amine polar
headgroups was improved to a greater extent.225 The dimethylamino headgroup (tertiary
amine headgroup) performed better than piperazino, morpholino, trimethylamino or bisdimethylamino counterparts in delivering small interfering RNA (siRNA). 226 The amine
headgroup should maintain a neutral or low zeta potential at pH 7.4 because of crowding
with the neighboring groups, providing longer half-life in the circulation and reducing
nonspecific cytotoxicity. Another strategy was the introduction of different hydrophobic
group, cholesteryl carbamate, which does not form bilayers but rather intercalates into
bilayers formed by DOPE. DC–Chol-DNA complexes were the first to be used in clinical
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trials.227, 228 Because DC–Chol does not present enough compactness to DNA, it generally
is co-formulated with an additive lipid to obtain significant transfection levels.
In conclusion, cationic lipids bearing primary, secondary and/or tertiary amine
headgroups typically have neutral or low cationic surface charge density at pH 7.4, which
can be changed by the introduction of other amine headgroups or varying the spacer lengths
and linker to improve transfection efficiency.

3.3.3. Cationic lipids containing both quaternary ammonium and amine headgroups
2,3-Dioleyloxy-N-(2-sperminecarboxamido)ethyl-N,N-dimethyl-1-propanaminium
trifluro-acetate (DOSPA) (Figure 3.9) was the first cationic lipid containing both
quaternary ammonium salt and polyamines in one lipid. This was co-formulated with
DOPE to give LipofectamineTM.229,230 LipofectamineTM, although very efficient as
transfecting agent, has relatively high cytotoxicity in vitro and in vivo and this has thwarted
its clinical development. Subsequent, introduction of GAP-DLRIE comprising one amine
and one quaternary ammonium salt (Figure 3.9), which demonstrated a high level of
transfection with low cytotoxicity,231 has led to the proposal by Life Technologies of
DOSPA and GAP-DLRIE and compounds 3.10a and 3.10b (Figure 3.9) containing
carbamate linker bonds, to overcome the toxicity issue and improve bioavailability.232
These compounds exhibited low toxicity when tested in vitro and in vivo. Vical Inc., a
biotechnology start-up founded by Felgner in 1988 to advance lipid-mediated transfection
to the clinic, synthesized a series of polar head cationic lipids, 3.10c, 3.10d, and 3.10e with
piperazine backbone (Figure 3.10),233,234 which demonstrated comparable or higher
transfection efficiency against C2C12, and COS-7 cells as compared to the DMRIE-DOPE
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system when co-formulated with DOPE. Compound 3.10c showed higher transfection
activity than GAP-DLRIE in-vivo in mouse tumor and intra-lung transfection assays.
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Figure 3.9.Cationic lipids containing quaternary ammonium salt and amine headgroups-I

Also, transfection assay after IP administration in C57/B16 mice showed a modest result
in some cases but was lower than those obtained for GAP-DLRIE. Another cationic lipid
containing both quaternary ammonium salt and lipoamines is spermine scaffold–based
diamino-bis-quaternary ammonium salt lipid, 3.10f introduced by Haes (Figure 3.10).235
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The transfection efficiency of these compounds, when co-formulated with DOPE was
more than five-fold higher than LipofectinTM (DOTMA) when tested in primary human
tracheabronchial cells as well as 2- to 2.4-fold more than N,N’,N’’,N’’’tetraethylpalmitylspermine (TMTPS) against HepG2 and Hela cells.

52

3.3.4. Amidinium salt lipids and miscellaneous cationic entities
Amidine-based lipids were first introduced in 1994 by Ruysschaert et al. as efficient
transfection vectors236 and subsequently developed by Megabios Corporation as the first
amidinium lipid-based gene delivery system.237 ADPDE and ADODE co-formulated with
cholesterol demonstrated comparable transfection efficiency with DDAB–Chol
complexes, when chloramphenicol acetyl transfer (CAT) gene activity was monitored in
lung, liver, and heart of mice after the intravenous administration. Further, when
guanidinium group was introduced in the position of linker between lipids and polyamine
compounds, compound 3.11a was formed (Figure 3.11), which demonstrated enhanced
transfection efficiency on NIH3T3, rabbit SMC, 3LL Lewis lung, and CaCO-2 colon
carcinoma cell lines as compared to LipofectamineTM. 238-244
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Figure 3.11. Amidinium salt lipids and miscellaneous cationic entities.
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When compound 3.11b (Figure 3.11) was co-formulated with DOPE, it demonstrated
transfection efficiency similar to LipofectinTM and DC–Chol using β galactosidase plasmid
when injected intra-dermally into Swiss Webster mice.
3.4. Nanoparticle-mediated siRNA delivery
Amongst the numerous technologies being explored as potential siRNA
nanocarriers, the use of lipid nanoparticles (LNPs) appears promising. A LNP, typically
120 nm in diameter or smaller, is prepared by means of a spontaneous vesicle formation.
The LNP is composed of neutral lipids (e.g., cholesterol and 1, 2-distearoyl-sn-glycero-3phosphocholine), cationic lipids, and PEG-conjugated lipids.131 Interestingly, a recent
study indicated that LNPs have a solid core and an electron-dense complex structure with
physico-chemical properties that are totally different from liposomes, even if containing
ingredients that are often seen in liposomes.240 The performance of LNPs has been
comprehensively examined in vivo and in clinical trials. In animals, Zimmermann et al.
revealed that there was no substantial complement activation, pro-inflammatory cytokine
production, delayed coagulation, or other changes in hematology parameters.241 Also, no
signs of hepatotoxicity were detected in a Phase I clinical trial to evaluate LNP delivery of
siRNA against apolipoprotein B. However, the trial was terminated because of the
observation of a flu-like symptoms likely associated with immunostimulation by the high
siRNA payload in one of the subjects treated at the highest dose level.242 Briefly, LNPs
demonstrate excellent potential for RNA delivery, but more toxicity data, especially related
to the immunogenicity, are still needed to validate their clinical value.240
Liposomes are made up of a phospholipid bilayer with an aqueous core243, 244 and
can easily be prepared with biocompatible lipid/phospholipid ingredients. Liposomes can
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also be functionalized with PEG-lipids for extended circulation. Liposomes are perhaps the
most regularly used nanosystems for delivery of RNAi agents.131 Nonetheless, the use of
RNAi for therapeutics has to confront various challenges based on its stability and
property. Despite several efforts from academia and industry in applying the siRNAs in
biological research, the first clinical trials using naked siRNAs have generated unfavorable
results due to the inflammatory toxicities and off-target effects.245 Without any chemical
modifications, siRNAs might encounter several obstacles involving their ready degradation
in serum, difficulties in overcoming cell membranes, or short half-life.246 Therefore,
effective delivery systems are urgently needed to mitigate these drawbacks of siRNAs.
Modifications of delivery strategies, has in recent years, significantly added to the progress
especially the approval of siRNA drug (patisiran) by the US Food and Drug Administration
(FDA) in 2018, representing a milestone for clinical siRNA therapies. The approval of
patisiran (Onpattro), epitomizes the clinical translation of nanomedicines, which play a
significant role on the treatment of multiple diseases.247,

248

To date, based on

nanotechnology, significant progress has been achieved as more than 10 LNPs systems for
drug delivery into targeted tissues or organs have been approved by the FDA.247, 248
3.5. Brief description of the mechanisms of RNAi machinery
In 1998, the RNAi mechanism hypothesis was formally introduced and
characterized in the nematode worm.142 Fire et al.142 demonstrated that double-stranded
RNA (dsRNA) provoked more substantial interference effects to at least tenfold compared
with sense or antisense RNAs alone as dsRNA was shown to have triggered RNAi to
induce gene silencing.142 This was after Guo and Kemphues had found that sense RNA was
as effective as antisense RNA for suppressing gene expression in worms.249 The
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indications, as discovered in plants and animals, were that dsRNA could act as a guide for
the identification of substrates for RNAi.249 Therefore, dsRNA could navigate short antisense RNA (guide strand) to interact with Ago2 protein, under the function of RNA
helicase A (RHA), whereas the passenger strand was cleaved, leading to the formulation
of RNA-induced silencing complex (RISC) complex.250 The single-stranded siRNA would
be directed by RISC at the post-transcriptional point, based on base-pair binding. This
induces its complementary combination with endogenous mRNA,251, 252 making the gene
unable to express proteins and lead to cleavage in the end. On the foregoing, RNAi can be
regarded as a transcriptional machinery that combines genomic editing technology and
RNA together. In this circumstance, exploiting siRNAs for performing gene silencing
work, especially targeting tumor-associated mRNAs is an auspicious adventure.
Unfortunately, direct transportation of siRNA drugs into cytoplasm without inducing its
degradation is one crucial question that still needs to be answered.

3.5.1 Limitations of siRNA technology
Two major impediments are encountered during the process of delivering a siRNA
cargo in vivo, which is primarily induced by the physiognomies of siRNAs (strong anionic
charged, hydrophilicity) and the complex circumstances of innate systems (Figure
3.12).251, 252 Naturally, siRNAs have a short length (21–23 nucleotides) and are easily
recognized by endogenous enzymes in serum and filtered by the kidneys, prompting a
temporary half-life.253,

254

This notwithstanding, siRNAs have to overcome the

impediments of crossing the negatively charged cellular walls of the plasma membrane,
which can repel siRNAs that are also anionic in nature.251 Lastly, the blood–brain barrier
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and immune recognition system, under the systematic administration, also create siRNA
delivery challenges.255, 256 The physiological effect of the mononuclear phagocytic system,
which is responsible for conducting the process of endocytosis, cannot be negligible.251, 257
The siRNAs, similar with other molecules, cannot escape from the endosomal system,
resulting in the further challenge at reaching the cytosol of the cell.258 To enhance the way
siRNAs are delivered intracellularly, the above-mentioned drawbacks on siRNAs delivery
should be considered. Consequently, it is important to explore practical platforms that can
overcome these challenges and enhancing RNA transfection efficiency.

Figure 3.12: Extracellular barriers to RNAi therapy. (A) Endonucleases degrade siRNA in circulation; (B)
the mononuclear phagocytic system, in particular the macrophages of the major clearance organs (e.g., liver,
lungs, and spleen), removes siRNA from circulation; (C) tissue penetration of siRNA is hindered by charge
repulsion between the anionic siRNA and the plasma membrane of endothelial cells, as well as tight junctions
in selective regions (e.g., the blood–brain barrier) that require transcellular or paracellular transport to reach
the target tissue. Used with permission from Ref. B. Kim, J.-H. Park, M. J. Sailor, Adv. Mater. 2019, 31,
1903637; Copyright ˝WILEY publications.
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3.6. Lipid nanoparticles
The first FDA approved siRNA drug (trade name Onpattro)247 was successfully
translated in vivo and was shown to prompt considerable gene silencing efficiency when
formulated as an LNPs preparation. Compared with conventional transfection lipids (which
are likely to retain positive charge regardless of pH conditions), the LNP system is
ionizable and neutral under physiological pH.247 LNPs can generally be categorized into
those containing cationic or ionizable lipids as their main active component with a
phospholipid, and a PEG-lipid and they differ in both their structure and mechanism of
uptake.226 While “ionizable” lipids maintain a virtually neutral charge at physiological pH,
“cationic” lipids have an overall slightly positive charge. Importantly, LNPs have a low
surface charge, a diameter of 120 nm or less, and a high encapsulation efficacy under
intravenous administration.247 Different chemical structures of ionizable lipids exhibited
diverse potency for nucleic acid delivery.226 Another setback to the clinical use of LNPs is
the hepatic clearance. As the predominant targeted cells of the liver, hepatocytes are
responsible for gathering LNPs via different pathways, preventing the clinical use of LNPs,
which primarily involve the robust apolipoprotein E-mediated low-density lipoprotein
receptor

pathway,

as

well

as

the

more

gradual

N-acetyl-D-galactosamine

(GalNAc)/asialoglycoprotein receptor pathway.259 Hence, reducing clearance ratio and
enhancing the bioavailability are crucial factors to be considered for the design of LNPs to
deliver RNAs. In a recent work, Dan Peer and coworkers established that certain ionizable
amine lipids based on the linker moieties such as hydrazine, hydroxylamine, and
ethanolamine can efficiently deliver siRNAs into leukocytes, which are among the hardest
to transfect cell types, by varying the formulations based on the linker moieties. 260, 261 This
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shows that the delivery efficiency of a lipid could efficiently influence by the varying the
linker region. Three common amino molecules, hydrazine, hydroxylamine, and
ethanolamine are used for surface modification.260, 261 The LNPs were synthesized by using
a microfluidic mixing device. The formulation contained an ionizable lipid, cholesterol,
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and PEGylated lipids in molar ratios
of 50:38.5:10:1.5, respectively.260, 261 The authors showed that lipid 3.12j performed more
effectively than the other lipids (Figure 3.13). Moreover, the gene silencing effects shown
by 3.12j-based LNP encapsulated with Cy5-labeled siRNA(siCy5), without any immune
responses were attributed to the linker effect, which are more prominent in the case of
ethanolamine and hydroxylamine linkers, with pKa values of 6.2–6.5. 260, 261
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Figure 3.13. Chemical structures of ionizable amino lipids used in a study by Ramishetti
et al.260, 261
3.6.1. Polymeric nanoparticles
In addition to lipids, polymers are also commonly used for delivery of siRNA
payloads. Chitosan (CS), poly(lactic-co glycolic acid) (PLGA), poly-L-arginine, and
polyethylenimine (PEI) are the widely recognized components of polymers applied for
siRNA delivery.260, 261 Cationic polymers can also associate with the negatively charged
siRNA molecules via electrostatic interactions, binding between the amino groups and
phosphate groups of siRNAs, which are valuable for circumventing the chemical
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modification of siRNAs.263 Nonetheless, some parameters like the relative proportion
(charged groups and concentration) of the polymer-based nanovector should be considered
to optimize the polymer/siRNA formulation.262 Even though, low solubility is a major
obstacle for its application in the synthesis of nanomedicines, CS is a natural cationic
polysaccharide with favorable biocompatibility and low toxicity, endowing its capacity to
bind with siRNA via charge-to-charge connections.263 To circumvent the solubility
problem, a core-shell platform for siRNA delivery was designed264 in which PLGA
(lactide:glycolide, 75:25) served as a solid shell to inhibit the degradation of siRNA and
protect the innate core. At pH 7.0, this system offered a size of 110Å ±5.7 nm in diameter
with negatively charged surface (−22.4Å ±2.1 mV).264 Furthermore, to enhance the
endo/lysosomal escape in a pH dependent manner, the CS (1 kDa) was altered by guanidine
group (chitosan–guanidinate [CG]) as the reagent bound to siRNA.264 Across different cell
lines,

this

pH-responsive

nanoparticle

displayed

low

cytotoxicity

and

good

biocompatibility and the siRNA/NPs targeted RNA Polymerase II Subunit A (POLR2A)
significantly reduced the gene expression and inhibited POLR2A tumor growth by∼80%
in vivo.264 Subsequently, a CS (20 kDa) based platform coated with cancer cell membrane
(CCM) was obtained from DOX-resistant HeLa/DOX cells, aimed at increasing the tumorhoming capacity of this delivery system.265

This nanoparticle, with mass ratio of

CCM/CS/RNA, particle size and a zeta potential as 7.5, 122.39Å ±4.69 nm, and −27.76Å
±3.12 mV respectively, showed good stability and high transfection efficiency (∼60% at
72 h).265 To optimize the formulations, CS was modified with PEI by a reductive amination
reaction, and then a pH-sensitive linker 4-hydrazinovenzoic (HBA) was attached to
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produce a CS-based nanoparticle which showed high siRNA encapsulation potency
(∼81.3% at 10 h) and considerable antitumor effects (∼88.0%) in vivo.266
3.6.2. Hybrid nanoparticles
Considering the current drawbacks and notwithstanding the properties of the lipidbased and polymer nanocarriers, the fabrication of hybrid nanoparticles focuses on the
integration of the nano-system to give a distinctive intuition into nanomedicines, holding
the advantages of combining characteristics of different nano-vectors. Shi et al. introduced
an innovative hybrid system that particularly targeted macrophages in atherosclerotic
lesions.267 A cationic G0-C14 (Figure 3.14) was first incorporated with siRNA and
surrounded with PLGA to construct a stable inner core. Then, a S2P peptide
(CRTLTVRKC) was used to specifically target the macrophages in a ligand-receptor
binding mode. Results intimated that the proportion of S2P should be kept at no more than
50%, in case of overlapping PEG-layer and weakening stability of the whole platform.
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Figure 3.14. Structure of G0-C14.

Based on this delivery strategy, the expression level of a plaque-destabilizing gene was
significantly decreased by ∼60%, resulting in less necrotic core area thereby enhancing
plaque stability, and little toxic effect in mice after intravenously injection (1 nmol siRNA
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per mouse).267 Similarly, a pH-responsive nanomaterial, encapsulating with mitoxantrone
(MTO)-based prodrug was formulated.268 The therapeutic siRNA and MTO prodrug, in
this case, were incorporated into the tumor microenvironment (TME) polymer and coated
with a PEG shell (N/P molar ratio: 15, particle size ∼100 nm) to increase siRNA
encapsulation efficiency (EE) by ∼50%, prolonged blood circulation, and enhanced the
effectiveness of siRNA release, across the tumor tissues, occasioning a seven-fold higher
accumulation compared with naked siRNA (at a dose of 1 nmol siRNA per mouse.268
However, original liposomes experience low cellular internalization and short circulation
time during transportation, leading to inefficient knockdown.251 Consequently, the surface
of these liposomes is modified with PEG approved by the FDA and recognized as gold
standard for modifying with the ability of increasing hydrophilicity and stability.269 Other
options are to dope traditional liposomal formulation with gold nanoparticles, termed as
“auroliposomes.”270 In such circumstance, the liposomes are fabricated with other lipid
components, such as PE-PEG (1,2-distearoyl sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000]) to extend circulation time, DOTAP (1,2-dioleoyl3-trimethylammonium-propane),DOPE(1,2-dioleoyl-sn-glycero-3 phosphoethanolamine),
DOPC (1,2-dioleoyl-sn-glycero-3 phosphocholine) for charge modulation, and the lowlevel Tween 20 for promoting cellular uptake.270 Compared with the commercial
transfection reagents and traditional cationic nanoparticles, the siRNA EE increased to
∼90% due to the incorporation of a 20-nm gold nanoparticle. Such findings demonstrated
the potential benefits of hybrid nanoparticles not only to surmount the limitations in
delivering small molecule drugs, but also to enhance the beneficial effects obtained when
different kinds of nanoparticles are combined. Other hybrid nanoparticles have been
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prepared by a particular kind of biomimetic engineering-based siRNA delivery system. In
this context, porous metal-organic framework (MOF) nanoparticles were coated by cellderived platelet membrane.271 The formulation of P-MOFsiRNA nanoparticles
incorporated 500 nm siRN siRNA loading.272,

273

These hybrid nanoparticles, as an

integrated nano-system, provide promising prospects for further translation and application
into the clinic.

3.7. Cationic aminooxy lipids
In the application of cationic lipids as transfection agents, the linker region, and to
a lesser extent the cationic headgroup, have emerged as the fundamental determinants of
cytotoxicity.274-276 The flexibility, stability and biodegradation of a given cationic lipid is
strongly associated with its linker region. Some of the well-known linker region
functionalities of transfection lipids are ether, ester, ortho ester,

277, 278

carbamate,279

amide,163, 280 and phosphono281 moieties. One way to reduce cytotoxicity is by attaching
the amphiphile hydrophobic domain via cleavable ester linkages, as demonstrated by the
DOTMA (ether) to DOTAP (ester) alteration disclosed by Silvius and Leventis.158 The
strategy is to allow degradation of the cationic lipid by endogenous esterases, thus making
the cationic DNA binding domain non-amphiphilic and to minimize the incidence of
cationic lipid accumulation in the plasma membrane. The development of DOTAP, a
cationic lipid with an improved biocompatibility relative to DOTMA, was premised on this
proposal. Relying further on this concept, Nantz and coworkers developed a cationic
amphiphile 3.13 (Figure 3.15)274 with tetraester linkages and also pioneered the fabrication
of novel cationic lipids 3.14a-3.14d (Figure 3.15) with oxime ether linkages.282 These
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lipids displayed lower toxicity as delivery vehicles for nucleic acids (pDNA and siRNA)
to cultured cells under in vitro conditions.282 In the past several years, the application of
oxime ether linkages in medicinal chemistry and chemical biology research and the
approval of pharmaceuticals such as fluvoxamine,283 which contains an oxime ether
linkage, by the FDA is a testament of their safety. Oxime ether linkages are also used in
pro-drug formulation, which suggests routes for their metabolism after cellular
incorporation.284, 285
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Figure 3.15. Cationic lipids with ester (3.13) and oxime ether linkages (3.14-3.15).

Further to improving the transfection efficiency of the oxime ether lipids (OELs), the Nantz
group synthesized OELs with hydroxyl groups in the hydrophilic domain as well as
modifying the hydrophobic core by varying the chain lengths and/or degree of unsaturation,
as illustrated by OELs 3.15a and 3.15b (Figure 3.15).286 The hydroxylated OELs were
established to be superior carriers for siRNA delivery to cells. The fatty acyl chain length
and degree of unsaturation both influenced transfection and silencing activity in vitro.286
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For example, Gupta et al.286 demonstrated that OELs 3.14d and 3.15b (Figure 3.15) with
unsaturated hydrophobic domain showed better uptake efficiency of Alexa488 RNA/DNA
hybrid duplexes at higher concentrations whereas OELs 3.14b and 3.15a with saturated
tails showed better uptake at lower concentrations. The uptake efficiency of OELs 3.14d–
3.15b with unsaturated hydrophobic domain and/or hydroxylated headgroup was also
demonstrated to be better than that of commercial transfection agent Lipofectamine (L2K)
at different concentrations. Unsaturation in the OEL lipid hydrophobic domain also
strongly impacted nucleic acid protection of the resulting complexes.286 Uptake of lipid–
siRNA complexes by the cells showed concentration dependence wherein unsaturated-tail
lipids outperformed at higher concentrations of the added complexes whereas saturatedtail lipids were optimal for mid-range concentrations. Prior studies by Zhi et al.287 have
generated conflicting results on the optimal lipid chain length and unsaturation; which may
be in line with the concentration dependence observed by Gupta et al. Nucleic acid
protection was also superior for the saturated lipids (3.14b, 3.14c and 3.15a); however, the
silencing of GFP was not compromised with the longer-chain unsaturated lipids, despite
weaker binding to the nucleic acid. The Springer group reported that transfection efficiency
is enhanced by the effects of unsaturation as unsaturated lipids are thought to fluidize
endosomal bilayers and thus facilitate the lipoplex escape.184 With regards to silencing of
the GFP gene, hydroxylated lipids 3.15a and 3.15b were shown to outperform their
nonhydroxylated counterparts with GFP gene silencing in human breast cancer cells with
OEL 3.15b doing better than OEL 3.15a. Also, at higher concentration of 10 and 20 μM
OEL 3.15b was observed to be a better transfection agent than the commercial transfection
agent L2K. Interestingly, the higher binding affinity of OEL 3.15b to nucleic acids did not
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correlate well with protection against DNase. This, however, may facilitate dissociation of
the nucleic acid from the lipid resulting in a higher degree of silencing by OEL 3.15b).

3.7.1. Aminooxy functionality and oximation
Prof. K. Barry Sharpless of The Scripps Research Institute both established and
promoted simple but high-yielding reactions that he termed click chemistry.288, 289 Four
main categories of chemical transformations under click chemistry include: 1. carbonyl
chemistry of the “non-aldol” type, such as formation of oxime ethers, hydrazones, and
amides; 2. cycloadditions of unsaturated species, such as the Diels-Alder family of
transformations and 1,3-dipolar cycloaddition reactions; 3. nucleophilic substitution
chemistry of SN2 type, like ring-opening reactions of strained heterocyclic electrophiles
such as epoxides and aziridines; and 4. additions to carbon-carbon multiple bonds,
especially oxidative cases such as epoxidation, dihydroxylation and aziridination, but also
thiol-ene and thiol-yne reactions. Oximation, the reaction between an aminooxy moiety
and a carbonyl group (Figure 3.16) falls under criteria 1 above. Preferably, click reaction
is expected to be wide in scope, not require chromatographic purification of products and
have a benign byproduct. The underlying principle of click chemistry, such as oximation,
is to imitate nature’s ability to spontaneously form a molecule by joining separate
molecules via covalent carbon-heteroatom bonds with high efficiency. This principle has
since been exploited in numerous applications and has been extensively reviewed.290

R ONH2 +

O
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N
R(H)
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+

R(H)
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E/Z isomers

Figure 3.16. Representative oximation reaction.
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The oximation reaction is an important reaction in organic synthesis in that it does
not require a catalyst and that it is highly chemoselective. The reaction is viable at room
temperature and in a different variety of solvents, including water, and generates a robust
oxime ether linkage. Among other features of the oxime ether linkage is its resistance to
hydrolysis relative to the imine or enamine counterpart. Aminooxy compounds are known
to be highly nucleophilic due to the presence of the electronegative oxygen atom adjacent
to nitrogen, the so called α-effect in aminooxy compounds.291 The protonated form of
aminooxy compounds have a lower pKa of 5-6 compared to the pKa of the primary
aminium ion (9-10). The aminooxy group reacts chemoselectively with aldehydes and
ketones to form E/Z oxime ethers at room temperature and under neutral conditions while
primary amine with pKa = 36-38 react with aldehydes, ketones to form imines, and with
esters to form secondary amides at room temperature and under neutral conditions. In 1962,
Edwards and Pearson introduced the term α-effect292 to describe the irregularly high
nucleophilic reactivity of compounds having one or more lone pair electrons at an atom
adjacent (i.e., in the α-position) the nucleophilic center. The differences in reactivity
between primary amine and aminooxy are attributed to the α-effect.293 The presence of
heteroatom (oxygen) in aminooxy compounds impacts its α-effect. In a similar fashion,
hydrazine derivatives react with ketones and aldehydes to afford comparatively stable
hydrazones, but are also reactive with esters, phthalimides, and anhydrides. The greater
intrinsic hydrolytic stability exhibited by both hydrazones and oximes relative to that of
imines can be rationalized by the contribution of the resonance form in alkylhydrazones
and oxime ethers. Kalia and Raines reported that the resonance form increases the electron
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density on carbon C1, reducing its electrophilicity and imparting greater hydrolytic
stability294 as depicted in Figure 3.17
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Figure 3.17. Resonance structures of oxime ethers and hydrazones.

The stability of hydrazones and oximes was proposed by Winberg et al. to be due to
the reduction of lone-pair repulsion, relative to the hydrazine and aminooxy state.295
Oximes and oxime ethers can be hydrolyzed at low pH (pH range 0-4), such as by using
an aqueous solution of hydrochloric acid. This evident from a kinetic and mechanistic study
by More O’Ferrall et al. that showed even though the acid-catalyzed hydrolysis reaction
remains independent of pH below pH 2, it occurs above pH 2.296 Although the aminooxy
moiety reacts chemoselectively with aldehydes and ketones under neutral conditions at
room temperature, the rates of the oximation reaction are not adequate under normal
conditions for some applications.297 There are many instances in the literature of other
forms of reactivity for the aminooxy group. The tendency of the aminooxy group to react
under neutral conditions at room temperature has been exploited to attach polymers to
proteins.298 However, Dirksen et al. showed that the reaction rates and yields for oximation
reaction were significantly improved by aniline catalysis (Scheme 3.1).299 Reaction of
carbohydrates with aminooxy substrates under the aniline catalysis was demonstrated by
Thygensen et al. 300 (Scheme 3.1).
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Scheme 3.1. Main pathways of aniline catalysis as proposed by Thygensen et al.300

In 2013, Crisalli and Kool reported oximation reactions enhanced by water-soluble
catalysts.301 Also, Rashidian et al. revealed that m-phenylenediamine (mPDA) is 15 times
more effective than aniline for the oximation catalysis.302 The solubility of mPDA in
aqueous media, makes it even more appealing for some biological applications.
The aminooxy group is a good nucleophile and can react as such with a variety of
electrophiles.303-307 These non-oximation electrophiles in the order of most to least reactive
include: acyl chlorides > activated carboxylic acids > anhydrides and imides > esters >
epoxides > alkyl halides. Acylating the aminooxy moiety with protecting groups such as
Boc (tert-butoxycarbonyl) is common.308-310 The reaction of aminooxy with alkyl halides
is however more rare and low-yielding.311, 312 Two-step (oximation and reduction) pathway
are sometimes preferred to achieve the same hydroxylamine intermediates in higher yields
(Scheme 3.2).313-316
O

OBz

1. BnONH2
2. NaBH3CN

BnO

H
N
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56%, 2 steps

Scheme 3.2. Oxime ether reduction using NaBH3CN as performed by Daher et al.315
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The aminooxy group does not only act as nucleophile, however, when activated by an
electron withdrawing group, it behaves as an electrophile to allow electrophilic amination
reactions. This is demonstrated in Figure 3.18 below where an activated aminooxy group
undergoes a nucleophilic attack to transfer the nitrogen to the nucleophile thus forming
primary amines, hydrazines, etc.
LG
EWG

O

NH2

Nu

Nu

NH2

+

EWG–O

Activated Aminooxy

Figure 3.18. Representation of an aminooxy-based electrophilic amination reaction.

3.7.2. Generating the aminooxy moiety
3.7.2.1. Alcohol to aminooxy transformations
The primary method of introducing the aminooxy group into molecule is via the
alcohol. There are two main approaches to this 1) to displace a hydroxyl group after its
activation, and 2) to directly aminate an alcohol. To displace hydroxyl, the modified
Mitsunobu reaction317 disclosed by Grochowski et al.318 is a widely used route. Generally,
primary alcohols 3.16, and to a lesser degree secondary alcohol, are first converted into Oalkyl phthalimides 3.17. This is followed by hydrazinolysis of the phthalimide group to
produces the desired aminooxy product (Scheme 3.3).
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Scheme 3.3. Alcohol to aminooxy transformation using Mitsunobu conditions
followed by hydrazinolysis.
The aminooxy moiety has been used in functionalizing other molecular fragments like
oligonucleotide glycoconjugate. Example of such is the double functionalization of the
branching unit of oligonucleotide glycoconjugate319 (Scheme 3.4) by Karshkela et al.
forming 3.22 at 53%, at an alcohol-to-N-hydroxyphthalimide transformation of 73% yield
per alcohol.
OH

ONphth
NHP, Ph3P, DIAD

MMTrO

O
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THF, rt, 20h
MMTrO

ONphth

O
3.22 53%

Scheme 3.4. Mitsunobu reaction mechanism.
Interestingly Su et al.320 developed a polymer containing reactive Nhydroxyphthalimide for a Mitsunobu-based solid phase synthesis of aminooxy molecules,
mindful of the prolonged purification process (Figure 3.19). Their protocol totally
eliminated the need for purification in both synthetic steps—Mitsunobu and
hydrazinolysis—making it a very attractive approach for the synthesis of aminooxy
products.
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Figure 3.19. Polymer-supported N-hydroxyphthalimides for solid phase aminooxy
functionalization.
Even though we use the Grochowski approach in our aminooxy lipid syntheses, several
other methods exist for aminooxy group incorporation including the Palandoken,321
Choong322 and the Jones323 methodologies among others.

3.7.3. Formation and stability of oxime ether bonds
In 1994, Rose initiated the oxime-based ligation for the coupling of aminooxy
peptides onto a linear polypeptide with aldehyde groups.324 The formation of oxime
linkages is fast and quantitative, leading predominantly to the formation of the Zstereoisomers and a mixture of E- and Z-stereoisomers when unsymmetrical ketones or
aldehydes are used. The aminooxylated derivatives are shown in various studies, to be
conjugated to the anomeric center of reducing sugars,325-330 and to provide a mixture of
open-chain E- and Z-oxime isomers. It is worth noting that, Peri et al.331 validated that the
utilization of N, O-substituted oxyamines leads to the formation of oxyiminium
intermediates that deliver cyclic sugars with high diastereoselectivity after ring closure
with OH at position 5. The condensation of less reactive carbonyl compounds such as
oligosaccharides,

can

be

catalyzed

with

nucleophiles

such

as

aniline,332-334

methoxyaniline,299,335 5-methoxyanthranilic acid,301 3,5-diaminobenzoic acid,301 and m
phenylenediamine,302 which mediate the formation of iminium intermediates that enhance
the reactivity toward oxyamines, even at pH 7. Because of these considerations, a large
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variety of methods have been developed to introduce aldehydes and oxyamines into
biomolecules to construct bioconjugates by oxime ligation.336, 337 To provide access to a
wide variety of bioconjugates under physiological conditions, imines, hydrazones, and
oxime linkages, represents a powerful and simple ligation methodology.

These are

generated via condensation of nucleophiles of amines, hydrazides, thiosemicarbazides, and
oxyamines with carbonyl groups (Figure 3.20).338-340
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Figure 3.20. Chemistry of C=N double bonds, including aminooxylated species (R1 = H:
oxime; R1 = alkyl: oxime ether).
Oximes and to some extent hydrazones, unlike imines that have limited stability in aqueous
media, are hydrolytically more stable making it an attractive functional group for biological
applications.341

3.7.3.1. Current uses of the oxime ether molecules
In the past several years, oxime ether molecules have witnessed a drastic rise in
applications, especially in chemical biology and medicinal chemistry research. This can be
attributed to the better understanding of the benefits of chemoselectivity. Sharpless and co-
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workers have demonstrated the utility of chemoselective click ligation184,288 in the synthesis
of numerous bioconjugates. Oxime ether containing compounds are regarded not only for
their rich and varied chemistry, but also for many important biological properties. The
oxime ether moiety is present in an enormous number of medicinal scaffolds with a broad
range of biological and pharmaceutical properties, such as antifungal,342 antibacterial,343
anti-enteroviral,344 anti-protozoan,345 anti-inflammatory,346 anticonvulsant,347 anticancer,348

and antitumor349 activities. Recently, Gupta et al.286 examined the use of oxime ether
linkage as the backbone feature of cationic lipids for pDNA and siRNA delivery. Building
on the use of oxime ether linkage in cationic lipids for pDNA and siRNA delivery, we
examine its application in human lung cancer A549 tumor bearing mouse xenografts.

3.8. Research hypothesis
The above review highlighted the many structural modifications to the headgroup,
linker, and hydrophobic regions of lipids that led to improvements in cationic lipidmediated transfection efficacy. Apart from structural modifications, formulation factors
are equally important to consider when looking to improve transfection efficacy of a given
lipid formulation. PEGylation and addition of DOPE have shown promising results when
formulated with cationic lipids.350 Helper components can assist with endosomal escape of
the derived lipoplexes via different mechanisms, which is one of the crucial hurdles to
achieve effective transfection.351
As mentioned previously, the design of OELs followed from the many structural
advancements in cationic lipid design. The inspiration to continue the work on OELs is
based on observations that this class of lipids demonstrated much promise as a vehicle for
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siRNA delivery to cells286 without any extensive investigations into formulation
parameters. OELs have been demonstrated to mediate transfection under serum conditions
and were shown to have lower toxicity in human breast cancer cells compared to other
cationic lipids.286 The low toxicity exhibited by OELs in human breast cancer cells may be
due to the oxime ether nitrogen functioning as a ‘proton sponge’ after endosomal
incorporation. The ‘proton-sponge’ hypothesis was put forth to explain the endosomal
escape of cationic polymers with titratable amine groups at pH 5-7.352 Szoka et al. reported
that the ability of many cationic polymers to mediate efficient nucleic acid delivery can be
attributed to their strong buffering capacity in the pH range from 5 to 7. They hypothesized
that strongly buffering polyamines prevent acidification of the endosomes by acting as
‘proton sponges’.353, 354 Again, the low toxicity of OELs may be due to acid-mediated
hydrolysis of the linker domain while functioning as a proton sponge within endosomes.
Disassembly of cationic lipids is known to ameliorate toxicity. We also hypothesize that
OELs will have better release of nucleic acid payloads because OELs are comprised of a
mixture of E- and Z-isomers about the oxime linkage, which creates a more fluid bilayer.
Fusogenic systems overcome the endosomal barrier more readily since they stimulate
breakdown of the endosomal membrane resulting in cytoplasmic translocation of their
nucleic acid payloads. In contrast to stable bilayer forming lamellar phase (Lα), lipidic
systems are most fusogenic when arranged in the reversed hexagonal phase (HII). A low
phase transition temperature between the two states indicates a lower activation energy for
the formation of the fusogenic HII phase. Therefore, lipids that adopt the HII phase are
regarded as ‘fusogenic’. The degree of saturation of a lipid hydrophobic domain has been
reported to affect the ability of the lipid to adopt the HII phase354 and that increasing number
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of unsaturation corresponds with an increasing susceptibility to form the HII phase. The
oxime ether linkage behaves like an E or Z double bond, and consequently lowers the
melting transition of the overall hydrophobic domain, compared to the higher melting
transitions of the densely packed saturated lipids. Furthermore, Heyes et al.355 reported that
increases in alkyl chain unsaturation increase the capacity for RNA interference, with about
80% knockdown in gene expression.

3.9. An improved synthesis of hydroxylated cationic OELs
The first-generation oxime ether lipids (Scheme 3.5) were evaluated in DNA and
siRNA delivery experiments using epithelial cell lines, including two human cancer cell
lines, by Biswas et al.356 Specifically, the authors fisrt prepared aminooxy phthalimide via
Mitsunobu reaction by adding N-methyl-diethanolamine, in a dropwise fashion, to a
solution of triphenylphosphine and N-hydroxyphthalimide in THF at 0 °C (Scheme 3.5,
step a). Diisopropyl azodicarboxylate (DIAD) was slowly added to the mixture after 30
min of stirring at 0 oC. The reaction mixture was stirred for an additional 30 min at 0 °C
and then allowed to warm to room temperature for 12 h and then purified to afford
aminooxy phthalimide. The phthalimide was N-methylated by the addition of iodomethane
in a sealed tube at 60 °C for 2 h, to afford the crude ammonium iodide as a light yellow
solid (Scheme 3.5, step b). Compound 3.27 (Scheme 3.5) was then prepared by performing
hydrazinolysis reaction on the crude iodide salt by dissolving in a mixture of EtOH and
H2O before additing hydrazine monohydrate to the reaction mixture (Scheme 3.5, step c)..
The mixture was stirred for 4 h at room temperature to afford the bis(aminooxy)ammonium iodide 3.27 (78%) as a light yellow amorphous solid.
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Biswas et al. prepared OELs by reacting bis(aminooxy) ammonium salt 3.27356 with
hydrophobic aldehydes dodecanal, tetradecanal, and (Z)-octadec-9-enal (oleyl aldehyde) in
methanol at room temperature to afford oxime ethers 3.14a, 3.14b and 3.14d, respectively
(Scheme 3.5).
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Scheme 3.5. Oximation route to first-generation OELs. Conditions: a. Nhydroxyphthalimide, PPh3, DIAD, THF, 0 oC to rt, 12 h; b. CH3I, sealed tube, 60 oC, 2 h;
c. N2H4∙H2O, EtOH, rt, 12 h.
Bearing in mind the benefit of hydroxylated polar domains in gene delivery, Drs. Stephanie
Mattingly and Xuan Huang prepared new OELs by installing hydroxyl groups in the OEL
headgroup region as illustrated in Scheme 3.6.,286, 356
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Scheme 3.6. Conditions: a. N-hydroxyphthalimide, PPh3, DIAD, 0 °C to rt, 12h; b.
N2H4∙H2O, CH2Cl2, rt, 2.5h (16%, 2 steps); c. corresponding dodecyl, tetradecyl, or oleyl
aldehyde, CH2Cl2, rt, 10h (47-71%); d. TFA, CH2Cl2, 0 °C to rt, 3h (91-100%) e. glycidol,
EtOH, rt, 60h (38-41%); f. CH3I, CH2Cl2(sealed tube), 55 °C, 5h (63-64%).

The headgroup 1,2-diol was introduced via nucleophilic addition (step e, Scheme 3.6B) of
the amines generated from step d of Scheme 3.6B. The amine is added to the C-3 carbon
of glycidol as shown in Figure 3.21.357 The reaction was conducted in ethanol (rt, 24h)
instead of in water as originally reported by Azizi et al.358
2
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R2NH

O
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OH
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Figure 3.21. Nucleophilic addition of a secondary amine to C-3 of glycidol.
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In transfection studies to examine structure–function relationships of OELs/siRNA
lipoplexes, the hydroxylated OELs were found to be better siRNA delivery agents than the
non-hydroxylated OELs.286 Following from this observation and anticipating the crucial
role that lipid-based delivery systems will play in systemic delivery of siRNA, we set out
to evaluate the hydroxylated OELs in animal studies to validate their suitability as in vivo
nucleic acid carriers. To do so, we focused on synthesizing, in large quantity, OEL4 and
OEL5.
Our attempts to scale the syntheses of OEL4 and OEL5, unfortunately,
encountered synthetic challenges in the early steps that led us to modify the synthetic route.
In particular, the first step of the OEL synthesis (Scheme 3.6) in which Boc-protected
diethanolamine

is

reacted

with

N-hydroxyphthalimide

in

the

presence

of

triphenylphosphine and diisopropyl azodicarboxylate (DIAD) to generate the Bocprotected bis(phthalimide) 3.31 (Scheme 3.6, step a) was not amenable to scale-up. In this
step, the formation of mono-phthalimide 3.44 from intermediate 3.43 (Scheme 3.7, step a)
by SN2 displacement of triphenylphosphine oxide proved to be problematic. There is a
competing process wherein the carbonyl oxygen of the Boc-group participates in the
displacement of triphenylphosphine oxide (step a’) to form side product 3.45 and thus
complicates the purification process. The same challenge is faced for the alcohol-tophthalimide conversion in any 3.44 that is formed. Consequently, a low yield of 3.32
(16%) was obtained for the first two steps. It is also worth noting that this first OEL
synthesis route only afforded 3% of the target molecule overall (Table 3.1).
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Scheme 3.7. Principal side reaction encountered in the first synthesis of hydroxylated
OELs.

To overcome this unwieldy step, we designed a new route to OEL4. First, we installed
the 1,2-diol functionality of the OEL headgroup via nucleophilic addition of
diethanolamine to glycidol (Scheme 3.8, step a). This reaction is typically accomplished
at elevated temperatures with an excess of amine or using catalysts, such as lithium
perchlorate.358,359 For example, Kuwabe et al.360 reported addition of a secondary amine
to glycidol after 48 hours refluxing in ethanol. However, a recent report by Sela and
Vigalok361 on reactions of secondary amines with glycidol at room temperature in water
or without solvent seized our attention.361 We stirred a mixture of glycidol (2.5 g, 34.2
mmol) and diethanolamine (3.0 g, 28.5 mmol) without solvent in a 250 mL two-necked
round bottom flask equipped with stir bar and septum at room temperature for 3 h to obtain
3.47 in near quantitative yield. The 1H NMR of 3.47 was consistent with the literature,361
as shown in Figure 3.22. As such, tetrol 3.47 was used in the next step without further
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purification. The excess glycidol from step a was removed after the acetalization step (step
b) via column chromatography (SiO2, CH3OH:CH2Cl2, 1:9) of crude 3.48. We protected
the 1,2-diol as an acetal by reacting 3.47 with cyclohexanone and cat. TsOH in toluene at
reflux using a Dean-Stark apparatus. As mentioned above, the crude acetal 3.48 was
purified by column chromatography with 10 % MeOH in DCM. The diol installation in the
original OEL synthesis was executed at a late stage (Scheme 3.6, step e) and afforded
amino diol 3.39 in low yield (~41%). In comparison, protected amino diol 3.48 was
obtained in a two-step yield of 70% in the revised synthesis.
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Scheme 3.8. Conditions: a. glycidol (1.2 eq), rt, neat; b. cyclohexanone (1.5 eq), TsOH
(1.0 eq), toluene, reflux, 8 h, 70% (2 steps); c. N-hydroxyphthalimide (2.2 eq), PPh3 (2.2
eq), DIAD (2.15 eq), THF/toluene, 0 °C to rt, 12h (59 %); d. CH3I, CH2Cl2, (sealed tube),
50 °C, 8 h (64 %); e. i. N2H4•H2O, CH2Cl2, rt, 4 h, ii. tetradecylaldehyde or oleyl aldehyde
(2.2 eq), CH2Cl2, rt, 12h (87%, 2 steps); f. 5 % AcOH, THF/Hexane, 0 °C to rt, 48 h (58
%).
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Figure 3.22. Stacked 1H NMR spectra of 3.47. Top: Spectrum from synthesis of 3.47 (in
D2O, 400 MHz); Bottom: literature spectrum (in D2O).361

The appearance of upfield signals in the 1HNMR spectrum of acetal 3.48 at d 1.29, 1.47,
and 1.51 ppm indicate the presence of the cyclohexane ring system. Reaction of 3.48 using
the protocol disclosed by Grochowski et al.318 generated the bis-phthalimide 3.49 after 12
h of stirring at rt. Next, the crude bis-phthalimide 3.49 was purified by first decanting a
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solution of the product from the by-products phosphine oxide and hydrazine dicarboxylate,
which precipitated on cooling the Et2O suspension of crude bis-phthalimide 3.49. This
procedure was repeated two more times before purifying the crude material via column
chromatography (7:3 EtOAc: hexane). In this way, purified bis-phthalimide 3.49 was
obtained in reproducible 59% yield. The characteristic 1H NMR downfield shift of the
methylene protons for the –CH2OH (d 3.51ppm) to –CH2ONPhthal (d 4.35ppm)
transformation confirm the phthalimide groups were successfully introduced (Figure
3.23).

–CH2OH

–CH2ONPhthal

Figure 3.23. Stacked partial 1H NMR spectra of 3.48 (top, 400 MHz) and 3.49 (bottom,
500 MHz) (in CDCl3).

Amino bis(phthalimide) 3.49 was N-methylated by reaction with excess iodomethane in a
pressure tube heated to 50 °C for 12 h (Scheme 3.8, step d). After cooling, the excess
iodomethane and solvent were evaporated using a rotary evaporator in a closed fume hood.
The crude methylated bis-phthalimide was purified by column chromatography to yield
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ammonium iodide 3.50 in 64% yield. Figure 3.24 shows the 1H NMR shift of the N-methyl
protons for –(R3)NCH3 at d 3.88 ppm.

–(R3)NCH3

Figure 3.24. Partial 1H NMR spectrum of 3.50 (in CDCl3, 400 MHz).

Two lipids were prepared, OEL4 and OEL5 (Scheme 3.8) with varying chain
lengths (C14, and C18) by reaction of bis(aminooxy) compound generated in Scheme 3.8
(step e.i.) via hydrazinolysis. The bis(aminooxy) was immediately reacted with 2
equivalents of tetradecylaldehyde or oleyl aldehyde (Scheme 3.8, Step e.ii), prepared from
tetradecanol or oleyl alcohol by Swern oxidation,362 to form the bis(oxime) ether adducts
(3.51 and 3.52, Scheme 3.13). The bis(oxime) ether adducts (3.51 and 3.52) were formed
as mixtures of E,E, and E,Z isomers and were used without further isolating them as
separate diastereomers. The dissymmetry provided by incorporation of the (E,Z)containing lipid fraction likely will contribute to the formation of more fluid lipid bilayers
as it prevents tight lipid packing. The crude bis(oxime) ether products were purified by
silica column chromatography, eluting with a 9:1 mixture of CH2Cl2:CH3OH, to afford
3.51. The acetal 3.51 was dissolved in a 1:1 mixture of THF:hexane and hydrolyzed in 5%
aq. AcOH (Scheme 3.8, Step f). After removing the excess reaction solvent, the crude
product was dried under vacuum for 30 minutes and carefully neutralized by dropwise
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addition of saturated aq. NaHCO3. After extracting the organic portion, the crude diol was
purified via column chromatography (SiO2, CH2Cl2:CH3OH, 9:1) to yield 3.15a. Acetal
3.52 was transformed in similar manner to afford 3.15b.
Table 3.1. Comparative analysis of common reactions
Starting Material
Gupta et al.
Scheme 3.6
Ibrahim et al.
Scheme 3.8

(HOCH2CH2)2NBoc
(5.01 g, 24.4 mmol)
(HOCH2CH2)2NH
(10.0 g, 95.1 mmol)

No. steps,
overall
yield (%)

Glycidol
Addition

ROH à
RONH2

41%
(step 6)
100%
(step 1)

16%
(steps 2, 3)
59%
(steps 3, 5i)

7 (3%)
7 (13%)

NbisMethylation Oximation
64%
(step 7)
64%
(step 4)

71%
(step 4)
87%
(step 5ii)

Figure 3.25 is depicts the 1H NMR of OEL4 (Top spectrum). The triplets for the oximyl
protons in E and Z configurations are shown downfield at around d 7.40 and 6.75 ppm,
respectively, in approximately 2:1 ratio (59% to 41 % respectively). The 1HNMR spectrum
shows similar shift compared to the literature spectrum (Bottom spectrum).286
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Figure 3.25. Stacked 1H NMR spectrum of 3.15a (in CDCl3, 500 MHz). Top: Spectra from
synthesis of OEL4. Bottom: literature spectrum.286
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3.10. Synthesis of 2,3-dihydroxy-N-methyl-N,N-bis(2(tetradecanoyloxy)ethyl)propan-1-aminium (DMDEG)
The linker orientation has recently been shown to have dramatic effect on the
transfection properties of the lipid.363 To ascertain the effect of oxime ether linkage on the
transfection activity of OEL4, a structurally analogous lipid DMDEG, was synthesized
(Scheme 3.9). DMDEG differs from OEL4 by the presence of an ester linkage instead of
the oxime ether linkage that characterizes OEL4 (Figure 3.26).
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Figure 3.26. Structural comparison of OEL4, DMDEG and DC-6-14.

An analogous lipid to DMDEG, DC-6-14 (Figure 3.26) has been developed by Kikuchi
et al.364 and shown to be a lead cationic lipid among series of quaternary ammonium lipids,
for delivering pDNA to human peritoneal disseminated tumors both in vitro and in vivo.364
Both DMDEG and DC-6-14 (Figure 3.26) have same carbon backbone except that
DMDEG has hydroxyl groups in the polar region. A vitamin A-coupled DC-6-14 LNPs
has also been reported to deliver of gp46 siRNA in rats for effective treatment of liver
fibrosis and prolonged survival time by targeting hepatic stellate cells.365
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The synthesis of DMDEG followed the first 3 steps of the modified OEL route in
Scheme 3.8 after which 2 equivalents of myristoyl chloride were added to the bis(ethanol)
adduct (Scheme 3.14).
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DMDEG 3.54

OR

3.53: R = C(O)(CH2)12CH3

Scheme 3.9. Synthesis of DMDEG. Conditions: a. Myristoyl chloride (2.2 eq), DMAP
(5 mol%), Et3N (2.2 eq), CH2Cl2, 0 °C to rt, 12h (78 %); b. CH3I, CH2Cl2, (sealed tube),
50 °C, 8 h (89 %); c. 5 % TFA/H2O, CH2Cl2, 0 °C to rt, 36 h (71 %).

The acetal alcohol 3.48 (Scheme 3.8) was esterified by addition of myristoyl chloride (2.2
eq) in the presence of DMAP (5 mol%) and Et3N (2.2 eq). The generated byproduct
(Et3N×HCl) was filtered and the crude diester purified by silica column chromatography
using 10 % EtOAc in hexane. The diester then was N-methylated as previously described
and again purified by silica column chromatography to afford ammonium iodide 3.53
(Scheme 3.9) in 69% yield from 3.48 (2 steps). Acetal 3.53 was dissolved in CH2Cl2 and
hydrolyzed using 5% aq. TFA (Scheme 3.9, step c). The crude diol was purified as
previously described for OEL4 and OEL5 to afford DMDEG (3.54) (Scheme 3.9 and
Figure 3.26) in 71 %. A representative HRMS spectrum for DMDEG is depicted in Figure
3.27.
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O
Exact Mass: 614.54

Figure 3.27. HRMS spectrum of the observed mass of DMDEG 3.54 (top) and the
theoretical mass (bottom).
The characteristic 1H NMR downfield shift of the methylene protons for the –CH2OC(O)R
at d 4.55 ppm integrates to 4H confirming that 3.54 was successfully synthesized and that
the esters are equivalent (Figure 3.28).
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Figure 3.28. 1H NMR spectrum of DMDEG (in CDCl3, 500 MHz).

To further confirm the formation of DMDEG 3.54, Figure 3.29 depicts the FTIR spectrum
of DMDEG showing a characteristic hydroxy group around 3331 cm-1.

Figure 3.29. FTIR spectrum of DMDEG 3.54 (in CH2Cl2).
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3.11. Conclusions
Since the first clinical trial studies by Davis and coworkers,366 RNAi formulations
have emerged as promising therapeutic agents. However, one factor militating against the
success of a clinically suitable RNAi agent is the development of a suitable delivery
agent.367 Since lipid-based DNA/siRNA delivery is largely dependent on the positive
charge of the lipid, it is evident that cationic lipids with easily accessible chemical synthesis
routes, desired biodegradability, and the ability to complex with nucleic acids may be a
means to achieving success in RNAi-based therapies.131
It is evident from the literature that aminooxy chemistry is useful for attaching
complex moieties, so using this technology for lipid assembly makes sense, especially if it
improves the toxicity profile and activity profile of the resultant lipids. These appealing
properties of the aminooxy group and the oximation reaction serve as a springboard for us
to further pursue its development and other applications. As indicated earlier, OELs have
been previously used as transfection agents to deliver siRNA in cell culture experiments
and were shown to be efficient transfection agents. Oxime ether-based cationic lipids also
have been established as promising candidates for nonviral nucleic acid delivery in serum
conditions.286 The release properties of OELs have been shown to be greatly influenced by
polar domain hydroxylation, where hydroxylated lipids OEL4 and OEL5 outperformed
their nonhydroxylated counterparts regarding nucleic acid release upon cellular
internalization, as indicated by GFP silencing.286 Although Nantz et al. reported that tight
lipid complexation with nucleic acids is desirable for protection against enzymatic
degradation, the interactions between the nucleic acid phosphate and lipid ammonium368
in concert with hydrophobic domain packing and any polar domain hydrogen bonding
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interactions must be readily overcome at a later stage for lipoplex disassembly to occur. In
light of the above, the OELs appear well positioned for effective siRNA protection and
release. These promising results inspired us to pursue the development of OELs as a key
feature in our research.
Our goal here was to develop a new synthesis route for the cationic hydroxylated
OELs 4 and 5 (compounds 3.15a and 3.15b, respectively) and an ester analogue
counterpart to examine the structure–function relationship in vivo. OELs were successfully
synthesized on a larger scale via a new synthesis described in Scheme 3.8. After installing
and protecting the 1,2-diol functionality through acetalization of 3.47 (Scheme 3.8, Steps
a and b), we carried out the Mitsunobu reaction on 3.48 to generate 3.49 (Scheme 3.8,
Steps c) via the modified synthesis route presented in Scheme 3.8. The modified route
circumvented the competing process encountered in the initial synthesis (Scheme 3.6, Step
a), as illustrated in Step a’, Scheme 3.7, where the introduction of a side product
complicated the purification process of the Mitsunobu product. Starting with 10 g of the
cyclohexanone acetal 3.48, we successfully prepared the bis-phthalimide 3.49 in good
yield. However, particular attention is required in the purification process to remove the
byproducts phosphine oxide and hydrazine dicarboxylate. The purification procedure
previously described under section 3.9 and under experimental section must be strictly and
cautiously adhered to. Another step that deserves some attention is the hydrazinolysis step
(Scheme 3.8, step e.i). The reaction of bis(aminooxy) 3.50b with tetradecylaldehyde or
oleyl aldehyde (Scheme 3.8, step e.ii), must be immediate to avoid the bis(aminooxy)
reacting with residual carbonyl compounds in the air. The aminooxy group is very reactive
and if not immediately used, the bis(aminooxy) product could easily react with residual
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carbonyl in the air derailing the oximation reaction. It is however stable under inert
atmosphere conditions. Overall, the yield from the new synthesis route was significantly
improved from 3% (Scheme 3.8) to 13% (Scheme 3.8) as depicted in Table 3.1.
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CHAPTER 4

OEL-MEDIATED IN VITRO AND IN VIVO RNA DELIVERY STUDIES

4.1. Introduction
RNAi therapeutics for cancer treatment is a reasonably formidable protocol to
develop.369 Although there are promising delivery prospects for small molecule drug
formulations in the field of cancer nanomedicine, further advancements are needed for
polynucleotide delivery. The development of suitable stealth nanoparticles over several
decades370-372 has culminated into a method for successfully evading the mononuclear
phagocytic system (MPS, also known as the reticuloendothelial system (RES)) upon
intravenous injections.373,374

Stealth nanoparticles (Figure 4.1) are PEGylated

nanoparticles that elude the RES better than ‘naked’ unfunctionalized nanoparticles.
Poly(ethylene glycol) (PEG) was first introduced in the early ’90s375 to modify the surface
of liposomes for improved pharmacokinetics (PK) after intravenous (i.v.) administration.
PEGylation technology has been widely used since then to improve the PK of a variety of
nanoparticles. The introduction of this hydrophilic and inert polymer introduces a steric
impediment to the surface of nanoparticles and abates their protein binding (also termed
opsonization).
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The mechanism for the RES to recognize the circulating nanoparticles is dependent on the
binding of plasma proteins and this causes a major loss of the injected dose (ID) (>50%)
within a few hours after i.v. injection.375 Opsonized nanoparticles are recognized by
macrophages, such as the Kupffer cells in the liver, via the scavenger receptor. Liver,
spleen and bone marrow are the major RES organs for nanoparticle clearance.
Specifically, stealth properties (Figure 4.1B) of nanoparticles (NPs) also acquiesce
with anticipated plasma stability and longer blood circulation.376-379 Polyethylene glycol
polymer (PEG) is the most studied surface-modifying molecul382 added to lipid
nanoparticles, such as liposomes, either via a lipid anchor (Figure 4.1A)380 or as a coat in
pre-assembled nanoparticles (Figure 4.1B). The first approach (lipid anchor) involves the
mixing of two phases: 1. organic phase containing the lipid, helper phospholipid, and lipidanchored PEG; 2. an acidic aqueous phase containing the nucleic acid, in a microfluidic
channel,380 resulting in the formation of nucleic acid-loaded LNPs. An example of the first
approach was demonstrated by Kauffman et al.380 where they developed a generalized

strategy for lipid nanoparticle formulations for in vivo delivery of mRNA to the liver.
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A.

B.
Stealth liposome benefits
more stable;
evades MPS;
lowers toxicity;
extend blood circulation time;
decreased clearance;
decreased immunogenicity

+

Liposome

DSPE-PEG
Stealth liposome

Figure 4.1. Formulation of PEGylated lipid nanoparticles A. PEG as a lipid anchor; B.
PEG as a coat in pre-assembled nanoparticles. Figure A used with permission from
Kauffman, K. J.; Dorkin, J. R.; Yang, J. H.; Heartlein, M. W.; DeRosa, F.; Mir, F. F.;
Fenton, O. S.; Anderson, D. G. Nano Lett. 2015, 15, 7300−7306.
The second approach (coat pre-assembled nanoparticles), however, involves the premixing of the lipid (including DOPE) and PEG to generate the stealth liposome before
complexing the stealth liposome with the nucleic acid to form the lipoplex (i.e., nucleic
acid-lipid nanoparticle).
For targeted applications to tumor tissue and reduced accumulation in the liver and
other organs associated with the MPS, the biophysical features of a delivery vehicle and its
components need to be strategically designed.381, 382 Upon intravenous injections, RNAi
therapeutics often encounter a number of barriers, such as uncontrolled aggregation of the
RNA lipoplex formulations by blood proteins/components, RNA degradation, limited
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endosomal escape following cellular internalization, and off-target effects.383,384 As
discussed in the previous Chapter, we have designed cationic oxime ether lipids (OELs)
with the principal purpose of systemic (ex-hepatic) delivery of siRNAs. Although the
oxime ether linkages are well established in some approved pharmaceuticals, like
fluvoxamine,131 their application as linkers in transfection lipids is relatively new.385 Based
on our previous studies, we envisage that OELs are not likely to exhibit any long term in
vivo toxicity.
Previous studies by Gupta et al. show that gene silencing activity of OELs is
modulated by structural modifications at both the polar headgroup region as well as in the
hydrophobic region. Gupta et al. demonstrated that introduction of hydroxyl groups at the
polar headgroup region of OELs resulted in clearly superior biological function.286
This Chapter presents the research that we performed to examine the in vivo
suitability of hydroxylated OELs to deliver functional siRNA to tumor-bearing mice. To
determine any advantage that the oxime ether linkages of OEL may confer, the structurally
analogous lipid DMDEG, which contains carbonyl ester linkages instead of oxime ether
linkages, was used for comparison (Figure 3.26).
All animal studies and experiments were conducted by our collaborators, Dr. Xiuling Lu
and her graduate student, André O'Reilly Beringhs, at the School of Pharmacy, University
of Connecticut, Storrs, CT. The initial attempts to deliver native OEL4:DOPE:RNA
formulations to tumors in mice xenographs were unsuccessful. OEL4 vesicles were
prepared using trace amounts of the fluorescent lipid DiR (Figure 4.2) for mouse imaging.
Tissue biodistribution of OEL4-derived RNA lipoplexes (RNA-NPs) in human lung cancer
tumor (A549) bearing mice xenographs was first examined. Animals were intravenously
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injected with RNA-NPs and images were collected. Data on various tissues after 24 and
48-hr post injections is shown in Figure 4.3.
H 3C

H 3C
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(CH=CH)3–– CH2
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(CH2)17
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Figure 4.2. 1,1'-Dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide.

Regrettably, no DiR signals were detected above background levels in tumors,
indicating no accumulation of the RNA-NPs in tumors (Figure 4.3i, ii). We noted that
there was significant accumulation of the RNA-NPs in lungs in addition to liver and spleen.
The lack of tumor accumulation can be speculated to be the result of aggregation of the
cationic RNA-NPs in blood plasma (Figure 4.4).283,386-389 Aggregation by blood plasma
components appears to cause significant accumulation in lungs.
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(i)

(iii)

(ii)

(iv)

Ex vivo DiR imaging
Figure 4.3. Tissue biodistribution of RNA-NPs in human lung cancer tumor (A549)
studies by DiR imaging. OEL-zero = OEL4:DOPE (no PEG added) OEL-GSL=
OEL4:DOPE:glycosphingolipids. Organs were harvested 24h and 48h post iv injection.
Scale: The closer to red the color, the higher the radiance, which indicates higher
concentrations of the RNA-NPs as a function of the fluorophore. The closer it is to blue,
the lower the concentration of the RNA-NPs.
When included in similarly formulated phospholipid vesicles, sialic acidcontaining sphingolipids imparted an overall negative charge, enhanced hydrophilicity and
relative tissue biodistribution.390 In this case, the glycosphingolipids presumably altered
the surface properties of the vesicles and most likely prevented and/or decreased vesicle
aggregation in the presence of plasma proteins. Therefore, we added human erythrocyte
glycolipids extracts at 10 mol% to the OEL4 vesicles with an aim to similarly modulate
surface properties to increase accumulation in tumors. This modification did not lead to
any accumulation in tumors either (Figure 4.3iii, iv). Consequently, we redirected our
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attention to the classical PEGylated phospholipids as stealth components of the OEL4
vesicles. The results are described in subsequent section below.

Blood plasma protein
In blood
circulation

Lipid nanoparticle

Aggregates

Figure 4.4. Aggregation of cationic nanoparticles in blood plasma.

To address the blood plasma aggregation hurdle, we initially modified the
OEL4:DOPE liposomal formulation with a commonly used PEG lipid, DSPE-PEG2000
(Figure 4.5). Specifically, we added 1 and 5 mol% of DSPE-PEG2000 to OEL4:DOPE
formulations (Table 4.1) to create corresponding stealth liposomes.
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Figure 4.5. Representative structure of 1,2-distearoyl-sn-glycero-3-phosphoethanolamineN [amino(polyethylene glycol)-2000] ammonium salt (DSPE-PEG2000).
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TABLE 4.1. Compositions of OEL4 formulations used in this study.
Lipid Mole Ratiosb

Formulation
PEGylated Lipid
a

Description

OEL4:DOPE:PEGylated lipid

OEL-350(1)

49.5:49.5:1

OEL-350(3)

18:0 PEG350 PE

48.5:48.5:3

OEL-350(5)

47.5:47.5:5

OEL-1000(1)

49.5:49.5:1

OEL-1000(3)

48.5:48.5:3
18:0 PEG1000 PE

OEL-1000(5)

47.5:47.5:5

OEL-2000(1)

49.5:49.5:1
18:0 PEG2000 PE

OEL-2000(5)

47.5:47.5:5

a

Values in parentheses indicate mol% of the PEG lipid used in the formulation; b all
formulations included equimolar amounts of DOPE and OEL4.
The DSPE-PEG2000-modified liposomes, however, occasioned a complete
inhibition of gene silencing in cell culture assays. The inhibition of gene silencing by the
DSPE-PEG2000-modified OEL4:DOPE liposomes can be attributed to ineffective
association of the PEGylated liposomes with the DsiRNA duplexes (Figure 4.6) based on

gel-shift assays. A gel-shift assay, also known as an electrophoretic mobility shift assay
(EMSA), is a rapid and sensitive method to detect protein-nucleic acid interactions.391 It is
based on the observation that the electrophoretic mobility of a protein-nucleic acid complex
is typically less than that of the free nucleic acid.
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(a widely used stealth
lipid molecule)
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RNA duplex

PEGylated lipid headgroup

PEG2000 does not associates with DsiRNA duplexes

Figure 4.6. DSPE-PEG2000 lipid as a surface-modifier.

We next examined the relatively low molecular weight PEG lipids DSPE-PEG1000
and DSPE-PEG350 as modifiers for OEL4:DOPE liposomes (Figure 4.7). Unlike DSPEPEG2000, the lower molecular weight PEG lipids did not appear to block the crucial
interactions (e.g., packing) with RNA, which resulted in observable gene silencing activity.
Table 4.1 depicts compositions of the low MW PEG-modified OEL4:DOPE formulations
used in our studies.
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Figure 4.7. DSPE-PEG1000 and DSPE-PEG350 lipid as surface-modifiers.
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4.2. Properties of PEGylated OEL4:DOPE liposomes
Stealth-modified OEL vesicles were prepared by adding PEGylated lipids to the
OEL4:DOPE lipid mixtures at 1, 3 or 5 mol%. The average vesicle sizes ranged between
90-100 nm in diameter (Table 4.2). These vesicles readily formed stable complexes (RNA
lipoplexes) when incubated with the nucleic acid duplexes with a size range of 140-170
nm in diameter (Table 4.2). Interestingly, inclusion of DSPE-PEG350 in the vesicles did
not have any significant effect on the zeta potential (~34 mV), whereas inclusion of DSPEPEG1000 at high mole ratios (5 mol%) decreased the average zeta potential from 33 to 22
mV. Similar trends were observed in the zeta potential of the respective nucleic acid-NPs
(Table 4.2).
Table 4.2. Effect of RNAcomplexation on hydrodynamic size and zeta potential of lipid
vesicles
Hydrodynamic Size

Zeta Potential (mV)

Liposome
Formulation

Liposome/RNAa
Liposome

Liposome/RNA
Liposome

Complex

Complex

OEL-350(1)b

139.6

170.7

32.8

29.8

OEL-350(3)

89.07

177.2

34.7

29.4

OEL-1000(1)

92.24

151.3

31.8

19.1

OEL-1000(3)

72.41

147.8

22.2

19.4

a

10 µM DsiRNA (2 uL) was complexed with 120 µL of a given liposome formulation (1 mg/mL); b
values in parentheses indicate mol% of the PEG lipid used in the formulation. All formulations included
equimolar amounts of DOPE and OEL4.
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4.3. Preparation of lipid films and liposomes
Stock solutions of OEL4:DOPE with or without PEG lipid were prepared at 10
mg/mL in CHCl3 and stored at –20 °C in crimped vials until use. Liposomes were prepared
at either 1 or 10 mg/mL total lipid in nuclease free water by probe sonication.388 Lipid films
were prepared under a stream of nitrogen in a glass tubes, and were kept overnight in
desiccator. The films were hydrated with 1 mL of enzyme free water under vortex mixing,
subjected to freeze/thaw cycles and then were probe sonicated for 10 minutes on ice bath
with 1 min cycle of sonication and 1 min rest (Figure 4.8). The resulting PEGylated
OEL4:DOPE or OEL4:DOPE liposomes were characterized (TABLE 4.1) and stored at 4
°C until subsequent use.

evaporation of solvent
(chloroform) under of N2
stream while carefully
rotating the test tube to
form a thin film

lipid solution
in CHCl3 in a
glass tube

place the dry lipid in
descicator for 16-24 h
to dry excess CHCl3

lipid film

dry lipid
film

desiccator

vortex
T = 55 oC
sonication

transfer to
plastic tube

T = -80 oC
freeze-thaw
multi-lamellar
cycle
liposomes
(MLV)

sonicated
liposomes
probe sonicator

Figure 4.8. Procedure for preparation of lipid films and liposomes.
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hydrate lipid film
in nuclease-free
ultra pure water

4.3.1. Liposome size and zeta-potential measurements
The liposomes were analyzed for their hydrodynamic size and zeta potential before
and after complexation with DsiRNA duplexes (Zeta Sizer Nano ZS, Malvern Instruments,
MA) (Table 4.2). For size analysis, 5-10 µg lipid vesicle alone or lipid-complexed
DsiRNA duplexes were diluted in 0.4 mL HBS (pH 7.4) and samples were run in triplicate
in an automatic mode at 25 °C equipped with a 633 nm laser and a back-scattering detector.
Hydrodynamic size of the samples was measured using the Stokes-Einstein equation.
The zeta potential of vesicles and vesicle-complexed DsiRNA were measured by
diluting the samples in 10 mM NaCl. Using the zeta-cuvettes and a total volume of 1 mL,
the values were calculated from the electrophoretic mobility using Smoluchowski
approximation.

4.4

Preparation of RNA-lipid liposome complexes (RNA-LNPs)

4.4.1. Optimization of liposome/nucleic acid binding ratios
To determine the optimal ratios of lipid liposome and RNA duplexes and to ensure
complete complexation of the RNA, a gel-based assay was performed as previously
reported.287 Various concentrations of liposomes (ranging from 0-2.5 µg lipid) were
prepared in RNase/DNase free water. The samples were placed on a parafilm surface as
droplets and mixed with the Alexa546-labled DNA/RNA duplexes (25 ng per sample).
Subsequently, 3 µL glycerol carrier was added to the droplets and the volume of each
sample was raised to 20 µL. Incubations were carried out for 20-30 minutes and samples
were loaded on a 2% agarose gel, using free Alexa546 DNA/RNA duplexes as the standard.
The gel was run in TBE buffer (89 mM Tris, 89mM boric acid, 2 mM EDTA, pH 8.2) for
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20 minutes at 120 V. Nucleic acid mobility was detected by image analysis using the
Typhoon Trio variable mode imager (GE Healthcare, using a band-pass filter set of Ex/Em
532/580 nm) (Figure 4.9).
Gupta et al. reported that OELs are promising candidates to deliver RNA to cells.286
Since the chemical structure of OELs primarily differs from other reported transfection
lipid molecules in the linker region, we aimed to determine the significance of the oxime
ether linkages in these lipids with respect to polynucleotide delivery activity. To do so, we
replaced the oxime ether bonds of OEL4 with classical carbonyl ester bonds while keeping

OEL-Zero

OEL-350

OEL-1000

OEL-2000
Std RNA

25

50

100

125

250

500

750

1000

2500

Std RNA

Liposome concentration (ng)

RNA duplexes used per sample = 25 ng; 2 % agarose gel

Figure 4.9. Relative binding efficiencies of various OEL liposomes to
Alexa546-labeled RNA duplexes. All OEL liposomes show similar dosedependence as the non-PEGylated OEL liposome (OEL-Zero) with
complete binding of RNA duplexes at 500 ng liposome concentration
(indicated by blue box).
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the polar and hydrophobic domains identical. These changes led to the cationic lipid
DMDEG (Figure 3.26). DMDEG liposomes were prepared and characterized (Table 4.3).
The size, RNA binding and gene silencing activity of DMDEG-derived vesicles were
compared with OEL4 vesicles in paired experiments. Data presented in Figure 4.10 shows
that DMDEG and OEL4 vesicles show similar size distribution (DLS analysis, Figure 4.10
top panel).
Table 4.3. Effect of RNA on size and zeta potential of DMDEG-derived liposomes.
Hydrodynamic Size
Zeta Potential (+mV)
Liposome

(diameter, nm)

Formulation

liposome-RNA a
Liposome

liposomes-RNA
Liposome

complex

Complex

DMDEG-zero b

82.34

133.2

55.4

54.8

DMDEG-350(1) c

112.5

129.2

42.9

45.6

DMDEG-1000(1)

94.08

105.0

40.1

36.5

a

10 µM DsiRNA (2 uL) was complexed with 120 µL of a given liposome formulation (1 mg/mL); b
(DMDEG-zero = native DMDEG, No PEGylation; c values in parentheses indicate mol% of the PEG
lipid used in the formulation. All formulations included equimolar amounts of DOPE and DMDEG.

In addition, the extent of binding of the OEL4- and DMDEG-derived liposomes to
the RNA duplex appear to be similar, as assessed by the gel electrophoresis assay (Figure
4.11, bottom panel). Complete binding to RNA duplex was achieved with both lipids at a
ratio of 250 ng lipid/25 ng RNA. Therefore, substitution of ester bonds with oxime ether
bonds had no effect on liposome formation or subsequent association with an RNA duplex.
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Figure 4.10. Top: hydrodynamic size (diameter, nm) of OEL4 and DMDEG liposomes;
Bottom: agarose gel binding experiment showing binding of lipid to Alexa-546 labelled
RNA duplexes with varying lipid-RNA ratios showing binding to Alexa-546 labelled RNA
duplexes.

4.5. Gene silencing studies of OELs in cell cultures
After the physical characterization of the liposomes, we examined the gene
silencing activity of OEL4-anti-eGFP DsiRNA and DMDEG-anti-eGFP DsiRNA
lipoplexes (Figure 4.11). MDA-MB-231-eGFP cells were plated on 12-well plates at a
density of 30,000 cells/well in culture medium in Dulbecco’s modified Eagle’s medium
(DMEM) one day prior to the experiments. siRNA-LNPs were prepared (as described in
the Experimental section in Chapter 6) just prior to conducting the studies. The media was
removed, and 0.5 mL of corresponding siRNA-NPs in DMEM were added to the wells.
Incubations were continued for 4-6 hours at 37 °C before replacing the media with fresh
media (1 mL/well). The plate was incubated for additional 48-72 hours and eGFP silencing
was measured by FACS. Cells only (without binding to the siRNA LNPs) or cells incubated
with the lipofectamine bound DsiRNA were used as controls in our assays (Figure 4.11).
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First, we prepared OEL4:DOPE and DMDEG:DOPE DsiRNA lipoplexes for gene
silencing experiments and animal studies based on the optimal binding ratios established
in the gel-binding assay (Figure 4.10). Ratios of 5 nmol DsiRNA/µmol liposome lipid
were used for eGFP and luciferase gene silencing studies. For in vitro cell culture assays
and animal studies, lipid liposomes were prepared at 1 mg/mL and 10 mg/mL respectively.
OEL4-derived lipoplexes showed an efficient eGFP downregulation of 65%
whereas the DMDEG-derived lipoplexes resulted in only a 34% eGFP reduction (Figure
4.11). Whereas lipofectamine, a commonly used transfection agent that was used as a
reference lipid for comparison, showed 80% gene silencing, the lipofectamine-mediated
gene transfer was done in serum-free media per recommendations of the manufacturer,
whereas the OEL4 and DMDEG formulations were added to cells under serum-containing
media. The histogram (Figure 4.11, Top) shows mean fluorescence intensity (X-axis, log
fluorescence) for a given number of cells plotted on y-axis (gated to capture live cells). The
counts or cells within the gate can be further analyzed for silencing the gene. The peak on
the histogram for the control cells fall within 105–106 mean fluorescence intensity (x-axis,
log fluorescence). Any relative shift in fluorescence peak to the left of the given window
(105–106 mean fluorescence intensity) indicates silencing of the gene. About 65% of the
peak on the histogram derived from OEL4-DsiRNA lipoplex as against 34% from the
DMDEG-derived lipoplex fall outside the gated region, indicating the relative eGFP
downregulations.

Given that the principal structural difference between OEL4 and

DMDEG is the linker region, the results presented in Figure 4.11 demonstrate that
replacement of ester linkages with oxime ether linkages led to a more efficacious
transfection agent.
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OEL4 (65%)

DMDEG (34%)

L2K (80%)

eGFP fluorescence

eGFP Fluorescence
(arbitrary units)

250,000.00
200,000.00
150,000.00
100,000.00
50,000.00
0.00
Control cells

OEL4 (0)
DMDEG (0)
Liposomes

L2K

Figure 4.11. Comparison of gene silencing of OEL4(0)- and DMDEG(0)DsiRNA. Top: Fluorescent-activated cell sorting analysis of OEL4(0)- and
DMDEG(0)-DsiRNA. Data show mean fluorescence intensity (x-axis, log
fluorescence) for a given number of events plotted on y-axis (representing
live cells). Bottom: Bar graph showing the silencing activity of GFP gene
mediated by OEL4 and DMEG DsiRNA complexes. eGFP fluorescence in
cells (mean fluorescence intensity, MFI) is plotted at % of control cells.
4.6. PEGylated OEL liposomes promote efficient gene silencing in cells
After establishing the appropriate PEG lipid to include in the OEL liposome
formulations, we subsequently examined the gene silencing efficiency of OEL-complexed
DsiRNAs. eGFP-expressing breast cancer cells (MDA-MB-231-eGFP) monitored eGFP
down regulation by FACS post 48- or 72- hours at 37 oC was initially used. The results
presented in Figure 4.12 shows mean fluorescence intensity (MFI) of eGFP in the cells
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(gated to capture live cells) for various formulations tested. Percent eGFP downregulation
are listed above the respective bars in the graph in reference to the MFI of eGFP in
untreated control cells.

350000

eGFP Fluorescence
(arbitrary units)

300000
250000
37.50%

200000
55.41%

150000
70.0%

100000
81.53%

79.92%

81.53%

50000
0
CTRL CELLS

OEL4:PEG350(0)

OEL4:PEG350(1)

OEL4:PEG350(3)

OEL4:PEG350(5) OEL4:PEG1000(1) OEL4:PEG1000(3)

Liposomes

Figure 4.12. Efficiency of GFP gene silencing in MDA-MB231-GFP cells by PEGylated
oxime ether liposomes/anti-eGFP DsiRNA duplexes. Values in parentheses indicate mol%
of the corresponding PEG lipid used. All formulations included an equimolar amount of
DOPE relative to OEL. The data are presented as mean fluorescence intensity of GFP.
These results demonstrated that the OEL-350 formulations serve as suitable
candidates for animal studies.

PEGylated OEL formualtions also efficiently down-

regulated luciferase gene in A549-luc2 cells (Figure 4.13). These cells express luciferase
gene and were used for tumor implantation. Cells were plated on 96-well clusters and
incubated with various complexes (in quadruplicate). The luciferase expression was
measured after 48-72 hours at 37 °C and the data is presented in Figure 4.13. Anti-eGFP
DisRNA duplexes were used to determine non-specific effects by the DsiRNA, whereas
lipofectamine-2000 was used as positive control for luciferase down-regulaiton. Data
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clearly show that all OEL formulations tested down-regulated luciferase in these cells with
high efficiency.

4.7. Luciferase gene down-regulation by PEGlyated OELs in cell cultures
Before assessing the efficiency of PEGylated OELs in tumor-bearing mice, we
confirmed that our formualtions efficiently down-regulated luciferase gene in A549-luc2
cells. These cells constitutively express luciferase gene and were used for tumor
implantation (data below). A549-luc2 cells were plated on 96-well plate at a density of
5x103 per well one day prior to transfections. Typically, 3 µL vesicles (10 mg/mL) were
incubated with 2 µL anti-luc DsiRNA duplexes (10 µM) for 30 minutes at room
temperature and the samples were diluted to a final concentration of 10 nM in culture
medium. The media were removed from the wells and the various diluted complexes (50
µL per well) were added to the wells in quadruplicate and then incubated for 48-72 hours
at 37 oC. Control wells contained media only or scrambled DsiRNA duplexes. Luciferase
expression was assayed post 48- and 72-hours incubations using the luciferase assay kit
(Promega) in a luminometer. The data is presentated in Figure 4.13, showing
chemiluminesce for various formulations. Anti-eGFP DisRNA duplexes were used to
determine non-specific effects by the DsiRNA, whereas lipofectamine was used as positive
control for luciferase down-regulaiton. The data clearly shows that all of the OEL
formulations that were tested down-regulated luciferase with high efficiency.
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Figure 4.13. Luciferase gene down-regulation in A549-luc2 cells by
PEGylated OEL4:DOPE formualtions. Values in parentheses indicate
mol% of the corresponding PEG lipid used. All formulations included an
equimolar amount of DOPE relative to OEL.
4.8. Cellular toxicity of OEL lipoplex
Cationic lipids exhibit cellular toxicity on their own due to their positive surface
charge.392 Therefore, we desired to determine the effect of PEGylated OEL-complexed
DsiRNAs on their non-specific cellular viability. Various formulations were incubated
with anti-luciferase DsiRNA (anti-luc) duplexes and the resulting lipoplex were added to
human lung cancer cells (A549). The cytotoxicity of OEL4 was studied with OEL4/antiluc DsiRNA complexes. The A549 cells were plated on 96-well clusters 3x103 per well,
one day prior to the assays and incubated at 37 oC overnight. The OEL/anti-luc DsiRNA
complexes were diluted in DMEM at various concentrations ranging from 0-100 µM lipid
liposome. Samples were added to the cells (0.1 ml per well in triplicate) and incubated for
48 hours at 37 °C. The cell viability was determined using the cell titer blue assay
(Promega) according to manufacturer’s instructions using a fluorescent ELISA plate reader
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(Spectra MAX, Molecular Devices, Sunnyvale, CA). All OEL formulations tested did not
show any non-specific cellular toxicity (Figure 4.14). However, we noted that there was
an enhancement of cellular viability above control cells (no liposomes added) at low doses
of the liposomes. This effect is probably due to an effect on signaling pathways.393, 394
20000
Fluorescence (Ex/Em 560/590 nm)
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Liposome concentration
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12000
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control

2000
0
OEL4:PEG350 (1)

OEL4:PEG350 (3)

OEL:PEG350 (5)

OEL4:PEG1000 (1)

Lipoplex formulation

Figure 4.14. Dose-dependent cytotoxicity of PEGylated OELs complexed with anti-luc
DsiRNA duplexes. OEL-RNA-NPs do not show Non-specific Cellular Toxicity.A549 cells
plated on 96-well clusters were incubated with various preparation of OEL-RNA-NPs as
indicated in triplicate for 48 hours at 37oC. Cell viability was determined by measuring
fluorescence at 560/590 nm (Methods). The values are expressed as an average for three
well form a single experiment.
4.9. PEGylation modulates OEL-DsiRNA complexation
To monitor the effect of liposome PEGylation on the extent of binding with RNA,
we examined association of known concentrations of Alexa-546-labeled RNA duplexes
with various amounts of PEGylated OEL liposomes. The binding was monitored on 2%
agarose gels. Results are shown in Figure 4.15. All OEL-350 formulations showed similar
dose-dependence as the non-PEGylated OEL liposomes with complete binding of RNA
duplexes at 125 ng lipid (indicated by red arrows, Figure 4.15). OEL-1000(1) also showed
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similar biding pattern. In contrast, complete binding of the RNA duplexes with OEL1000(5) and OEL-2000 (both 1 & 5 mol%) required at least 2x concentrations of the vesicle
lipid (250 ng, indicated by arrow). Based on these observations, we investigated OEL350(1), OEL-350(3), OEL-350(5) and OEL-1000(1) for their gene silencing activity in
cell culture assays and subsequently for their in vivo effectiveness in the A549 tumors.
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Figure 4.15. Relative binding efficiency of various OEL liposomes to Alexa546-labeled
RNA Duplexes. The Alexa-546-labeled RNA duplexes/liposome mixture were incubated
for 30 minutes. Various concentrations of OEL vesicles were incubated with 25 ng
Alexa546-labeled RNA duplexes and samples were analyzed by agarose gel
electrophoresis. Gels were scanned for fluorescence using the filter set at Ex/Em 532/580
nm. Red arrows indicate lipid concentration where binding of the RNA duplexes with
liposomes was observed.
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4.10.

Degree of PEGylation in the lipid molecules modulates biophysical properties
of OEL liposomes and their gene silencing activity
After unsuccessful tumor uptake in mice bearing human lung cancer A549 tumors

using a OEL4:DOPE formulation, PEGylated OEL4:DOPE formulation was employed to
accomplish the task. PEGylated lipids have been successfully used as components of the
lipid-based formulations and a number of drug-loaded formulations are currently in clinical
use for patient care (recently reviewed by Zhang et al.).395 PEGylated lipids provide stealth
characteristics by providing hydrophilicity and enhance stability in plasma. Since the OEL
formulations in their native configuration could not deliver RNA to the tumors, we
modified the surface properties of our designed OEL vesicles by addition of PEG lipids.
We first tried incorporation of DSPE-PEG2000, one of the most used PEG lipids in
drug-delivery nanomedicines with a hydrophobic domain comprised of C18/C18 saturated
chains and a hydrophilic domain with ~45 PEG units, into OEL4 vesicles at a molar ratio
of 1-5 mol% of the total lipid (Table 4.1). Although the resulting vesicles, labeled as OEL2000(1) to indicate 1 mol% PEG lipid incorporation and OEL-2000(5) for 5 mol% PEG
lipid incorporation, showed a relatively suitable size distribution by DLS analysis, their
association with RNA duplexes was decreased as compared to OEL vesicles (Figure 4.15).
In addition, OEL-2000 with both 1 mol% and 5 mol% PEG lipid did not show significant
eGFP downregulation (data not shown). We attributed this limitation of OEL-2000 to
weaker binding to the RNA due to the masking of the small polar head group by the PEG
polymer (Figure 4.7). It is also possible that inefficient intracellular uncoating may have
limited timely RNA location into the cytoplasm.
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To expediate adequate association with the RNA duplexes as well as regulated RNA
release for efficient RNAi and gene down-regulation as desired, we assessed two other
PEGylated phospholipids with lower number of PEG molecules, namely DSPE-PEG350
(7 PEG units, 1 PEG unit = –OCH2CH2) and DSPE-PEG1000 (22 PEG units).

4.11.

Morphology studies of OEL liposomes and OEL-RNA NPs by cryo-electron
microscopy(Cryo-EM)
Cryo-electron microscopy (cryo-EM) has become the frontier for imaging the

biological samples in their native functional condition. In addition, it provides the
opportunity to directly visualize and measure the size of the particles and compare to the
results from other biophysical techniques, such dynamic light scattering (DLS) data from
a particle size analyzer. To assess the effect of inclusion of PEGylated lipids on OEL
vesicle morphology, various formulations (Table 4.1) were imaged by cryo-EM. The
cryoEM imaging was carried out by Mr. Kanai, T., Ms. Dillard, R., and Dr. de Val, N., at
the Centre for Molecular Microscopy, Frederich National Laboratory for Cancer Research,
Leidos

Biomedical

Research,

Inc.,

Frederick,

MD.

One of our lead formulations OEL-350(3) was also imaged after complexation with antiluc DsiRNA duplexes. The complexes were prepared as described in the experimental
section (Chapter 6) and used for cryo-EM experiments without delay. The liposome
samples possess an interesting feature (double lipid bilayer) when it was analyzed by cryoEM under liquid nitrogen conditions.396, 397 Furthermore, to understand the binding of the
PEGylated liposomes with DS siRNA, we prepared lipoplexes by mixing the OEL-derived
liposomes and DS siRNA in the ratio of 1.5 to 1, respectively, and then incubated the
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complex for 30 min at RT. Both liposome and corresponding DS siRNA lipoplexes were
used for cryo-EM experiments. The cryo-EM image of OEL4-350(3) liposomes shown in
Figure 4.16A indicated the formation of lipid bilayers common to liposome formulations.
Interestingly, the images of the DS siRNA lipoplexes (Figure 4.16B and C) collected in
cryo-EM experiments suggest that the RNA associates with the liposomes to give rise to a
different structural morphology than observed with the liposomes alone. The RNA
molecules appear to associate with the liposomes in an ordered manner at the liposome
surface along with producing an extended edge of the lipid bilayer in some cases.

Figure 4.16. A: Cryo-EM image of OEL4-350(3) liposomes; B and C:
Cryo-EM of the OEL-350(3) formulation complexed with anti-luc DsiRNA
duplex (taken at different spots). Cryo-EM images were collected at
18000X relative magnification using a Krios Titan microscope.
4.12

Animal studies
The in vivo experiments were conducted using either severe combined

immunodeficient (SCID) or athymic nude mice. Luciferase-expressing subcutaneous
tumor xenografts were established in mice using human epithelial lung carcinoma cells
transfected to express luciferase (A549-Luc2 cell line, CCL-185-LUC2TM, ATCC®)
following a modified implantation protocol as reported elsewhere.398 Cells were sterically
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cultured and injected into the mice’s right flank subcutaneous space at an implantation
density of 2x106 cells/mouse. The mice were monitored twice a week for weight changes
and tumor volume measurements. All procedures regarding tumor model, treatment and
imaging were conducted in accordance with pre-approved procedures by the University of
Connecticut’s Institutional Animal Care and Use Committee (IACUC).

4.12.1

In vivo DsiRNA-LNPs biodistribution
RNA-lipoplex biodistribution was investigated in A549-Luc2-bearing SCID

mice with tumor volumes averaging 1500 mm3 (n=3 per group). Briefly, animals were
anesthetized with 1.5% isoflurane under 2.0 L/min O2 flow and the right flank was
carefully shaved, exposing the skin surrounding the tumor tissue site. Lipoplexes (OEL350(1), OEL-350(3), OEL-350(5)) were immediately prepared prior to animal
administration by physically mixing the DiR-labeled (0.5 mol%) lipid nanoparticle
formulation with DsiRNA duplexes at a 1.5:1 volume ratio, followed by 30 min incubation
at room temperature. Animals were immobilized and 100 µL doses were administered
intravenously via tail vein. Animals were imaged using the In Vivo Imaging System
(IVIS®) SpectrumCT (PerkinElmer, USA) before and 1, 3, 6, 24 and 48 h post nanoparticle
administration. Optical imaging was conducted under anesthesia (1.5% isoflurane, 2.0
L/min O2) employing epi-illumination with excitation and emission filters set at 745 and
782 nm, respectively. At the end of the study, animals were sacrificed, and tissues
harvested for ex vivo imaging, which was conducted under the same imaging conditions
described in this section.
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4.12.2. Tumor accumulation in mice by PEGylated OELs
After demonstrating the effectiveness of PEGylated OELs for delivery of functional
DsiRNA in cell culture experiment (Figure 4.12), we redirected our attention to in vivo
studies with the OEL4 formulations. Lipoplexes were administered to tumor-bearing mice
and optical imaging was conducted in vivo to assess real-time tumor accumulation post
systemic administration of DiR’-labeled lipoplex formulations. Due to possible quenching
and fur interference, in vivo optical imaging was conducted for qualitative biodistribution
assessment of nanoparticles. At the end of the study, tissues were collected and imaged
separately to provide quantitative data of nanoparticle accumulation as a function of radiant
efficiency. Formulation selection for subsequent gene silencing studies was conducted
based on potential for selective accumulation in tumors. Figure 4.17A. displays
representative serial in vivo optical imaging data collected for animals treated with 3
distinct lipoplex formulations: OEL-350(1), OEL-350(3) and OEL-350(5). To facilitate the
visualization of lipoplex accumulation in tumor tissues by reducing fur-associated
interference, the fur around the tumor site was shaved. In vivo optical imaging displays
distinguishable biodistribution among formulations, showcasing two main features in the
whole-body fluorescence images: tumor on the right flank and liver/spleen in the proximal
end of the animals’ bodies. OEL-350(1) appears to thoroughly distribute systemically,
displaying the highest liver radiant efficiency as early as 1 h post lipoplex administration
and reducing over time (Figure 4.17A). For this formulation, tumor signal is detected at
the first time-point and remains fairly consistent throughout tracking. OEL-350(3) and
OEL-350(5) exhibited similar behavior, presenting slower kinetic accumulation into liver
and tumor tissues when compared with OEL-350(1) lipoplex (Figure 4.17A). To facilitate
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formulation selection for luciferase silencing studies, tissues were collected at the end of
the study (t = 48 h) and optical imaging was conducted to provide quantitative data,
supporting qualitative observations from the in vivo whole-body imaging data. Figure
4.17A displays total radiant efficiency values found for major tissues and tumors for
animals treated with lipoplexes (n=3).

A.

1h

Time post dosing
3h
6h
24 h

48 h

OEL-350 (5)

OEL-350 (3)

Total Radiant Efficiency [p/s] / [µW/cm2]

OEL-350 (1)

Before
dosing

OEL-zero
No PEGylation

PEGylated OEL
OEL-350 (1)

B.
Tumor
Tumor

Figure 4.17. A: Representative serial in vivo optical imaging of animals treated with
PEGylated OELs; B: comparison of lipoplex uptake in mice bearing human lung cancer
A549 tumors by OEL4-siRNA lipoplexes without (0) and with (1 mol %) PEGylation.
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For all formulations, heart and kidneys displayed negligible signal. Liver displayed the
highest lipoplex-associated fluorescence when compared with all other formulations, as
also evidenced by the whole-body imaging. High liver accumulation was expected due to
reticuloendothelial system uptake of particulates from blood circulation.399 Lung
accumulation was the highest for OEL-350(1) and lowest for OEL-350(5). Regarding
tumor accumulation, the overall highest radiant efficiency was found for tumors of animals
treated with OEL-350(3).
When comparing formulations with respect to their main sites of accumulation
(tumor, liver, spleen and lungs), the most promising formulation for selective tumor
accumulation would lead the highest ratio between radiant efficiency in tumor and other
tissues. Figure 4.18B shows the ratio in values of the aforementioned tissues for all
treatment groups as imaged ex vivo (n=3). Due to high liver accumulation, tumor/liver
ratios were low for all groups and did not show statistical differences (p>0.05) (Figure
4.18).
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B.
Ex vivo epifluorescence imaging (t = 48 h)
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Figure 4.18. Effect of PEGylation on tissue biodistribution and uptake. A: Total radiant
efficiency ex vivo quantification of tissues harvested from animals at the end of the
biodistribution study (t = 48 h, n=3). B: Ratio between total radiant efficiency values of
tumors and selected tissues imaged ex vivo (n=3). Statistical differences were determined
via two-way ANOVA and Tukey’s multiple comparisons test. ns = not significant.
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Tumor signals corresponded solely to 5.4 ± 2.4%, 15.1 ± 9.7% and 9.9 ± 8.5% of liver
signal for OEL-350 (1), OEL-350 (3) and OEL-350 (5), respectively. Regarding spleen
and lungs, OEL-350(1) displayed much lower signal ratios when compared to the two
other formulations (Figure 4.18); p<0.01), indicating its relative lack of selectivity with
respect to tumor accumulation. Tumor signals corresponded to 61.5 ± 29.4%, 159.7 ± 6.2%
and 155.9 ± 57.0% of spleen signal for OEL-350(1), OEL-350(3) and OEL-350(5),
respectively. Relative lung accumulation displayed similar trend, with tumor signals
corresponding to 27.4 ± 11.6%, 170.2 ± 9.1% and 181.3 ± 44.7% of lung signal for OEL350(1), OEL-350(3) and OEL-350(5), respectively. Based on the ex vivo data, OEL350(3) was the most promising lipoplex platform for tumor delivery as it presented the
highest tumor signal while showing relative selectivity with respect to other major sites of
accumulation.

4.13. In vivo luciferase gene silencing
For luciferase silencing studies, a selected formulation (OEL-350(3), chosen based
on the qualitative tumor accumulation performance) was administered intravenously to
A549-Luc2-bearing athymic nude mice under a multiple regimen assessment. Animals
were randomly sorted into two groups, one treated with two consecutive intravenous
administrations of lipoplex OEL-350(3) (at t = 0 and t = 24 h) and another one not treated
and monitored as luciferase activity control. Lipoplexes were immediately prepared prior
to animal administration by physically mixing the DiR’-labeled (0.5 mol%) OEL-350(3)
formulation with DsiRNA duplexes at a 1.5:1 volume ratio, followed by 30 min incubation
at room temperature. Animals were immobilized and 100 µL doses were administered

124

intravenously via tail vein. Dosing was conducted twice: at the beginning of the study (t=0)
and 24 h later (t=24 h). Bioluminescence imaging was conducted before, 24 h and 48 h
post administration of the first lipoplex dose. Briefly, animals were anesthetized (1.5%
isoflurane, 2.0 L/min O2) and received 500 µL of a 7.5 mg/mL D-luciferin (sodium salt)
solution, followed by a 25 – 30 min hold period prior to imaging to ensure luciferin
distribution and tumor exposure. Imaging was conducted in luminescent mode using the
IVIS® SpectrumCT (PerkinElmer, USA) pre-clinical imager under automatic exposure and
open emission filter. At the end of the study, animals were sacrificed, and tissues harvested
for ex vivo imaging, which was conducted under the same imaging conditions described in
the “In vivo nanoparticle biodistribution” section.
Bioluminescence imaging was conducted before, 24 and 48 h post the start of the
study and first dose administration. Prior to the beginning of the study, a luciferin kinetic
curve was determined using selected animals, indicating the optimal timing from luciferin
administration to imaging as 25 to 30 min to ensure consistent results. Figure 4.19A
displays representative images of animals assigned to either control or treatment groups.
Total fluxes were determined for each animal at the tumor site and relative flux changes
(flux at t=0 relative to flux at a later time-point) were calculated, as demonstrated in Figure
4.19B. In general, from the start of the experiment, animals in the control group displayed
steady increase in bioluminescence due to the natural progression and growth of the tumor
tissue. In contrast, animals treated with OEL-350(3) displayed steady decrease in
bioluminescence, demonstrating the silencing effect of the lipoplexes post systemic
administration. Furthermore, at the end of the study, tissues were collected, and
epifluorescence optical imaging was conducted to confirm the presence of lipoplexes in
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tumor tissues (Figure 4.19C). The radiant efficiency quantified from these tumor tissues
were 2.66x108 ± 3.61x107 [p/s]/[µW/cm2] and 2.21x109 ± 6.53x108 [p/s]/[µW/cm2] for
control and treatment, respectively, translating into an 8.3-fold difference in fluorescence
intensity.
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Figure 4.19. In vivo luciferase silencing in A549-Luc2 tumor-bearing mice. A: Representative

time-lapse bioluminescence imaging of animals subjected to the multi-dose silencing study. OEL350 (3) was administered intravenously at t=0 and t=24 h. Normalized color scale set within each
group. B: Total flux (p/s) change with respect to t=0 over time. C: Epifluorescence optical imaging
of tumors harvested from animals subjected to the multi-dose silencing study, confirming the
accumulation of DiR’-labeled lipoplexes. D: Total radiant efficiency quantification of tumors
presented in C. Statistical differences were determined via two-way ANOVA and Tukey’s multiple
comparisons test.

4.14.

Conclusions
Modulation of gene expression by RNA interference (RNAi) in mammalian cells

is an important event that is currently undergoing intense exploration for clinical
manifestations. The Post-transcriptional gene silencing using RNAi can be triggered by a
range of RNAi inducers using multiple pathways. Some of the inducers include short
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interfering RNAs (siRNAs), microRNAs, short hairpin RNAs and piwi-interacting RNAs.
Among these, the use of siRNA is the most popular, widely studied method that has
demonstrated success in the clinic.
Clinical translation of siRNA relies on suitable carrier molecules that can carry the
siRNA unharmed to the target site while having no or minimum toxicity of their own.
Cationic lipids are suitable delivery agents for this purpose. For example, the recent
successes in the delivery of mRNA-based COVID-19 vaccines by Moderna and PfizerBioNTech is due to strategically designed lipid molecules. The Pfizer-BioNTech mRNA
vaccine formulations contained not only an ionizable lipid (ALC-0315 = (4hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyl-decanoate), but also a PEGylated
nonionic surfactant (2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), 1,2distearoyl-sn-glycero-3-phosphocholine, cholesterol, potassium chloride, monobasic
potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.
The Moderna vaccine, on the other hand, consists of mRNA, an ionizable lipid (SM-102 =
heptadecan-9-yl 8-((2-hydroxyethyl)-(6-oxo-6-(undecyloxy) hexyl) amino) octanoate),
polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2distearoyl-sn-glycero-3-phosphocholine

[DSPC]),

tromethamine,

tromethamine

hydrochloride, acetic acid, sodium acetate, and sucrose. The emergence of the COVID-19
pandemic is clearly leading the lipid nanoparticle resurgence for effective mRNA vaccines,
mRNA therapies, as well as DNA gene therapies for the future.
To this end, we examined a relatively new class of lipid molecules, oxime ether
lipids (OELs), in delivery experiments involving siRNA. We have demonstrated that
surface modification of OEL4:DOPE liposomes is essential for their in vivo tumor uptake,
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biodistribution and subsequent gene silencing activity. We also have shown the value in
replacing the more traditional ester linkages of a cationic lipid with oxime ether linkages
to boost transfection efficacy. Taken together, we have presented a novel system for exhepatic delivery of functional DsiRNA to the tumors.
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CHAPTER 5

NOVEL BORON-CONTAINING CATIONIC LIPIDS

5.1 Introduction
In nature, boron compounds are found mainly in vegetables, fruits, and nuts. Boric
acid, a natural chemical, is used as a preservative in eyewash solutions in addition to its
wide use as a buffer in biological assays.400 Among the many boron compounds in organic
chemistry (Figure 5.1), the boronic acid moiety is the most commonly studied boron
functionality.400 Boronic acid was first synthesized and isolated in the mid-19th century by
Edward Frankland401 and characterized by Loland, Edwards, and others in the mid-20th
century.402-414 Due to its unique properties, boronic acids have since become almost
ubiquitous and wildly adopted in many areas of chemistry including C–C bond formation,
acid catalysis, asymmetric synthesis, carbohydrate analysis, metalcatalysis, molecular
sensing, and as therapeutic agents, enzyme inhibitors, and novel materials.405
H
H B
H
Borane

OH
R B
R
Borinic acid
(R = alkyl or aryl)

OH
R B
OH
Boronic acid
(R = alkyl or aryl)

OH
HO B
OH
Boric acid

OR
H B
OR
Boronic ester
(R = alkyl or aryl)

Figure 5.1. Organoboron compounds.
Structurally, boronic acid is sp2-hybridized with a single B–C bond and two B–OH bonds
to fill out the valence. As such, boronic acid has six valence electrons and an empty p-
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orbital that lies perpendicular to the plane of the molecule. The ability of boron to accept
electrons from a Lewis base can lead to a conversion from a neutral, sp2-hybridized species
to an anionic, sp3-hybridized species. This acid-base reaction is pH-dependent. At a pH
greater than the pKa of the boronic acid (i.e., ~4–10)408 the tetravalent form predominates
(Scheme 5.1).406 Boronic acids have been found to readily interact with 1,2- and 1,3-diols
to form stable 5- and 6-membered boronic esters at more alkaline pH.
OH
+ –OH
B
OH
Boronic acid
R

pH > 10

HO

HO

HO

- 2H2O

- 2H2O
O
B
O

OH
B OH
OH
Hydroxyborate

HO

R

R

pH < 10, H+
+ H2 O

Boronic ester

OH
B O
O
Hydroxyboronate ester

Scheme 5.1. Boronic acid equilibrium is dependent on factors including the pKa values of
the boronic acid and the diol as well as the pH of the solution.

The stability of the boronic esters is pH- and solvent-dependent. At a pH lower than
the pKa of the boronic acid, the trivalent boronate is the prominent species. Due to increased
ring strain, the boronic esters will hydrolyze to the free boronic acid (Scheme 5.1).407 The
trivalent form of both the free acid as well as the boronic esters can coordinate water and
release a proton. The neutral –B(OH)2 is electron-withdrawing, whereas the anionic –
B(OH)3− is electron-donating. Understandably, the acidity of boronic acids depends on the
charge density at the B-atom; electron-withdrawing groups increase the acidity, whereas
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electron-donating groups decrease it. Boronic esters are considered more acidic than the
free acids because the –OR group is more electron withdrawing (i.e., shows more -I effect)
than the –OH group. 405, 408 In the presence of 1,2- or 1,3-diols, cyclic boronic esters are
formed by reaction of the neutral boronic acid with the diol.408 The boronic acid–diol
complexation is understood to be dependent on a number of factors, such as steric strain,
the pKa of both the boronic acid and the diol of interest, and the pH of the solution. 406, 407411

However, several observed trends regarding the strength of boronic acid–diol

interactions in the literature are probably not corroborated.408,411,412 The ability of boronic
acids to form reversible, covalent complexes with 1,2- or 1,3-diols is perhaps the most
important chemical characteristic that has led to boronic acids finding usefulness in a
plethora of biomedical applications.408, 413
Phenylboronic acid C6H5B(OH)2 (PBA) is used as a ligand in several applications,
such as glucose sensors, chromatographic separation of carbohydrates, and RNA affinity
columns, etc.414-418 because of its ability to selectively bind to cis-diol moieties of common
sugars.407, 408 There are two modes of stimuli-responsiveness related to the binding of PBA
to a sugar moiety.419,420 The first stimuli-response feature is that the binding affinity of
PBA with sugar depends on the pH. At physiological and even more basic pH, the affinity
is strong, but weak under acidic pH conditions, such as in an endosome. Researchers have
exploited this pH-responsiveness as a modulator for controlling the affinity of PBA to
sugars.408,421 Secondly, a diol moiety complexed to PBA (i.e., boronic ester complex) will
undergo an exchange with another diol in the event greater thermodynamic stability is
achieved, thus reorganizing the binding pair.422,423 One of the most profuse intracellular
biomolecules in the cell, adenosine triphosphate (ATP) has a cis-diol moiety in its ribose
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ring, and can consequently interfere with the PBA-sugar interaction, resulting in formation
of PBA-ATP.418, 424 Based on the affinity of PBA and sugar, which is dependent on the
dual stimuli of intracellular pH and [ATP], an effective delivery system could be designed.
Another important prerequisite for an efficient delivery system is selective delivery of
therapeutic molecules to target cells.425-427 For targeted delivery, PBA could be used as a
target ligand because of its ability to specifically bind to sialylated epitopes that are
overexpressed on the surface of various types of tumors.428-430 PBA can be easily modified
and has low immunogenicity compared to common targeting moieties like peptides.
Deshayes et al. reported PBA-functionalized micellar nanocarriers incorporated with the
parent complex of the anticancer drug oxaliplatin for targeting sialylated epitopes
overexpressed on cancer cells.428-430 The authors demonstrated that PBA conjugation on
the surface of polymeric micellar nanocarriers enhanced their tumor targeting ability by
specific interaction with sialic acid (SA) without affecting their long circulating properties.
Deshayes et al. also showed a higher binding constant and selectivity of the phenyboronic
acid

(PBA)–functionalized

polymer

micelles

(PBA

end-functionalized

poly(ethyleneglycol)-b-poly(L–glutamic acid) copolymer = PBA-PEG-PLGA) for sialic
acid (SA) targeting (Figure 5.2).428-430
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Figure 5.2. (A) 3-Aminophenyboronic acid-PEG-b-Poly(L-glutamic acid;
(B) sialic acid; (C) PBA-PEG-b-PLGA bound to SA on a cancer cell.
The relevance of boronic acids to medicinal chemistry can be attributed to their low
toxicity and ability to coordinate with Lewis basic amino acids such as serine. Smallmolecule boronic acids have been developed as transition-state protease and proteasome
inhibitors, as well as anti-cancer and anti-bacterial agents.413, 431-433 The apparent lack of
toxicity or in vivo instability issues of boronic acids is an encouraging sign for the use of
boronic acids in medical applications. In May 2003, the US Food and Drug Administration
approved Bortezomib, also known as VelcadeÒ (Figure 5.3 a), a boronic acid-based
proteasome inhibitor, for the treatment of multiple myeloma without any toxicity issues.434436

Subsequent to the approval of VelcadeÒ and due to the overall desirable features of

boronic acids, there has been growing interest for boronic acids in medicinal chemistry,
leading to the discovery of two more medications—ixazomib and vaborbactam. Ixazomib
(Figure 5.3 b), a N-dipeptidyl boronic acid approved by FDA and European Medicines
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Agency (EMA) in 2015 and 2016, respectively, is also used for treatment of multiple
myeloma, having the same mechanism of bortezomib.437-439
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Figure 5.3. Drugs containing boronic acid approved by the FDA and the EMA.

Vaborbactam (Figure 5.3 c) was approved by FDA in 2017 and by EMA in 2018. This
cyclic boronic acid, a ß-lactamase inhibitor, has been used in combination with antibiotics
for the treatment of urinary, abdominal, and lung infections.440-442 The ensuing end product
in the breakdown of boronic acid-containing compounds is generally boric acid. Boric acid
is not particularly toxic to humans.434,443,444 Boron is present in various foods445 and a
variety of consumer products.446 However, despite these encouraging signs, individual
assessment of the toxicity of each boronic acid considered for biological use is
required.434,443,444 Boronic acid-containing polymers with their unique reactivity and
stimuli-responsive behavior have potential applications as self-healing materials,
therapeutic agents, self-regulated drug delivery systems, nucleotide adsorbents, and
sensors for sugars and glycoproteins.418,447-456 The cellular delivery of large
macromolecules presents a new and promising application of boronic acid. In particular,
boronic acids are being developed to facilitate the internalization of protein-based
biopharmaceuticals across biological membranes.
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5.1.1. Challenges of biopharmaceuticals
The bi-directional transport of ions, small molecules, peptides, and proteins across
cellular membranes is naturally developed and follows efficient and selective
mechanisms,457-459 and are crucial for sustaining homeostasis and allowing cellular
interaction and fortification.457 To aid the study of cellular function, and for the effective
delivery of therapeutic molecules to the site of action, primarily the cytosol of the cell,
scientists in both academia and industry have ramped up interest in the development of
artificial carriers to move molecules across biological membranes.459 Biopharmaceuticals
have high therapeutic value due to their specific mechanisms of action, high potency, low
dosing, and the opportunity for replacement therapy. Nevertheless, the delivery of proteinbased therapeutics to a site of action is extremely difficult.460-463 The structurally diverse
and complex nature of proteins molecules make them easily hydrolyzable and metabolized
in vivo, leading to poor bioavalibility.461 Moreover, the protein therapeutic could
potentially be neutralized by the natural immune response from the body and, in some
cases, negatively affect the patient. Finally, protein therapeutics are often unable to easily
cross biological membranes due to their large size and hydrophilic nature.460-463 Efforts to
design strategies to overcome challenges associated with delivery of nucleic acids and
stability are ongoing. Current approaches to alter or mask the physical properties of a
biologic to improve pharmacokinetic attributes such as bioavailability and cellular uptake
typically include cationic peptides,464 liposomes,465 polyethyleneimine derivatives,466
nanoparticles,467 dendrimers,468 and antibody- or viral-based methods469-471 Many of these
strategies possess inherent limitations, including instability, off-site reactivity, toxicity,
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immunogenicity, or poor bio-degradability.460,472,473 Boronic acids offer an alternative
approach to current delivery and protecting strategies that avoids many of these drawbacks.

5.1.2. Boronic acid as a carrier agent
Under certain conditions, insoluble boronic acid functionalized molecules, such as
m-dansylamido phenylboronic acid (Figure 5.4), could be solubilized in buffered solution
at neutral pH.474 These hydrophobic molecules were found to be taken up by living cells
and stained different cellular components.474
N

HO

OH
B

O S O
NH

Figure 5.4. Structure of m-dansylamido phenylboronic acid.

The “boronate-carrying buffer” typically contained a “receptor” agent, such as
diethanolamine (DEA), known to complex with boronic acids. The authors hypothesized
that the boronic acid–DEA adduct allowed the molecule to become more hydrophilic
overall, possibly due to the charged tetravalent boronate. This approach offers a mild and
non-toxic alternative to “shocking” cells with high levels of organic solvent in order to
deliver insoluble, hydrophobic molecules. These authors believed that this strategy could
be used to produce reagents to stain living cells, as well as to solubilize and deliver drugs,
enzyme substrates, heavy metal containing organic molecules, and radioactive reagents475
Structural modification to install a linker sensitive to enzymatic cleavage between a cargo
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of interest and boronic acid was hypothesized to allow for selective cleavage and the
subsequent release of the cargo from the boronic acid-carrier agent.
Based on the established facts that boronic acids have great affinity for 1,2-diol
moieties and also have the ability to bind to sialylated epitopes that are overexpressed on
the surface of various types of tumors, we hypothesized that incorporation of a boronic
acid group on a lipid or liposome formulation will increase the tumor targeting ability of
the subsequently derived lipoplex formulation. Therefore, we designed and synthesized a
boronic acid-based lipid and evaluated its effects on the transfection properties of OEL4derived lipoplexes.
5.2. Hypothesis
We synthesized new boron-based cationic lipids (Figure 5.5) to serve as co-lipids for
OEL4 formulations to improve lipoplex uptake. Our aim is to improve the efficiency of
intracellular delivery of lipoplexes into target cells with minimal immune responses by
incorporation of a boronic group into the lipid headgroup region. Our hypothesis is that a
boron in the polar domain, whether covalently linked or chelated by a headgroup diol
moiety, will enhance the tumor-targeting ability of a lipoplex, possibly by increasing the
retention time of the lipoplex at the tumor site or by reducing rapid washout from the target
cells.428
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Figure 5.5. Chemical structures of DMDBH and DODBH.

The effect of boron on transfection efficiency was clearly demonstrated by Kim et
al.476 The authors demonstrated the therapeutic potential of a cationic polymer architecture
composed of phenylboronic acid (PBA), sugar-installed polyethylenimine (PEI), and PEG,
PBA-PEG-CrossPEI. The polymer was demonstrated to deliver DNA with high
transfection efficiency and with low cytotoxicity. In addition, the PBA moiety with
PEGylation was shown to facilitate the binding of polymer/DNA polyplexes to sialylated
glycoprotein, which is overexpressed on the tumor cell membrane, and thus provided high
tumor targeting ability. Figure 5.6 presents the tumor-targeting ability of PBA-PEGCrossPEI and with PEG-CrossPEI without PBA, which was used as a control. PBA-PEGCrossPEI and PEG-CrossPEI polyplexes were monitored for luciferase gene transfection
in MCF-7 cells. PBA-PEG-CrossPEI showed better transfection efficiency than PEI 25 k,
but less efficient than CrossPEI. The authors attributed the lower transfection of PBAPEG-CrossPEI relative to CrossPEI to possibly the conjugation of PEG to the gene carrier
in PBA-PEG-CrossPEI and that the conjugation may have inhibited cellular uptake of
polyplexes to target cells. Moreover, PBA-PEG-CrossPEI achieved three times higher
transfection efficiency than non-targeted PEG-CrossPEI owing to enhanced cellular uptake
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of PBA-PEG- CrossPEI (Figure 5.6). To investigate the role of PBA as a tumor-targeting
moiety, MCF- 7 cells were pretreated with free PBA as a competitor before gene
transfection with polyplexes. After pre-incubation with 50 mM PBA, the transfection
efficiency of PBA-PEG-CrossPEI was significantly decreased, whereas that of PEGCrossPEI showed negligible change. This result indicates that PBA on the PBA-PEG
CrossPEI contributes to its high gene transfection efficiency.

Figure 5.6. Tumor-targeting ability of PBA-PEG-CrossPEI. Gene expression study using
polymers with or without PBA moiety (*P < 0.05, **P < 0.01).476 Figure used with
permission from Kim, J.; Lee, Y. M.; Kim, H.; Park, D.; Kim, J.; Kim W. J. Biomaterials.
2016, 75, 102-111.

5.3. Synthesis of boron-containing cationic lipids
Starting with 3-(dimethylamino)propane 5.1 (Scheme 5.2), we incorporated the
hydrophobic domain of our first boron-containing cationic lipid, N-(boronomethyl)-N,Ndimethyl-2,3-bis(tetradecanoyloxy)propan-1-aminium bromide (DMDBH, Figure 5.5),
via acylation using myristoyl chloride. Reaction of the resultant amino bis-ester 5.2a with
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commercially

available

2-(bromomethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

delivered the quaternary ammonium bromide salt 5.3a where -OC(O)R is myristoyl.
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Scheme 5.2. Conditions: a. myristoyl chloride or oleoyl chloride, TEA, DMAP, CH2Cl2,
0 °C, rt, 12h (97 %); b. 2 (bromomethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, CH2Cl2,
50 °C, sealed tube, 8 h (89 %); c. NaOI4, HCl (2.0 M), H2O/THF, 0 °C – rt, 12 h (71%).
First, 3-(dimethylamino)propane 5.1 was reacted with myristoyl chloride in the presence
of DMAP and TEA to generate 5.2a (Scheme 5.2). The byproduct (Et3N×HCl) was filtered
and the crude ester purified by silica column chromatography using 10 % methanol in
dichloromethane. The

13

CNMR of 5.2a in Figure 5.7 shows the characteristic carbonyl

carbon of 5.2a at d 173 ppm. Also evident are the methine proton –CHOC(O)R at d 5.19
ppm and the methylene protons –CH2OC(O)R) at d 4.08 and 4.36 ppm (Figure 5.7), which
resonate downfield relative to the diol starting material.
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Figure 5.7. 1H and 13CNMR spectra of 5.2a (CDCl3, 500 MHz).

The bis-ester 5.2a was converted to N,N-dimethyl-2,3-bis(tetradecanoyloxy)-N-((4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)propan-1-aminium 5.3a by reaction with 2(bromomethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in a pressure tube at 50 °C for 8 h
(Scheme 5.2, Step b). After cooling, the excess solvent was evaporated using a rotary
evaporator in a closed fume hood. The crude dioxaborolane 5.3a (Scheme 5.2) was purified
by silica column chromatography, (CH2Cl2:CH3OH, 9:1) to yield 89% of 5.3a as a lightyellow solid. Conspicuously evident is the downfield shift of the N-methyl protons in –
CH2N(CH3)2CH2B– to around d 3.6 ppm (Figure 5.8, bottom) from around d 2.2 ppm in
–CH2N(CH3)2 (Figure 5.8, top). Further, the methine proton –CHOC(O)R moved even
more downfield from d 5.19 ppm in 5.2a to 5.6 ppm in 5.3a (Figure 5.8). Also, the
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methylene protons –CH2OC(O)R) shifted downfield from d 4.08 and 4.36 ppm in 5.2a to
d 4.52 and 4.63 ppm in 5.3a (Figure 5.8).
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Figure 5.8. Stacked partial 1HNMR spectra of 5.2a and 5.3a (CDCl3, 500 MHz).

Amine quaternization was followed by hydrolysis of the boronic ester 5.3a in the
presence of NaIO4 to reveal the boronic acid group. Our initial synthesis using this route
delivered DMDBH as the bromide salt in 71% yield. The use of sodium periodate in the
hydrolysis step is critical to the success of the deprotection step as it cleaves the vicinal
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diol 5.7 that is formed on hydrolysis, otherwise boronic acid 5.6 would react with 5.7 on
extraction into organic phase and reform the boronic ester 5.5 (Scheme 5.3).
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O
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work-up
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organic solvent
OH

B
R

OH

Scheme 5.3. Role of sodium periodate in the boronic ester deprotection step.

To accomplish the hydrolysis, boronic ester 5.3a was dissolved in a H2O/THF mixture
(1:4) and deprotected with HCl (2.0 M)/H2O in the presence of NaIO4. The crude product
was subsequently dried under vacuum for 30 minutes and carefully neutralized by dropwise
addition of saturated aq. NaHCO3. After extracting the organic portion, the crude boronic
acid 5.4a was purified via column chromatography (SiO2, CH2Cl2:CH3OH, 9:1) to afford
pure 5.4a (Scheme 5.2, Step c). Figure 5.9 shows 1HNMR (bottom) and 11BNMR (top)
spectra of 5.4a. The protons –CH2B(OH)2– shifted upfield to d 2.80 ppm from the d 3.20
ppm and 3.46 ppm in 5.3a. The 11BNMR referenced to BF3•OEt2 in CDCl3 at d 0.00 ppm,
shows the RB(OH)2 peak at d 19.72 ppm.
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Figure 5.9. 1HNMR spectrum (bottom) and 11BNMR spectrum (top) spectra of 5.4a
(DMDBH) (CD3OD, 500 MHz).

Further support for the assigned structure of DMDBH is provided by HRMS data obtained
for this compound (Figure 5.10).
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Exact Mass: 598.5212

Figure 5.10. HRMS spectrum of the observed mass of DMDBH 5.4a (top) and the
theoretical mass (bottom).
We also prepared the bis-oleoyloxy analog DODBH (Figure 5.5), a mono-unsaturated C18
analog, using the same synthetic route. First, the 1,2-diol 5.1 (Scheme 5.2) was converted
to the bis-ester, 3-(dimethylamino)propane-1,2-diyl ditetradecanoate 5.2b (Scheme 5.2),
by reaction with 2.2 eq. of oleoyl chloride (Scheme 5.1, Step a). The presence of the
alkene protons –CH2CH=CHCH2– at d 5.33 ppm in the proton nmr spectrum of 5.2b
(Figure 5.11) are a clear indication of the success of the formation of the bis-ester 5.2b. In
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addition, the methine proton –CHOC(O)R at d 5.17 ppm in compound 5.2b is similar to
the d 5.19 ppm resonance of this proton in 5.2a (Figure 5.11).
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Figure 5.11. Stacked partial 1HNMR spectra of 5.2a and 5.2b (CDCl3, 500 MHz).

Bis-ester 5.2b then was converted to the corresponding ammonium bromide salt 5.3b
by reaction with 2-(bromomethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in a pressure
tube at 50 °C for 8 h (Scheme 5.2, Step b). After cooling, the excess solvent was
evaporated using a rotary evaporator in a closed fume hood. The crude dioxaborolane 5.3b
was purified by silica column chromatography, (CH2Cl2:CH3OH, 9:1) to yield 89% of 5.3b
as a light-yellow solid. Figure 5.12 shows partial 1HNMR spectra of 5.3a and 5.3b with
the methylene protons –CH2OC(O)R in 5.3b around d 4.49 and d 4.58 ppm, similar to what
was observed with 5.3a (d 4.52 and 4.63 ppm).
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Figure 5.12. Stacked partial 1HNMR spectra of 5.3a and 5.3b (CDCl3, 500 MHz).
The 1HNMR spectrum of the boronic ester d 5.3b also shows a downfield shift of the
methine proton –CHOC(O)R to d 5.59 ppm from d 5.17 ppm in compound 5.2b (Figure
5.13), clearly indicating the formation of the ammonium salt, which provides the electronwithdrawing influence responsible for the downfield shift.
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Figure 5.13. Stacked partial 1HNMR spectra of 5.2b and 5.3b (CDCl3, 500 MHz).
Finally, as in the synthesis of DMDBH, boronic ester 5.3b was dissolved in a H2O/THF
mixture (1:4) and deprotected with HCl (2.0 M)/H2O in the presence of NaIO4 to afford
the bis-oleoyloxy analog DODBH 5.4b.
5.4. Preparation and properties of DMDBH:DOPE lipid films and liposomes
Similar to the procedure for the preparation of stealth-modified OEL liposomes
described in section 4.2, we prepared PEGylated DMDBH:DOPE liposomes to test
whether DMDBH could function as a transfection lipid without assistance of a known
transfection lipid. Stock solutions of DMDBH:DOPE with or without PEG lipid were
prepared at 10 mg/mL in CHCl3 and stored at –20 oC in crimped vials until needed. Lipid
films were prepared at either 1 or 10 mg/mL total lipid under a stream of nitrogen in glass
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tubes and were kept overnight in a desiccator. The films were hydrated with 1 mL of
enzyme-free water under vortex mixing, subjected to freeze/thaw cycles, and then were
probe-sonicated for 10 minutes on an ice bath with 1 min cycles of sonication followed by
1 min of rest, as shown in Figure 4.9. The resulting PEGylated DMDBH:DOPE or
DMDBH:DOPE liposomes were characterized (Table 5.1) and stored at 4 °C until
subsequently used in transfection experiments. The average diameter of DMDBH
liposomes prepared in this way ranged between 115-165 nm compared to a diameter of 88107 for OEL4 liposomes (Table 5.1). The zeta potential of PEGylated DMDBH ranged
between 10-12 mV (Table 5.1). The zeta potential of DMDBH liposomes, though positive,
is somewhat low compared to the zeta potential of typical OEL4 liposomes, which
generally range from +32.8 to +34.7 mV (Table 4.2). Inclusion of DSPE-PEG350 in the
DMDBH liposomes did not have any significant effect on the zeta potential (~12 mV).
Table 5.1. Hydrodynamic size and zeta potential of lipid liposomes
Hydrodynamic Size
Liposome
Formulation

OEL liposomes

Size, db Z-Potentiala
(nm)
(mV)

Liposome
formulation

Size, d
(nm)

Z-Potential
(mV)

DMDBH:PEG350(0)

117.0

8.08

OEL4:PEG350(0)

106.6

33.0

DMDBH:PEG350(1)

135.5

12

OEL4:PEG350(1)

139.6

32.8

DMDBH:PEG350(3)

115.8

11.4

OEL4:PEG350(3)

89.07

34.7

DMDBH:PEG350(5)

164.6

10.9

OEL4:PEG350(5)

88.36

34.7

Liposomes were prepared in nuclease-free water and stored at 4 oC. Values in parentheses
indicate mol% of the PEG lipid used. All formulations included an equimolar amount of
DOPE relative to DMDBH. a Z = zeta; b d = diameter.
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After physical characterization of the DMDBH liposomes, we examined the RNA
binding properties and transfection activity of these liposomes. To determine transfection
activity, we compared the gene silencing activity of DMDBH-anti-eGFP DsiRNA and
OEL4-anti-eGFP DsiRNA lipoplexes (Figure 5.14). The gene silencing activity
experiment was carried out as described in Section 4.5. As before, OEL4-derived
lipoplexes showed efficient eGFP downregulation — up to 81.5% (Figure 5.14A). In
contrast, the DMDBH-derived lipoplexes showed little eGFP reduction (Figure 5.14A).
Further in Figure 5.14A, lipofectamine (L2K), the commonly used transfection agent that
was used as a reference lipid for comparison, showed 88% gene silencing (all L2K
transfections were done in a serum containing media). The size and RNA binding of
DMDBH-derived liposomes were compared with OEL4 vesicles in paired experiments as
shown in Figure 5.14. The data in Figure 5.14B shows that DMDBH and OEL4 liposomes
show similar size distribution (DLS analysis). In addition, contrary to the OEL4-derived
liposome, the DMDBH-derived liposomes did not bind to the RNA duplex as assessed by
the gel electrophoresis assay (Figure 5.14 C). Complete binding to RNA duplex was
achieved for OEL4 liposome.
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Figure 5.14. (A) A bar graph showing the silencing activity of GFP gene mediated by
DMDBH- and OEL4-DsiRNA complexes. eGFP fluorescence in cells (mean fluorescence
intensity, MFI) is plotted at % of control cells. (B) hydrodynamic size (nm) of DMDBH
and OEL4 liposomes. (C) 2 % agarose gel binding experiment showing binding of lipid to
Alexa-546 labelled RNA duplexes with 500 ng Lipid, 25 ng RNA duplexes per sample,
showing binding to Alexa-546 labelled RNA duplexes.

The inability of the DMDBH-derived liposomes to downregulate anti-eGFP may
be attributed to the boronic acid head group of DMDBH acting as Lewis acid in water.
Boronic acids remain at their protonated uncharged trigonal form at physiological pH.400
421,430,456

Boronic acids are weak Lewis acids and in aqueous media, a water molecule
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reversibly adds to its neutral trigonal form (I)477 (Scheme 5.4) to produce an anionic
tetrahedral form (II)477 (Scheme 5.4). A proton is released during the process. The cationic
nature of DMDBH (as a liposome) may be compromised, making the net charge of the
DMDBH negative. This may have resulted in an ineffective association of the DMDBH
liposomes with the DsiRNA duplexes.
H 2O
OH
OH
+
B OH
B
R
R
OH
OH
I
II
Scheme 5.4. Boronic acid as Lewis acid.

H

Consequently, we next examined the effect of DMDBH liposome on the transfection
efficiency of OEL4 liposomes. To this end, we prepared DMDBH:OEL4:DOPE liposomes
with varying percent of DMDBH with or without PEGylation. The size (Table 5.2) and
RNA binding (Figure 5.15) of DMDBH:OEL4-derived liposomes were determined and
shown to be comparable to those of the OEL4-derived liposomes as shown in Table 5.1.
Table 5.2. Hydrodynamic size and zeta potential of PEGylated DMDBH:OEL4
liposomes.
Liposome Description: OEL4:DOPE:PEG350(3)
Varying mol% of DMDBH

Size, db
(nm)

Z-Potentiala (mV)

1 mol%

102.4

28.8

3 mol%

97.35

32.7

5 mol%

69.88

21.4

10 mol%

66.9

11

Liposomes were prepared in nuclease-free water and stored 4 oC. The liposomes
were prepared using equimolar ratios of OEL4 and DOPE. Values in parentheses
indicate mol% of the PEG lipid used. All formulations included an equimolar
amount of DOPE relative to OEL. a Z = zeta; b d = diameter.
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The data in (Figure 5.15, top) shows that DMDBH:OEL4 liposomes show similar size
distribution as OEL4 liposomes (DLS analysis, Figure 5.15). Contrary to the DMDBHderived liposomes, the DMDBH:OEL4-derived liposomes show binding to the RNA
duplex similar to the OEL4-derived liposomes as assessed by the gel electrophoresis assay
(Figure 5.15, bottom), consistent with the higher zeta potentials measured for the liposome
formulations containing both DMDBH and OEL4.
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Figure 5.15. (Top) Hydrodynamic size (nm) of OEL4:DMDBH liposomes. Values in
parentheses indicate mol% of the DMDBH or PEG lipid used. All formulations included
an equimolar amount of DOPE relative to OEL. (Bottom) 2 % Agarose gel binding
experiment showing binding of lipid to Alexa-546 labelled RNA duplexes with 500 ng
lipid, 25 ng RNA duplexes per sample, showing binding to Alexa-546 labelled RNA
duplexes.

5.5. Cellular toxicity study of DMDBH:OEL4-derived lipoplexes
We determined the effect of PEGylated DMDBH:OEL4-complexed DsiRNAs on
non-specific cellular viability. Various formulations were incubated with anti-luciferase
DsiRNA (anti-luc) duplexes and the resulting lipoplexes were added to human lung cancer
cells (A549). The experiments were performed as described in Section 4.8. All
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DMDBH:OEL4 formulations tested did not show any non-specific cellular toxicity
(Figure 5.16). Data in Figure 5.16 shows that PEGylated DMDBH:OEL4 lipoplexes are
not toxic to these cells.
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Figure 5.16. Dose-dependent cytotoxicity of PEGylated DMDBH:OEL4 complexed with
anti-luc DsiRNA duplexes. Samples were incubated for 48 hours at 37 oC.

5.6. In vitro gene silencing study of DMDBH:OEL-derived lipoplexes
We examined the gene silencing activity of DMDBH:OEL4-anti-eGFP DsiRNA
lipoplexes in the manner similar to the OEL4 studies outlined in Section 4.5. We first
examined the formulation OEL4:DOPE:DSPE-PEG350 with varying concentrations of
DMDBH (0-10 mol%). Equimolar OEL4:DOPE liposomes were prepared at 1 mg/mL in
a nuclease-free water. As shown in Figure 5.17, inclusion of 3 or 5 mol% of DMDBH in
the lipoplex formulations improved the eGFP downregulation of OEL4 liposomes,
showing over 20% improvement (to 88% and 90% silencing, respectively) compared to the
activity of OEL4 liposomes without DMDBH. In comparison, L2K-treated cells showed
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~72% gene silencing. These results demonstrate that inclusion of DMDBH in lipoplex
formulation promotes higher transfection efficiencies, one of the important parameters for
in vivo translation.
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Figure 5.17. Comparison of gene silencing activity of OEL4:DOPE:DSPE350(3) DsiRNA
lipoplexes with and without DMDBH. Data show mean fluorescence intensity (X-axis,
log fluorescence) for a given number of events plotted on Y-axis (representing live cells).
OEL4:DOPE:DMDBH:DSPE-PEG350(3) liposomes (180 uL) were mixed with 1.8 uL of
10uM of anti-eGFP DsiRNA. Amount of DMDBH in the formulation ranges from 0 to 10
mol%. The OEL4:DOPE:DMDBH:DSPE-PEG350(3) liposome was prepared as a unit (a
single liposome) and added to siRNA duplex to form the lipoplex. All formulations
included an equimolar amount of DOPE relative to OEL. The % eGFP silencing was
determined relative to control cells (MDA-MB-231).
The improvement in transfection efficiency as a consequence of the addition of DMDBH
may be the result of an expected formation of a ‘dimeric’ lipid, a postulated boronic ester
complex between OEL4 and DMDBH (Figure 5.18). The boronic ester formation
(‘dimerization’) may influence bilayer fluidity, which in turn could promote greater
liposome stability.478
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Figure 5.18. Dimerization OEL4 and DMDBH.
Figure 5.19 shows a downfield shift of the indicated protons of OEL4 in the dimer (around
d 5.61 ppm) compared with those of the OEL4 (around d 3.99 and d 4.49 ppm), a result
that is consistent with boronic ester formation. This result, however, is preliminary — a
more detailed study on the reaction of OEL4 and DMDBH still needs to be conducted.
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Figure 5.19. Stacked partial 1HNMR spectra (in CDCl3) of DMDBH-OEL4
‘dimer’(bottom) and OEL4 (top).
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Indeed, the effect of dimerization in improving nucleic acids delivery has been
established and recently reviewed by Zhang et al.477 For example, the Cullis group478
prepared a class of dimers, TODMACS3 and TODMACS6 (Figure 5.20) from DODAC
with TODMACS6 exhibiting the best delivery ability. The authors proposed that the
second quaternary ammonium group may have strengthen the interactions with DNA.478
DODAC is an unsaturated version of didodecyldimethylammonium bromide (DDAB)
(Figure 5.20), which was previously used to prepare nanoparticles as gene delivery
vectors, such as cationic liposomes479 by introducing a second quaternary ammonium
group, giving cationic gemini lipids.480,481
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Figure 5.20. Synthesis of diquaternary ammonium lipids, TODMACS3 and
TODMACS6.
Having noted an effect of added DMDBH on the transfection efficiency of OEL4, we
set out to understand the role of DMDBH in improving transfection. We examined different
formulations by varying the amount of liposome added to the same amount of anti-eGFP
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siRNA duplex or the order of lipoplex formulation. The gene silencing activity of
DMDBH:OEL4 complexes prepared as a single liposome with varying percent of DMDBH
(0-100%) was compared with OEL4 liposomes in paired experiments. We achieved
maximum eGFP silencing of 89% at 100% DMDBH loading (i.e., equimolar mixture of
OEL4:DMDBH) (Figure 5.21). The results, however, are not conclusive in that much
variability is noted in the results (i.e., significant overlap of error bars in this preliminary
study).
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Figure 5.21. eGFP down-regulation of anti-eGFP siRNA duplex cells using
DMDBH:OEL4 lipoplex with varying mol% DMDBH. Amount of DMDBH in the
formulation ranges from 0 to 100 mol% relative to OEL4.
OEL4:DOPE:DMDBH:DSPE-PEG350(3) liposomes (45 uL) were mixed with 1.8
uL of 10uM of anti-eGFP DsiRNA. OEL4:DOPE:DMDBH:DSPE-PEG350(3)
liposomes were prepared as a single liposome and then added to siRNA duplex
to form the lipoplex. Data show mean fluorescence intensity (X-axis, log
fluorescence) for a given number of events plotted on Y-axis (representing live
cells). All formulations include an equimolar amount of DOPE relative to OEL. %
eGFP silencing was determined relative to control cells (MDA-MB-231).
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Pre-mix formulations. We also premixed a DMDBH:DOPE liposome with antieGFP siRNA duplex and incubated the mixture for 30 minutes to form a DMDBH-derived
lipoplex. PEGylated OEL4:DOPE liposomes, with varying amounts of PEG350 (1-5
mol%), were then added to the DMDBH-derived lipoplex. This formulation protocol is
termed a ‘pre-mix’ formulation hereforth.

The resultant pre-mix lipoplex then was

examined in a transfection experiment (Figure 5.22).
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Figure 5.22. Evaluation of pre-mix formulations. eGFP down-regulation of anti-eGFP
siRNA duplex cells using DMDBH-OEL4 lipoplexes with varying mol% PEG 350.
DMDBH:DOPE liposome (90 uL) was first pre-mixed with 1.8 uL of 10uM of antieGFP DsiRNA and incubated for 30 minutes to form a DMDBH lipoplex before
adding OEL4:DOPE liposomes to the DMDBH-derived lipoplex. The amount of
PEG350(3) ranges from 1-5 mol%. Fluorescent activated cell sorting analysis of OEL4DsiRNA and DMDBH-complexed OEL4-DsiRNA. Data show mean fluorescence
intensity (X-axis, log fluorescence) for a given number of events plotted on Y-axis
(representing live cells). All formulations include an equimolar amount of DOPE relative
to OEL and DMDBH. % eGFP silencing was determined relative to control cells (MDAMB-231).
The gene silencing activity of the pre-mix DMDBH:OEL4-derived lipoplex was compared
with the standard OEL4-derived lipoplex in paired experiments. An enhancement of about
17% anti-eGFP downregulation was achieved with the pre-mix DMDBH-OEL4(3)
complex relative to OEL4(3) (Figure 5.22).
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Reverse pre-mix formulations. We also examined a ‘reverse pre-mix’ formulation
where a OEL4:DOPE liposome was first mixed with anti-eGFP siRNA duplex and
incubated for 30 minutes to form a OEL4-derived lipoplex. PEGylated DMDBH:DOPE
liposomes, with different amounts of PEG350 (1-5 mol%), then were added to the OEL4derived lipoplex. This formulation protocol is the reverse of the pre-mix formulation, so it
is termed ‘reverse pre-mix’ hereforth. The inclusion of the PEGylated DMDBH:DOPE
liposomes to the OEL4-derived lipoplex resulted in impairment of the gene silencing
activity of the lipoplexes by about 25% in the case of OEL4-DMDBH(3) formulation (i.e.,
when DMDBH:DOPE:PEG350(3) was added to the OEL4-derived lipoplex) (Figure
5.23).
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Figure 5.23. Evaluation of reverse pre-mix formulation. eGFP down-regulation of antieGFP siRNA duplex cells using DMDBH:OEL4 complex lipoplex with varying mol% of
PEG350. OEL4:DOPE liposome (90 uL) was first pre-mixed with 1.8 uL of 10uM of
anti-eGFP DsiRNA and incubated for 30 minutes to form OEL4-derived lipoplex.
PEGylated DMDBH:DOPE liposome was then added to the OEL4-derived lipoplex.
The amount of PEG350 ranges from 1-5 mol%. The OEL4 and DMDBH liposomes were
prepared separately. Fluorescent activated cell sorting analysis of OEL4-DOPE lipoplex
and DMDBH:OEL4 complexed lipoplex was performed. Data show mean fluorescence
intensity (X-axis, log fluorescence) for a given number of events plotted on Y-axis
(representing live cells). All formulations include an equimolar amount of DOPE relative
to OEL and DMDBH. % eGFP silencing was determined relative to control cells (MDAMB-231).
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Based on results of Figures 5.22 and 5.23, it is safe to conclude that the pre-mix formulation
is a more active lipoplex formulation for achieving downregulation than the reverse premix formulation.
To further ascertain the role of boron in improving transfection and whether or not a
boron lipid (i.e., hydrophobic domain of DMDBH) is required, we examined using phenyl
boronic acid (PBA) via the procedure disclosed in section 4.3 and carried out a direct
comparison with the pre-mix formulation on their effects on the transfection ability of
OEL4. Similar to the DMDBH pre-mix formulation (as described above), a PBA:DOPE
‘liposome’ was separately incubated with anti-eGFP siRNA duplex for 30 minutes (PBA
pre-mix formulation) to generate PBA-derived lipoplex. OEL4:DOPE:PEG350(3)
liposome was subsequently added to both PBA and DMDBH derived lipoplexes (boronderived lipoplexes) to form PBA:OEL4 and DMDBH:OEL4 lipoplexes respectively.
Figure 5.24 shows the data on the eGFP downregulation of these lipoplexes compared
with just OEL4-derived lipoplex (without PBA or DMDBH). In Figure 5.24, the
DMDBH:OEL4-derived lipoplex (via DMDBH pre-mix formulation) showed over 20%
improvement (82.8%) on the eGFP downregulation of OEL4-derived lipoplex (60%)
whereas the PBA:OEL4-derived lipoplex (via PBA pre-mix formulation) resulted in just
about 9% improvement (69.6%) over the eGFP downregulation by the OEL4- derived
lipoplex (Figure 5.24).
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Figure 5.24. Evaluation of DMDBH and PBA pre-mix formulations. eGFP downregulation of anti-eGFP siRNA duplex cells using OEL4 lipoplex (with or without PBA or
DMDBH). Formulation examined: OEL4:DOPE:DSPE-PEG350 with or without boron
(PBA or DMDBH). All formulations include an equimolar amount of DOPE relative to
OEL. % eGFP silencing were determined relative to control cells (MDA-MB-231).
Lipoplexes were prepared via the pre-mixing procedure. The ratio of OEL4:boron
component = 1:1.

Conjointly, the pre-mixing procedure of lipoplex formulation in boron-mediated
transfections improves the silencing efficiency of OEL4. As indicated above in Figure
5.17, the OEL4:DOPE:DMDBH:DSPE-PEG350(3), prepared as a unit with 3 or 5 mol%
of DMDBH delivered over 20% improvement in gene silencing over OEL4 liposomes
without DMDBH. Also, DMDBH pre-mix formulation show similar improvements; over
17% and 20% enhancements in anti-eGFP downregulation relative to OEL4(3) in Figures
5.21 and 5.24, respectively. However, DMDBH pre-mix formulation is preferred over the
formation of a single OEL4:DOPE:DMDBH:DSPE-PEG350 liposome as the
corresponding lipoplex from the single liposome (standard formulation) resulted in a loss
of cells, even though cell viability study of DMDBH:OEL4 complexed did not show any
non-specific cellular toxicity (Figure 5.16).
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In summary, this Chapter has presented a new synthesis of a boronic acid-containing
lipid — DMDBH — in 3 steps from 3-(dimethylamino)propane-1,2-diol in 61% overall
yield. Preliminary in vitro transfection experiments established that inclusion of DMDBH
into lipoplex formulations appears to enhance the transfection activity of the excellent
transfection lipid (OEL4). These results point toward using the boronic acid lipid in
lipoplexes in in vivo studies. The role of DMDBH in improving transfection efficacy
remains to be established.

5.7. Conclusions
The design and synthesis of oxime ether lipids as transfection agents has been the
focus of the Nantz group over the past decade.282 Through series of publications, Nantz
and coworkers have established that oxime ether lipids can be developed as suitable
transfection agents.282 A structure–function study of oxime ether lipids on RNA delivery
revealed that hydroxylated oxime ether lipids are superior transfection agents than nonhydroxylated ones. The presence of the hydroxyl head group may strengthen the
association of the OEL not only with neighboring lipids, but also with the nucleic acid,
presumably via the formation of hydrogen bonds.157
The current work examined OEL liposomes in animal studies to certify their
suitability as in vivo nucleic acid carriers. To this end, we have successfully revealed that
hydroxylated OELs can be used as delivery agents to efficiently deliver siRNA in vivo in
mouse models. It is also worth noting that, the surface modification of OEL:DOPE
liposomes are essential for their in vivo tumor uptake, biodistribution and subsequent gene
silencing activity. Taken together, we have presented a novel system for ex-hepatic
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delivery of functional DsiRNA to the tumors. We have also established that inclusion of
the novel boronic acid-containing cationic lipid DMDBH in OEL4 lipoplex formulations
is promising for enhancing the gene silencing of capability of OEL4 in cell culture
experiments.

5.8. Future outlook
The development of suitable siRNA delivery agents is critical to the success of RNAibased therapeutics. This is the future focus of the technology. Lipids (including
phospholipids) have long been the desired carrier for drugs and/or nucleic acids for
chemotherapy and gene therapy including genetic vaccines.482 The application of lipid
molecules in the delivery of mRNA-based COVID-19 vaccines by Moderna and PfizerBioNTech is a clear testament to the usefulness of lipid carriers. The therapeutic
application of lipids is grounded on their ability to transcend cell membranes.282,351,483 The
net positive charge, user-friendly chemical synthesis routes, minimal associated cellular
toxicity, desired biodegradability, and the ability to complex nucleic acids all combine to
suggest OELs as lipids for successful RNAi-based therapies.282
This study has demonstrated the promising potential of OEL4 as a future carrier for
lipid-based delivery systems. However, more extensive studies are needed at the in vivo
level to ascertain the viability of the new boron lipids reported here.
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CHAPTER 6
EXPERIMENTAL PROCEDURES

6.1 General procedures
6.2. Experimental procedures for Chapter 2
6.3. Experimental procedures for Chapter 3
6.4. Experimental procedures for Chapter 4
6.5. Experimental procedures for Chapter 5
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6.1. General experimental statement
All manipulations were carried out under air unless otherwise noted. TLC plates
(UV 254 indicator, glass-backed, and thickness 200 mm) and silica gel (standard grade,
230 – 400 mesh) were purchased from Merck. Reagents were typically purchased from
Aldrich Chemical Company (Milwaukee, WI). Reagent grade ACS dichloromethane,
tetrahydrofuran (THF), acetone, diethyl ether, ethyl acetate, and hexanes were purchased
from Fisher Scientific. K3PO4 and other bases were purchased from Fisher Scientific and
used as such without any further purification. Ligands/catalysts were either purchased from
Sigma-Aldrich or gifted by Johnson Matthey. Palladium acetate was purchased from Strem
Chemicals and used as such without further purification. Allyl palladium complexes were
received as a gift from Johnson-Matthey. Pure NMR solvents were purchased from
Cambridge Isotopes Laboratories. Bromoquinolines, isobromoquinolines, and boronic
acids were gifted by Novartis Pharma AG, Basel, Switzerland. The coupling reactions were
performed in 4 mL close-cap microwave vials under an argon atmosphere. Microwave vials
were purchased from VWR International and Biotage. Reaction vials were also recycled
and reused. The bulk aqueous solution of surfactant, PS-750-M was prepared with
degassed HPLC grade water and thoroughly purged with argon before use. Purifications of
crude compounds were performed on silica gel (purchased from Sorbtech) with or without
using Combi-Flash Rf-150 equipment. Melting points were determined using a MELTEMP II melting point apparatus with samples in Kimble-Kimex 51 capillaries (1.5-1.8 x
90 mm). Unless otherwise mentioned, all NMR spectra were recorded at 23°C on Varian
Unity INOVA (400 and 500 MHz) spectrometers. Reported chemical shifts are referenced
to residual solvent peaks. All HRMS data were recorded either using electrospray
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ionization (ESI) or chemical ionization (CI). Electrospray ionization (ESI) data were
recorded on a Thermo LTQ Orbitrap XL mass spectrometer at 30,000 resolving power and
using reserpine (M+H+ = 609.2806) for internal calibration. Electron ionization (EI) and
chemical ionization (CI, 1.5*10-4 mbar of methane as reagent gas) data were recorded at
5,000 resolving power on a MAT-95 XP magnetic sector mass spectrometer using
perflourokerosene for internal calibration. IR spectra were obtained on a Perkin Elmer
(Spectrum 100 FT-IR Spectrometer) apparatus.Centrifugation was performed on an
Eppendorf Centrifuge type 5415R. Reaction progress was monitored by thin layer
chromatography (silica gel 60 Å F-254 plates) using UV visualization and staining with
ninhydrin, phosphomolybdic acid, or p-anisaldehyde solutions. Cell microscopy was done
on an EVOS FL Cell Imaging System (Advanced Microscopy Group, WA). Dynamic light
scattering and ζ–potential measurements were acquired on a Zeta Sizer Nano ZS, Malvern
Instruments, MA
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6.2.1. Detailed optimization results
Complete optimization results for the Suzuki-Miyaura couplings of unactivated
(iso)quinoline systems in water are detailed below.
6.2.2. Catalyst screening
Br

B(OH)2
+

2.0 equiv. base
1 mL 3 wt% aq. PS-750-M
45 oC, Ar

N
1

3 mol % catalyst

2

N
3

Entry

Catalyst

Time (h)

Yield (%)*

1
2
3
4
5
6
7
8
9

4
5
6
7
8
9
10
11
12

72
53
72
53
70
49
49
70
44

82(87)#
90(94)#
54(56)#
91(93)#
Traces
100
94
13
84

*GCMS conversions, 0.1 equiv. mesitylene as internal standard.
Conditions: 1 (52 mg, 0.25 mmol), 2 (52 mg, 0.3 mmol), [Pd] catalyst (3 mol %), K3PO4 (0.5 mmol), 1.0
mL 3 wt % PS-750-M, 45 °C, argon atmosphere. #Yield from second run of experiment

6.2.3. Base screening
Br

B(OH)2
+

2.0 equiv. base
1 mL 3 wt% aq. PS-750-M
45 oC, Ar

N
1

9 3 mol %

2

N
3

Entry

Base

3 %*

1

K3PO4•H2O

100

2

K2CO3

99

3

Na2CO3

87

4

Et3N

15

Conditions: 1 (52 mg, 0.25 mmol), 2 (52 mg, 0.3 mmol), catalyst 9 (3 mol %), base (0.5 mmol),
1.0 mL 3 wt % PS-750-M, 45 °C, argon atmosphere. *Conversions based on GCMS, 0.1 equiv.
mesitylene as internal standard.
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6.2.4 Role of palladium source and additive
Br

B(OH)2
+

2.0 equiv. K3PO4•H2O
1 mL 3 wt% aq. PS-750-M
45 oC, Ar

N
1

9 3 mol %

2

N
3

Entry

[Pd]

3 (%)*

1

9

100

2

Pd(OAc)2

38 (46)#

3

[Cy3P + Pd(OAc)2]†

99

4

9 and 6 mol% Cu(OAc)2

38

5

9 and 50 mol% Cu(OAc)2

33

6

Pd(OAc)2, 20 mol% Cu(OAc)2

40

Conditions. 1 (52 mg, 0.25 mmol), 2 (52 mg, 0.3 mmol), [Pd] (3 mol %) K3PO4•H2O (0.5 mmol, 2 equiv),
1.0 mL 3 wt % PS-750-M, 45 °C, 49 h, argon atmosphere. *Conversions based on GCMS, 0.1 equiv.
mesitylene as internal standard; †precomplexation of 3 mol % Pd(OAc)2 with 5 mol % of

Cy3P in 0.1 mL toluene. Toluene was evaporated before catalytic reaction. #Yields from
second run of experiment.
6.2.5. Equivalents of boronic acid

B(OH)2
+
N
0.25 mmol

Br

F3C

9 3 mol %

2.0 equiv. K3PO4•H2O
1 mL 3 wt% aq. PS-750-M
45 oC, Ar, 21 h

N
CF3

16

Entry

Equiv. of boronic acid

16 (%)*

1

1.0

99

2

1.2

100

3

1.5

100#

4

2.0

100#

*Conversion based on GCMS, 0.1 equiv. mesitylene as internal standard. #based on GCMS
conversion, excess boronic acid was deborylated. Note. Similar trend was observed when naphthyl2-boronic acid was used
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6.2.6. Catalyst loading

B(OH)2
+
0.25 mmol

N

2.0 equiv. K3PO4•H2O
1 mL 3 wt% aq. PS-750-M
45 oC, Ar, 21 h

F3C

Br

N

catalyst 9

0.3 mmol

16

Entry

9 (mol %)

16 (%)*

1

1

8

2

2

29

3

3

100

4

5

100

CF3

*Yields based on GCMS, 0.1 equiv. mesitylene as internal standard.
Note. Similar trend was observed when naphthyl-2-boronic acid was used.

6.2.7. Air versus argon atmosphere

B(OH)2

9 3 mol %

N
3 71%
51%*

2.0 equiv. K3PO4•H2O
1 mL 3 wt% aq. PS-750-M
45 oC, 21 h

9 3 mol %
+
Br

air atmosphere

2.0 equiv. K3PO4•H2O
1 mL 3 wt% aq. PS-750-M
45 oC, 21 h
argon atmosphere

N

N
3 100%
79%*

Conditions: 4-bromoquinoline (0.25 mmol), naphthyl-1-boronic acid (0.3 mmol), 9 (3 mol %), K3PO4
(0.5
mmol), 1.0 mL 3 wt % aq. PS-750-M, 45 °C, 21 h. Conversion based on GCMS using 0.1 equivalent
mesitylene as internal standard. *isolated yields.
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6.2.8. Recycle study
16 89%
N

Br

9 (1.25 mol %)

conditions

39

16 88%

+

K3PO4 H2O (1.2 equiv)
B(OH)2

first recycle

F3C
37

E Factor = 5.9
16 88%

fourth recycle

16 86%

9 (1.25 mol%)

9 (1.25 mol%)

K3PO4. H2O
(1.2 equiv)

K3PO4. H2O
(1.2 equiv)

third recycle

9 (1.25 mol %)
K3PO4. H2O
(1.2 equiv)
16 85%

second recycle

Conditions: 39 (52 mg, 0.25 mmol), 37 (57 mg, 0.3 mmol), 9 (3.6 mg, 3.0 mol %, 0.0075 mmol),
K3PO4·H2O (115 mg, 0.5 mmol), 1.0 mL 3 wt% FI-750-M, 45 oC, argon, 24 h
E Factor =

waste (in mg) in each cycle
product (in mg) in each cycle

=

=

352 + 348 + 352 + 350 + 356 (in mg)
61 + 60 + 58 + 59 + 60 (in mg)
1758 mg
298 mg

= 5.9

a) Zeroth cycle. An oven-dried 4 mL reaction vial equipped with a Teflon-coated magnetic
stir bar, 2-Bromoquinoline (52 mg, 0.25 mmol), 4-(Trifluoromethyl)phenylboronic acid
(57 mg, 0.3 mmol), K3PO4•H2O (115 mg, 0.5 mmol), and the palladium catalyst 9 (3.6 mg,
0.0075 mmol, 3 mol%) were added. The reaction vial was closed with a rubber septum.
The mixture was evacuated and then back-filled with argon. This process of evacuation
and backfilling was repeated two additional times. 1 mL Aqueous solution of 3 wt % PS750-M was added to the reaction mixture. The rubber septum was wrapped with PTFE
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tape, black electrical tape, and Parafilm. The reaction mixture was subsequently stirred at
45 oC for 24 hours.
After complete consumption of starting material as monitored by TLC and GCMS, stirring
was stopped and the mixture was allowed to cool to room temperature. The reaction
mixture was diluted with 0.2 mL EtOAc and the mixture was stirred for a minute at room
temperature. Stirring was stopped and the organic layer was allowed to separate. The
organic layer was withdrawn from the mixture via syringe. A similar procedure of
extraction was obtained using an additional 0.1 mL EtOAc. Combined organic layers were
dried over anhydrous sodium sulfate and volatiles were removed under reduced pressure
to obtain the semi-pure product as solid. The pure product was obtained by flash
chromatography over silica gel using EtOAc/hexanes as eluent (1:9), Rf = 0.56. Yield 61
mg (89%). The aqueous solution was retained for 1st recycle.
b) 1st recycle. To the aqueous system obtained from the above reaction, palladium
catalyst 9 (1.5 mg, 0.003 mmol, 1.5 mol%) was added, and the resulting aqueous solution
was purged with argon for 10 minutes. To this well purged aqueous solution, 2Bromoquinoline (52 mg, 0.25 mmol), 4- (Trifluoromethyl)phenylboronic acid (57 mg, 0.3
mmol), and K3PO4•H2O (70 mg, 0.3 mmol), were added. The reaction vial was closed with
a rubber septum and the mixture was purged with argon for five minutes. The septum was
sealed with black electrical tape and covered with parafilm. The reaction mixture was
stirred at 45 oC for 24 h.
After completion of the reaction as monitored by GCMS, similar extraction and
purification procedures were applied as in zeroth cycle Pure product was obtained as solid,
yield 60 mg, 88%.
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c) 2nd, 3rd, and 4th recycle. For the 2nd, 3rd, and 4th recycles, similar procedures were
used as described above. Yields of 58 mg (85%), 59 mg (86 %), 60 mg (88%) for the 2nd,
3rd, and 4th recycles were obtained.

6.2.9. Catalyst stability in PS-750-M

Figure 6.1. Stock solution of catalyst in 3wt% PS-750-M.
In a 4 mL microwave reaction vial, 21 mg catalyst 9 (for six catalytic reactions at 0.25
mmol scale) was added. The vial was closed with a rubber septum and evacuated and
backfilled with argon. 2 mL of 3 wt.% aqueous of PS-750-M was added to it. The reaction
vial was stirred at room temperature for up to 72 hours. After 72 hours, the catalytic activity
of the aged catalyst was compared with the fresh catalyst, and no difference in activity was
observed.
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6.2.9.1. Catalytic reaction with aged catalyst
In a separate 4 mL microwave reaction vial, 52 mg of 39 (0.25 mmol) and 57 mg of 37 (57
mg, 0.3 mmol) were added. The reaction vial was closed with a rubber septum and the
mixture evacuated and back-filled with argon. 0.33 mL of the aged solution of catalyst was
added to the reaction mixture. An additional 0.2 mL solution of PS-750-M was added to
the reaction mixture and stirred for 48 hours. Complete consumption of starting material
was observed. Stirring was stopped and the reaction vial was allowed to cool to rt. 0.5 mL
EtOAc was added to the reaction mixture and the mixture was stirred for a minute. Stirring
was stopped to separate organic and aqueous layers. The organic layer was withdrawn via
syringe. A similar extraction process was repeated for additional time. The combined
organic layer was dried over anhydrous sodium sulfate. Volatiles were removed under
reduced pressure to obtain semi pure compound as off-white solid which was then purified
by flash chromatography over silica gel using 10% EtOAc/hexanes, Rf 0.32 as eluent. The
pure product was obtained as an off-white solid, yield 61 mg (88%).

6.2.9.2. Stability confirmation by NMR spectroscopy
The remaining aged catalyst was stirred for a week. After a week, the catalyst was
extracted from the aqueous solution of PS-750-M and analyzed for 31P NMR
spectroscopy. 31P NMR spectroscopy was preferred over 1H NMR due to the presence of
surfactant in the extract. Results are shown below:
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6.2.10. Cryo-TEM analysis of aged catalyst
To confirm that palladium did not form aggregates, the sample of the aged catalyst was
filtered through highly porous filter paper and then analyzed by cryo-TEM analysis.
Analysis revealed a lack of nanoaggregates of palladium.

6.2.11. Effect of substrate to the size of nanomicelles – DLS experiments
5 mg of 4-brormoquinoline was dissolved in 2 mL of 3 wt.% aqueous solutions of PS-750M. The mixture was stirred for 2 hours to ensure dissolution in micellar media. The sample
was analyzed for the dynamic-light scattering experiment to fine average particle size.
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Compared to neat 3 wt.% PS-750-M/H2O, particle size was more than double when the
substrate was dissolved/accommodated in the nanomicelles.

6.2.12. Control experiments
6.2.12.1. NMR spectroscopy. In a reaction vial, 10 mg of 4-bromoquinoline (0.05 mmol)
and 23 mg catalyst 9 (0.05 mmol) were dissolved in 5 mL CDCl3. The mixture was
immediately analyzed by 31P NMR spectroscopy.
No oxidative addition was observed as per 1H NMR spectra.
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6.2.13. General Procedure for Suzuki–Miyaura Cross-Coupling reaction
In an oven-dried 4 mL reaction vial equipped with a Teflon-coated magnetic stir bar,
Bromo(iso)quinoline (0.1-0.5 mmol), boronic acid/MIDA boronate ester (1.2 equiv.),
potassium phosphate monohydrate (2.0 equiv.), and the palladium catalyst (3 mol %) were
added. The reaction vial was closed with a rubber septum and the mixture was evacuated
for a minute and backfilled with argon. This process was repeated twice. Freshly degassed
aqueous surfactant solution of 3 wt % PS-750-M (0.5 – 1.0 mL) was added to the reaction
mixture. The rubber septum was wrapped with PTFE tape. Black electrical tape was placed
on PTFE tape and then the septum was wrapped with parafilm. The reaction mixture was
stirred at 45 oC till the complete consumption of starting material. Progress of the reaction
was monitored by GCMS and/or TLC. After complete consumption of starting material,
reaction the mixture was allowed to cool to room temperature. The mixture was diluted
with a minimal amount of EtOAc (ca. 1 mL) and stirred for a minute at rt. Stirring was
stopped and organic and aqueous layers were allowed to separate. The organic layer was
separated by using a syringe or pasture pipette. If needed similar extraction process was
repeated. The combined organic layer was dried over anhydrous Na2SO4, volatiles was
removed under reduced pressure using a rotary evaporator to obtain a semi-pure product,
which was purified by flash chromatography over silica gel using EtOAc/hexanes as eluent.

6.2.14. Gram-Scale Synthesis of 16
An oven-dried 25 mL round-bottomed flask equipped with a Teflon-coated magnetic spin
bar, 2-Bromoquinoline (1.0 g, 4.8 mmol), 4-(Trifluoromethyl)phenylboronic acid (1.09 g,
5.76 mmol), K3PO4•H2O (2.22 g, 9.6 mmol), and the palladium catalyst 9 (35 mg, 0.072
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mmol, 1.5 mol%) were added. The reaction flask was closed with a rubber septum. The
mixture was evacuated and then backfilled with argon. This process of evacuation and
backfilling was repeated two additional times. An aqueous solution of 3 wt % PS-750-M
(10 mL) was added to the reaction mixture. The rubber septum was wrapped with PTFE
tape, black electrical tape, and Parafilm. The reaction mixture was stirred at 45 oC for 24
hours. After complete consumption of starting material as monitored by TLC and GCMS,
stirring was stopped and the mixture was allowed to cool to room temperature. Solid was
filtered over a frit and then washed with additional 10 mL water. Solid was dried under
reduced pressure to obtain pure compound as off-white solid, yield 1.22 g (94 %).
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6.2.15. Compound characterization
4-(1-Naphthalenyl)-quinoline (3)2a

N

Light yellow solid, mp 145-147 oC, yield 50 mg (78%), Rf 0.56 (1:9 EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3) δ 9.03 (d, J = 4 Hz, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7. 98 (q, J =
8.0 Hz, 2H), 7.72 (dtd, J = 8.4, 6.7, 1.4 Hz 1H), 7.61 (dd, J = 8.2, 7.0 Hz, 1H), 7.51 – 7.43
(m, 4H), 7.37 – 7.30 (m, 3H).
4-[4-(Trifluoromethyl)-phenyl]-quinoline (13)
CF3

N

Yellow solid, mp 55-57 oC, yield 50 mg (73%), Rf 0.45 (1:9 EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3) δ 8.99 (d, J = 8.4 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7. 84-7.71 (m, 4H),
7.64 (d, J = 8.4 Hz 2H), 7.54 (t, J = 8.0 Hz, 1H), 7.35 (d, J = 4.0 Hz 1H); 19F NMR (376
MHz, CDCl3) δ 62.61 (d, J = 11.6 Hz, 3F); 13C NMR (101 MHz, CDCl3) δ 150.1, 148.8,
147.0, 141.9, 141.8, 130.2, 130.1, 129.8, 127.2, 127.1 (q, J(C,F) = 272 Hz,), 126.5, 125.7,
125.5, 121.4. IR (cm-1) = 2928 (w), 1620 (s), 1572 (s), 1324 (s). HRMS [(ESI), (C16H10F3N
+ H)+] calcd = 274.0844, found m/z 274.0841.
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4-(2-Fluorophenyl)-quinoline (14)

F

N

Light yellow solid, mp 74-76 oC, yield 38 mg (68 %), Rf 0.24 (2:8 EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3) δ 8.98 (d, J = 4.4 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H), 7.76-7.69
(m, 2H), 7.54-7.49 (m, 2H), 7.43-7.37 (m, 2H), 7.32 (dd, J = 0.8, 1.2 Hz, 1H), 7.29 (dd, J
= 1.2, Hz, 1H); 19F NMR(376 MHz, CDCl3) δ -113.79 (s, 1F); 13C NMR (101 MHz, CDCl3)
δ 162.1, 159.7, 154.2, 148.5, 136.3, 131.7, 130.9 (d, J(C,F) = 8.4 Hz), 129.8 (d, J(C,F) = 10
Hz), 128.0, 127.6, 127.4, 126.8, 124.8, 122.6 (d, J(C,F) = 8.4 Hz), 116.4 (d, J(C,F) = 23 Hz).
IR (cm-1) = 3062 (w), 1587 (s), 1488 (s), 1449 (s), 759(s). HRMS [(ESI), (C15H10FN+ H)
+

] calcd = 224.0876, found m/z 224.0872.

4-(4-Chlorophenyl)-quinoline (15)2b
Cl

N

Yellow solid, yield 51 mg (84%), Rf 0.65 (1:9 EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3) δ 8.95 (d, J = 4.0 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.75
(t, J = 8.0 Hz 1H), 7.52 (q, J = 8.0 Hz 2H), 7.45 (d, J = 4.0 Hz 2H), 7.41 (d, J = 8.0 Hz
1H), 7.32 (d, J = 4.0 Hz 1H).
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2-[4-(Trifluoromethyl)phenyl]-quinoline (16)2c

N

CF3

Yield 61 mg (88%), Rf 0.32 (1:9 EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) δ 8.29 (q,
3H), 8.19 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.79-7.75
(m, 3H), 7.58(t, J = 8.4 Hz, 1H); 19F NMR (376 MHz, CDCl3) δ -62.61 (s, 3F).
2-(2-Methoxyphenyl)-quinoline (17)2c
OMe
N

Yield 40 mg (68%), Rf 0.55 (2:8 EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) δ 8.16
(dd, J = 8.4, 8.0 Hz, 2H), 7.89-7.82 (m, 3H), 7.71 (t, J = 7.6 Hz, 1H), 7.53 (t, J = 8.0 Hz
1H), 7.45-7.41 (m, 1H), 7.13 (t, J = 7.6 Hz 1H), 7.04 (d, J = 8.4 Hz 1H), 3.87 (s, 3H).
2-(3-Furanyl)-quinoline (18)2d

N

O

Dark brown solid, mp 61-62 °C, yield 35 mg (72%), Rf 0.29 (1:9, EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3) δ 8.14 (d, J = 8.0 Hz 2H), 8.08 (d, J = 8.0 Hz, 1H), 7.79 (d, J =
8.0 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.60 (d, J = 12 Hz, 1H), 7.55 (s, 1H), 7.49 (t, J = 4
Hz, 1H), 7.12 (s, 1H).
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2-(2-Fluorophenyl)-quinoline (19)2e
F
N

Yellow oil, yield 48 mg (86 %), Rf 0.32 (1:9 EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)
δ 8.22 (d, J = 8.0 Hz, 2H), 8.16 (d, J = 8.0 Hz, 1H), 7.91-7.85 (m, 2H), 7.76-7.72 (m, 1H),
7.58 (t, J = 8.0 Hz, 1H), 7.47-7.41 (m, 1H), 7.32 (t, J = 6.8 Hz, 1H), 7.20 (q, J = 8.0 Hz,
1H); 19F NMR (376 MHz, CDCl3) δ -117.29 (s, 1F).
1-[4-Fluoro-3-(2-quinolinyl)phenyl]-ethanone (20) CAS No.: 1499663-11-4
F
N

C(O)Me

Light yellow solid, yield 52 mg (77%), Rf 0.64 (1:9 EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3) δ 8.73 (dd, J = 2.4 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 8.108.06 (m, 1H), 7.91-7.87 (m, 2H), 7.79-7.75 (m, 1H), 7.61-7.57 (m, 1H), 7.29 (dd, J = 8.8,
8.4 Hz, 1H), 2.69 (s, 3H); 19F NMR (376 MHz, CDCl3) δ -109.82 (s, 1F).
2-(4-Chloro-phenyl)-quinoline (21)2e

N

Cl

White solid, mp = 110-112 °C, yield 43 mg (72 %), Rf 0.34 (1:9 EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3) δ 8.23 (d, J = 8.8 Hz, 1H), 8.12 (d, J = 9.2 Hz, 3H), 7.87 (q, J = 8.8 Hz,
2H), 7.75 (d, J = 8.0 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 8.4 Hz, 2H).
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2-[4-Nitrophenyl]-quinoline (22)2c

N

NO2

Yellow solid, yield 59 mg (93%), Rf 0.55 (1:9 EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3) δ 8.38 (d, J = 1.2 Hz, 4H), 8.30 (d, J = 8.8 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.94
(d, J = 8.8 Hz 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.79 (t, J = 7.2 Hz, 1H), 7.61 (t, J = 7.2 Hz,
1H).
2-[3-(Trifluoromethyl)-phenyl]- quinoline (23)2f

CF3

N

Light yellow solid, yield 61 mg (88 %), Rf 0.65 (1:9 EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3) δ 8.47 (s, 1H), 8.36 (d, J = 8.4 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 8.4
Hz, 1H), 7.88 (q, J = 8.8 Hz, 2H), 7.74 (m, Hz, 2H), 7.65 (t, J = 8.8 Hz, 1H), 7.57 (t, J =
8.8 Hz, 1H); 19F NMR (376 MHz, CDCl3) δ -62.44 (s, 3F).
2-[3, 5-Bis-(Trifluoromethyl)phenyl]-quinoline (24)2g

CF3

N

CF3

Light yellow solid, yield 71 mg (82 %), Rf 0.75 (1:9 EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3) δ 8.66 (s, 2H), 8.32 (d, J = 6.4 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 7.96-7.92 (m,
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2H), 7.88 (d, J = 8.0 Hz, 1H), 7.79 (t, J = 8.0 Hz, 1H), 7.60 (t, J = 7.2 Hz, 1H); 19F NMR
(376 MHz, CDCl3) δ - 62.69 (s, 6F).
2-[1,4-benzodioxane]-quinoline (25)2h

O

N

O

White solid, yield 56 mg (84%), Rf 0.62 (1:9 EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)
δ 8.18 (d, J = 12 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 16 Hz, 2H), 7.74 (d, J = 2.4
Hz 1H), 7.72-7.67 (m, 2H), 7.50 (t, J = 8.0, 7.2 Hz 1H), 7.00 (d, J = 8.0 Hz, 1H), 4.30 (s,
4H).
2-(2-Thienyl)-quinoline (26)2c

S

N

Yellow oil, yield 27 mg (51%), Rf 0.23 (2:8 EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)
δ 8.92 (d, J = 4.4 Hz, 1H), 8.30 (d, J = 7.2 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.77-7.73 (m,
1H), 7.59- 7.55 (m, 1H), 7.53 (dd, J = 1.2 Hz, 1H), 7.45 (d, J = 4.4 Hz, 1H), 7.40 (dd, J =
1.2, 0.8 Hz, 1H), 7.24 (q, J = 3.2, 3.6 Hz, 1H).
2-(2-Benzofuranyl)-quinoline (27)2i

O

N

White solid, mp = 118–119°C, yield 34 mg (55%), Rf 0.38 (1:9 EtOAc/hexanes). 1H NMR
(400
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MHz, CDCl3) δ 8.13 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 8.8 Hz, 1H),
7.79 (dd, J = 1.2, 6.8 Hz, 1H), 7.74-7.69 (m, 2H), 7.66 (q, J = 2.0, 3.6, 4.4 Hz, 1H), 7.617.54 (m, 2H), 7.50 (d, J = 8.4 Hz, 1H), 7.38 (dd, J = 2.4, 1.6 Hz, 1H); 13C NMR (101 MHz,
CDCl3) δ 148.7, 141.9, 138.5, 136.3, 132.4, 130.6, 129.4, 128.8, 128.5, 127.8, 127.6,
127.2, 127.1, 125.9, 124.5,122.3.
2-(Benzoxadiazole)-quinoline (28)

N

N
N O

Light yellow solid, mp = 161–162°C, yield 53 mg (85%), Rf 0.42 (2:8 EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3) δ 8.56 (d, J = 12 Hz,1H), 8.49 (s, 1H), 8.33 (d, J = 8.0 Hz, 1H),
8.20 (d, J = 12 Hz, 1H), 7.99 (d, J = 9.4 Hz, 2H), 7.89 (d, J = 9.4 Hz 1H), 7.80 (t, J = 8 Hz
1H), 7.6 (t, J = 4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 155.7, 155.3, 149.2, 148.4, 136.9,
129.8, 127.8, 126.9, 125.7, 123.4, 121.9, 118.9, 106.4. HRMS [(ESI), (C15H9N3O + H)+]
calcd = 248.0824, found m/z 248.0820.
2-(2-methoxy-3-pyridinyl)-quinoline (29)

N

MeO

N

Light yellow solid, mp = 55–56°C, yield 30 mg (51%), Rf 0.52 (1:9 EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3) δ 8.32-8.26 (m, 2H), 8.18 (d, J = 8.4 Hz, 1H), 8.15 (d, J = 8.4
Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.84 (dd, J = 1.2, 6.8 Hz, 1H), 7.72 (m, 1H), 7.55 (m,
1H), 7.09 (q, J = 5.2, Hz, 1H), 4.05 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 161.5, 155.3,
148.4, 147.6, 140.1, 135.7, 129.7, 129.6, 127.6, 127.3, 126.6, 123.7, 122.8, 117.7, 53.7. IR
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(cm-1) = 2949 (w), 1770 (s), 1580 (s), 1404 (s). HRMS [(ESI), (C15H12N2O + H)+] calcd =
237.1028, found m/z 237.1024.

2-(3-Fluorophenyl)-quinoline (30)

N

F

Light yellow oil, yield 35 mg (63 %), Rf 0.32 (1:9 EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3) δ 8.24 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 7.6 Hz, 2H), 7.867.83 (m, 2H), 7.77-7.73 (m, 1H), 7.57-7.53 (m, 1H), 7.51-7.46 (m, 1H), 7.20-7.14 (m, 1H);
19

F NMR (376 MHz, CDCl3) δ -113.3 (s, 1F); 13C NMR (101 MHz, CDCl3) δ 148.8, 138.9,

137.5, 131.1, 130.9, 130.7, 130.8, 130.4, 129.2, 128.9, 128.3, 128.0, 127.9, 116.7, (d, J(C,F)
= 21.4 Hz), 114.9 (d, J(C,F) = 22.9 Hz). IR (cm-1) = 2983 (w), 1735 (w), 1372 (s), 1237 (s).
HRMS [(ESI), (C15H10FN+ H)+] calcd = 224.0876, found m/z 224.0872.
4-(2,6-dimethoxyphenyl)-quinoline (31)

MeO

OMe

N

Yellow solid, mp = 136–137°C, yield 50 mg (75%), Rf 0.45 (2:8 EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3) δ 8.95 (s, 1H), 8.1 (d, J = 8.0 Hz 1H), 7.67 (t, J = 8 Hz, 1H), 7.49 (d, J
= 8.8 Hz 1H), 7.44-7.39 (m, 2H), 7.29 (d, J = 4.0 Hz 1H), 6.72 (d, J = 8.0 Hz 2H), 3.65 (s,
6H); 13C NMR (101 MHz, CDCl3) δ 158.1, 150.1, 148.5, 148.4, 142.5, 130.2, 129.7, 129.0,
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126.1, 123.4, 121.7, 115.1, 104.2, 55.9. IR (cm-1) = 2931 (w), 1600 (d), 1472 (s), 1249 (s),
1110 (s). HRMS [(ESI), C17H15NO2+ H)+] calcd = 266.1181, found m/z 266.1178.

8-[4-(Trifluoromethyl)phenyl]-5-isoquinolinamine (32)
CF3

N
NH2

Brown solid, mp = 162–163°C, yield 60 mg (83%), Rf 0.20 (4:6 EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3) δ 9.37 (s, 1H), 8.47 (d, J = 6.0 Hz, 1H), 7.74 (d, J = 7.6 Hz, 2H), 7.60
(d, J = 5.6 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 1H), 6.89 (d, J = 8.0 Hz,
1H), 4.55 (s, 2H);
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F NMR (376 MHz, CDCl3) δ -62.44 (s, 3F);
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C NMR (101 MHz,

CDCl3) δ 146.7, 143.8, 143.5,134.7, 132.4, 130.5, 129.5 (q, J(C,F) = 31 Hz), 129.2, 127.9,
125.6, 123.1 (q, J(C,F) = 272 Hz),118.7, 118.4, 110.4. IR (cm-1) = 2985 (w), 1737 (s), 1373
(s), 1236 (s), (s), 1044 (s). HRMS [(ESI),(C16H11F3N2+ H)+] calcd = 289.0947, found m/z
289.0949.
5-[4-(Trifluoromethyl)phenyl]-quinoline (33)
CF3

N

188

Off-white solid, mp = 57–58°C, yield 50 mg (73%), Rf 0.23 (1:9 EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3) δ 8.95 (d, J = 3.2 Hz, 1H), 8.16 (t, J = 9.2 Hz, 2H), 7.77 (t, J = 7.2 Hz,
3H), 7.58 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 6.4 Hz, 1H), 7.38 (dd, J = 4.0 Hz, 4.4 Hz, 1H);
19

F NMR (376 MHz, CDCl3) δ -62.84 (s, 3F). 13C NMR (101 MHz, CDCl3) δ 150.6, 148.6,

143.2, 139.0, 133.9, 130.5, 130.0, 129.7 (q, J(C,F) = 30 Hz), 129.0, 127.5, 126.5, 125.6,
122.2 (q, J(C,F) = 271 Hz), 121.5. IR(cm-1) = 3034 (w), 1737 (s), 1497 (s), 1321 (s). HRMS
[(ESI), (C16H10F3N + H)+] calcd = 274.0844, found m/z 274.0841
5-(1-Naphthalenyl)-quinoline (34)

N

Light yellow solid, mp = 125–126°C, yield 50 mg (78%), Rf 0.52 (1:9 EtOAc/hexanes). 1H
NMR
(400 MHz, CDCl3) δ 8.90 (d, J = 3.2 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.89 (t, J = 8.0, 7.6
Hz, 2H), 7.77 (t, J = 8.0 Hz, 1H), 7.67 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 7.2 Hz, 2H), 7.40
(d, J = 6.8 Hz, 2H), 7.32 (d, J = 6.4 Hz, 2H), 7.23 (q, J = 8.0 Hz, 1H); 13C NMR (126 MHz,
CDCl3) δ 150.5, 148.4, 138.9, 137.1, 135.0, 133.7, 132.9, 129.4, 129.1, 128.4, 128.2, 128.0,
126.4, 126.1, 125.9, 125.5, 121.2. HRMS [(CI), (C19H13N + H)+] calcd = 256.1126, found
m/z 256.1123.
1-(2-Fluorophenyl)-isoquinoline (35)2j
F
N

189

Yellow solid, yield 47 mg (84%), Rf 0.53 (1:9 EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3) δ 8.65 (d, J = 5.6 Hz, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.82 (dd, J = 2.8 Hz, 1H), 7.70
(t, J = 6.4, 6.8 Hz, 2H), 7.59-7.53 (m, 2H), 7.50-7.47 (m, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.23
(d, J = 8.8 Hz, 1H); 19F NMR (376 MHz, CDCl3) δ -114.23 (s, 1F).
1-(4-(Trifluoromethyl)phenyl)naphthalene (38)2k
CF3

Colorless crystalline solid, yield 66 mg (97 %), Rf 0.45 (1:9 EtOAc/hexanes). 1H NMR
(400 MHz,CDCl3) δ 7.92 (t, J = 8.4 Hz, 2H), 7.82 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 8.0 Hz,
2H), 7.62 (d, J =7.6 Hz, 2H), 7.54 (q, J = 7.2 Hz, 2H), 7.48-7.41 (m, 2H); 19F NMR (376
MHz, CDCl3) δ -62.35 (s, 1F).
6.2.15.1. References
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6.3.1. Synthesis procedure and analytical data
3-(Bis(2-hydroxyethyl)amino)propane-1,2-diol (3.47)
OH
OH
N
HO

OH

3.47
Aminotetrol 3.47 was synthesized according to the literature procedure by Sela and
Vigalok.2 A mixture of glycidol (2.5 g, 34.2 mmol) and diethanolamine (1) (3.0 g, 28.5
mmol) was stirred in a 250 mL two-necked round bottom flask equipped with stir bar and
septum at room temperature for 3 h to yield 2 as white jelly. The product was used without
further purification; 1H NMR (400 MHz, D2O) δ 2.60 (dd, J =13.7, 8.2 Hz, 1H), 2.68 (dd,
J=13.7, 4.2 Hz, 1H), 2.71-2.82 (m, 4H), 3.52 (dd, J =11.7, 6.1 Hz, 1H), 3.63 (dd, J =11.7,
4.2 Hz 1H), 3.66-3.72 (m, 4H), 3.76 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 55.9,
57.0, 58.8, 64.0, 69.2 ppm.

2,2'-(((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethan-1-ol) (3.48)

O
O
N
HO

3.48

OH

To a 500 mL two-necked round bottom flask equipped with stir bar and a glass stopper was
added aminotetrol 3.47 (10.0 g, 55.8 mmol) and TsOH (10.6 g, 55.8 mmol). To the mixture
was added dry toluene (120 mL) and the flask was attached to a Dean-Stark trap fitted with
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a reflux condenser. Cyclohexanone (8.2 g, 83.7 mmol) was added to the reaction mixture
via syringe through the side neck while stirring. The reaction mixture was heated at reflux
under argon for 8 h whereupon it was allowed to cool to room temperature. The solvent
then was removed by rotary evaporation. To the residue was added saturated aqueous
NaHCO3 (100 mL) and the mixture was stirred for 15 minutes and then extracted with
CH2Cl2 (3 x 80 mL). The combined organic layer was dried over anhydrous Na2SO4,
filtered, and concentrated by rotary evaporation. The crude product was purified by
column chromatography (SiO2, CH3OH:CH2Cl2, 1:9) to afford diol 3 as viscous yellow oil
(10.12 g, 70 %); TLC, Rf 0.45 (CH3OH:CH2Cl2, 1:9); FT-IR 3391, 2933, 2860, 1448, 1365,
1280, 1097, 1032 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.29 (s, 2H); 1.47 (d, J = 18.8 Hz,
6H); 1.51 (s, 2H); 2.55 (m, 6H); 3.49 (m, 4H); 3.51 (s, 3H); 3.80 (s, 2H); 3.96 (t, J = 8H,
1H); 4.15 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 23.9, 24.1, 25.2, 34.9, 36.6, 57.4,
58.2, 59.9, 67.3, 74.4, 110.2 ppm; HRMS m/z calcd C13H26NO4 [M + H]+ 260.1856,
observed 260.1857.

2,2'-(((((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethane-2,1diyl))bis(oxy))bis (isoindoline-1,3-dione) (3.49)
O
O
O

N

N O
O

O
O N

3.49

O

To a stirred solution of diol 3.48 (5.0 g, 19.2 mmol), triphenylphosphine (11.1 g, 42.3
mmol) and N-hydroxyphthalimide (6.9 g, 42.3 mmol) in a 1:2 mixture of THF:toluene (150
mL) at 0 °C and under argon atmosphere was added dropwise diisopropyl azodicarboxylate
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(DIAD) (8.3 g, 41.4 mmol). The resultant red mixture was allowed to warm to rt and stirred
for 16 h. The solvent then was removed by rotary evaporation. Et2O (100 mL) was added,
and the mixture was cooled to 0 °C for 3 h. The resultant suspension was decanted from
the off-white precipitate and the solution was chilled to –10 °C for another 3 h and again
decanted to remove a second crop of precipitated solids. The solvent then was removed by
rotary evaporation and a 1:1 mixture of hexanes:EtOAc, (100 mL) was added to the crude
residue. The precipitated solids were collected using a Buchner funnel. The filtrate was
concentrated and the residue was purified via column chromatography (SiO2,
EtOAc:hexane, 7:3) to afford a yellow solid (6.2 g, 59%); TLC, Rf 0.50 (hexanes:EtOAc,
3:7); FT-IR 3052, 2939, 1735, 1264, 1119 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.32 (s,
2H); 1.52 (d, J = 17 Hz, 4H); 2.92 (s, 2H); 3.20 (s, 4H); 3.65 (t, J = 7.5 Hz, 1H); 4.09 (t, J
= 7.5 Hz, 1H); 4.29 (m, 1H); 4.65(m, 5H); 7.71 (m, 4H); 7.78 (m, 4H) ppm; 13C NMR (100
MHz, CDCl3) δ 24.3; 24.4; 25.5, 35.4; 36.9; 53.5; 58.0; 68.1; 75.0; 110.3; 123.9; 129.4;
134.8; 163.8 ppm; HRMS m/z calcd C29H32N3O8 [M + H]+ 550.2184, observed 550.2185.

N-((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)-2-((1,3-dioxoisoindolin-2-yl)oxy)-N-(2((1,3-dioxoisoindolin-2-yl)oxy)ethyl)-N-methylpropan-1-ammonium iodide (3.45a)
O
O
O

I

N

N O
O

O
O N

3.45a

O

A pressure tube was charged with a solution of compound 4 (5.0 g, 9.1 mmol) in CH2Cl2
(45 mL). To the solution was added iodomethane (23.2 g, 163.8 mmol). The tube was
sealed and then heated at 50 °C for 12 h. After cooling, the tube was opened and the solvent
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and excess iodomethane were evaporated using a rotary evaporator in a closed fume hood.
The residue was purified by silica column chromatography, eluting with a 9:1 mixture of
CH2Cl2:CH3OH, to yield ammonium iodide 5 (4.0 g, 64 %) as a yellow solid; mp = 175
°C; TLC, Rf 0.44 (CH3OH:CH2Cl2, 1:9); FT-IR 2939, 2861, 1790, 1731, 1611 cm–1; 1H
NMR (125 MHz, CDCl3) δ 1.41 (s, 2H); 1.61 (m, 8H); 3.79 (q, J = 6.5 Hz, 1H); 3.88 (s,
3H); 3.96 (q, J = 11 Hz, 1H); 4.34 (q, J = 7 Hz, 1H); 4.57 (s, 3H); 4.68 (m, 2H); 4.82 (m,
5H); 7.81 (m, 4H); 7.86 (m, 4H) ppm; 13C NMR (125 MHz, CDCl3) δ 23.9, 24.2, 25.0,
34.9, 36.3, 51.8, 62.1, 62.5, 67.2, 69.5, 72.2, 112.8, 124.2, 128.6, 135.2, 163.2 ppm; HRMS
m/z calcd C30H34N3O8+ 564.2340, observed 564.2342.

N-((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)-N-methyl-2-((((E)tetradecylidene)amino)oxy)-N-(2-((((E)-tetradecylidene)amino)oxy)ethyl)propan-1ammonium iodide (3.51)

O
O
N

I

HO

O
O

O
N
O

N
N

3.51

OH

3.50b

To a solution of bis(pthalimide) 3.50a (3.0 g, 4.3 mmol) in CH2Cl2 (15 mL) at rt was added
dropwise hydrazine monohydrate (3.2 g, 65.1 mmol). After stirring at rt for 4 h, the reaction
mixture was filtered to remove the white precipitate and the retentate was washed with
small portions of CH2Cl2. The combined filtrate was evaporated by rotary evaporation to
afford the crude bis(aminooxy) 3.50b as a yellow oil, which was used immediately in the
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next step without purification. The crude product was dissolved in CH2Cl2 (20.0 mL) and
the solution was cooled to 0 °C. To the solution was added dropwise tetradecanal (1.9 g,
8.9 mmol). The reaction mixture was allowed to warm to rt and stirred for 10 h, whereupon
the solvent was removed by rotary evaporation. The crude product was purified by silica
column chromatography, eluting with a 9:1 mixture of CH2Cl2:CH3OH, to afford
bis(oxime ether) 3.51 (3.06 g, 87%) as off-white oil; TLC, Rf = 0.55 (CH2Cl2:CH3OH,
9:1); FT-IR 2924, 2853, 1662, 1449 cm–1; 1H NMR (500 MHz, CDCl3) (E,E)-isomer: δ
0.83 (t, J = 6.5 Hz, 6H); 1.25 (m, 40H); 1.43-1.56 (m, 10H), 1.62 (m, 4H); 2.15 (q, J = 6.5
Hz, 4H); 3.50 (s, 3H); 3.70 (m, 2H); 4.08 (m, 2H); 4.39 (m, 4H); 4.47 (m, 4H); 4.74 (m.
1H); 6.72 (t, J = 6.2 Hz, 1H); 7.49 (t, J = 6.2 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3)
δ 14.2, 23.9, 24.1, 25.0, 25.1, 32.0, 35.0, 36.4, 50.6, 56.0, 56.2, 64.5, 66.9, 67.2, 69.4,
102.7, 112.4 ppm; HRMS m/z calcd C42H82N3O4+ 692.6300, observed 692.6305.

2,3-Dihydroxy-N-methyl-N-(2-((((E)-tetradecylidene)amino)oxy)ethyl)-N-(2-((((E)tetradecylidene)amino)oxy)ethyl)propan-1-ammonium iodide (OEL4)

HO
HO

O

I
N

O

N
N
OEL4

Acetal 3.51 (2.0 g, 2.4 mmol) was dissolved in a 1:1 mixture of THF:hexane (15 mL) and
the solution was cooled to 0 °C whereupon 5% aq. AcOH (10 mL) was added. The reaction
mixture was allowed to warm to room temperature and stirred 48 hours. The reaction
mixture then was cooled to 0 °C before adding 10 mL of Et2O and rotary evaporated to
remove excess hexane. The product was dried under vacuum for 30 minutes and carefully
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neutralized by dropwise addition of saturated aq. NaHCO3. The neutralized solution was
extracted using dichloromethane (3 x 15 mL). The combined dichloromethane phase was
dried over anhydrous Na2SO4, filtered, and concentrated by rotary evaporation under
reduced pressure to afford the crude product. The crude diol was purified via column
chromatography (SiO2, CH2Cl2:CH3OH, 9:1) to yield OEL4 (1.04 g, 58 %) as a light
yellow hygroscopic solid; TLC, Rf 0.69 (CH2Cl2:CH3OH, 9:1, PAA stain); FT-IR
(dissolved in CH2Cl2) 3323, 2926, 2855, 1682, 1496, 1466, 1202, 906 cm-1; 1H NMR (500
MHz, CDCl3) (E,E)-isomer: δ 0.88 (t, J = 6.5 Hz, 6H); 1.25 (m, 40H); 1.46 (m, 4H), 2.18
(m, 4H), 3.36 (s, 3H); 3.69 (m, 2H); 3.74 (m, 4H); 3.95 (m, 2H); 4.45 (m, 4H); 4.49 (m.
1H); 6.72 (t, J = 6.2 Hz, 1H); 7.39 (t, J = 6.2 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3)
δ 14.3, 22.9, 26.3 (2 signals), 26.7, 29.4, 29.6 (3 signals), 29.7, 29.9, 32.1, 51.9, 62.9, 64.5,
66.3, 66.4, 67.0, 67.5, 154.0, 154.6 ppm.
(((1,4-dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethane-2,1-diyl)
ditetradecanoate (3.53a)
O

O
O

O
N
O
O

3.53a

To a stirred solution of diol 3.48 (1.6 g, 6.32 mmol), myristoyl chloride (3.4 g, 13.91
mmol), and 4-Dimethylaminopyridine (0.038g, 5 mol%) in CH2Cl2 at 0 °C was added
dropwise triethylamine (1.4g, 13.91mmol). The resultant red mixture was allowed to warm
to rt and stirred for 12h. (78 %) The resultant suspension was filtered to remove the solid
by-product and the filtrate was concentrated by rotary evaporation to afford the crude
product. The crude product was purified by silica column chromatography
(Ethylacetae:Hexane 1:9) to afford 3.53a as a light yellow semi-solid (3.35 g, 78%); TLC,
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Rf 0.34, (Ethylacetae:Hexane 1:9, PAA stain); 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J =
7.0 Hz, 6H); 1.27 (m, 44H), 1.60 (m, 10H); 2.30 (m, 4H); 2.67 (m, 1H); 2.75 (m, 1H); 2.85
(m, 4H); 3.58 (m, 1H); 3.61 (m, 1H), 4.05 (m, 1H); 4.14 (m, 4H); 13C NMR (500 MHz,
CDCl3) δ14.0, 22.6, 23.7, 23.9, 24.6, 24.8, 25.0, 28.9, 29.1, 29.2 (2 signals), 29.3 (2
signals), 29.4, 29.5, 31.8, 33.8, 34.2, 34.9, 36.5, 53.5, 57.5, 62.2, 67.6, 74.4, 109.7, 173.7,
178.6.
N-((1,4-dioxaspiro[4.5]decan-2-yl)methyl)-N-methyl-2-(tetradecanoyloxy)-N-(2(tetradecanoyloxy)ethyl)ethan-1-aminium iodide (3.53b)

O
O

O

I

O
N
O
O

3.53b

A pressure tube was charged with a solution of compound 3.53a (2.4 g, 3.35 mmol) in
CH2Cl2 (25 mL). To the solution was added iodomethane (15.0 g, 105.9 mmol). The tube
was sealed and then heated at 50 °C for 8 h. After cooling, the tube was opened and the
solvent and excess iodomethane were evaporated using a rotary evaporator in a closed fume
hood. The residue was purified by silica column chromatography, eluting with a 8:2
mixture of CH2Cl2:CH3OH, to yield ammonium iodide 3.53b (2.58 g, 89 %) as a yellow
solid; mp = 185 °C; TLC, Rf 0.69 (CH3OH:CH2Cl2, 2:8, PAA stain); FT-IR (dissolved in
CH2Cl2) 2918, 2850, 1740, 1701, cm-1; 1H NMR (500 MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz,
6H); 1.27 (m, 40H), 1.35 (m, 14H); 2.36 (m, 4H); 3.48 (t, J = 13 Hz, 1H); 3.56 (s, 3H);
3.76 (t, J = 6.5 Hz, 1H); 4.0 (m, 1H), 4.11 (m, 1H); 4.17 (m, 2H); 4.38 (m, 1H); 4.61 (m,
4H); 4.76 (m, 2H);
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C NMR (500 MHz, CDCl3) δ14.2, 22.8, 23.9, 24.1, 24.8, 29.3, 29.4,

29.5, 29.6, 29.7, 32.0, 33.8, 34.2, 34.6, 36.4, 57.5, 67.2, 69.4, 110.1, 112.8, 172.9.
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2,3-dihydroxy-N-methyl-N,N-bis(2-(tetradecanoyloxy)ethyl)propan-1-aminium
iodide (DMDEG)

O
HO
HO

I
N

O
O
O

DMDEG 3.54

Acetal 3.53b (1.6 g, 1.9 mmol) was dissolved in CH2Cl2 (15 mL), and the solution was
cooled to 0 °C whereupon 5 % TFA/H2O (10 mL) was added. The reaction mixture was
allowed to warm to room temperature and stirred 36 hours. The reaction mixture then was
cooled to 0 °C and the excess CH2Cl2 was rotary evaporated. The product was dried under
vacuum for 30 minutes and carefully neutralized by dropwise addition of saturated aq.
NaHCO3. The neutralized solution was extracted using dichloromethane (3 x 15 mL). The
combined dichloromethane phase was dried over anhydrous Na2SO4, filtered, and
concentrated by rotary evaporation under reduced pressure to afford the crude product. The
crude diol was purified via column chromatography (SiO2, CH2Cl2:CH3OH, 9:1) to yield
DMDEG (1.041 g, 71 %) as a light yellow solid; mp = 175 °C; TLC, TLC, Rf 0.44
(CH2Cl2:CH3OH, 9:1, PAA stain); FT-IR (dissolved in CH2Cl2) 3331, 2922, 2853, 1739,
1676 cm-1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 6.5 Hz, 6H); 1.25 (m, 42H); 1.58 (m,
4H), 2.33 (t, J = 7 Hz, 4H), 3.30 (s, 3H); 3.49 (s, 1H); 3.72 (m, 4H); 3.94 (m, 4H); 4.54 (m,
4H); 13C NMR (100 MHz, CD3OD) δ 14.5, 23.7, 25.8, 30.2, 30.8 (3 signals), 33.1, 34.7,
51.1, 58.6, 63.4 (2 signals), 65.2, 66.9, 67.4. HRMS m/z [(ESI), (C36H72NO6 + H) +] calcd
C36H72NO6+ 614.5354, observed 614.5354.
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6.3.2. NMR Chemical shift assignments
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Table 6.3.1 1H NMR chemical shift assignments (CDCl3, 400 MHz)
C(1) C(2) C(3) C(1’) C(2’) C(1”)
3
4
5
6
7

2.55
3.49
4.15
2.61
3.96
3.65
2.92 4.29
4.09
3.79
4.34
4.85
3.96
4.57
3.70
4.08
4.74
3.95
4.17
3.69
4.49 3.95
3.70

OH

C(a)

C(b)

C(c)

C(d)

C(e)
/ Ci

C(f)
/ Ca

C(g)
/ Cb

C(h)
/ Cw

2.61

3.51

–

3.80a

–

1.51

1.47

1.29

–

–

–

–

3.20

4.35

–

–

–

1.56

1.52

1.32

–

–

7.78

7.71

4.82

3.88

–

–

1.61
1.71

1.61

1.41

–

–

7.86

7.81

4.47

3.50

–

0.83

3.36

2.15
2.24b
2.18
2.26b

1.62

4.45

7.39
6.70b
7.39
6.72b

1.46

0.88

4.72
4.68
4.30
4.39
3.74
3.77

–

1.43–1.56
–

–

–

–

13

C NMR (CDCl3, 100 MHz)

3

58.2 74.4 67.3 57.4

59.9

–

–

4

53.5 75.0 68.1 53.5

58.0

–

–

5

62.1 72.2 69.5 62.5

67.2

51.8

–

6

64.5 69.4 67.2 56.2

65.9

50.6

–

aConfirmed by D O shake; bshift of minor diastereomer.
2

110.2
110.3
112.8
102.7

34.9
36.6
35.4
36.9
34.9
36.3
34.7
36.4

23.9
24.1
24.3
24.4
23.9
24.2
23.9
24.1

25.2

–

–

–

–

25.5

163.8

129.4

134.8

123.9

25.0

163.2

128.6

135.2

124.2

25.1

112.4

32.0

25.0

14.2
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Table 6.3.2. 1H NMR Chemical shift assignments (CDCl3, 400 MHz)

9

C(1)
2.55
2.61
2.67
2.75
3.49
4.77

4.76

C(3)
3.49
3.96
3.61
4.02
3.76
4.38

10

3.65

3.48

3.80

3
8

C(2)
4.15
4.12

C(1’) C(2’) C(1”)

OH

C(a)

C(b)

C(c)

C(d) C(e)

Ca

Cb

Cw

–

–

–

1.56

0.87

2.61

3.51

–

3.80a

–

1.51

1.47

1.29

–

2.842.87

4.094.16

–

–

–

1.59– 1.62

1.37

–

4.004.23

4.61

3.56

–

158

1.63

–

2.36

1.65

0.88

3.94

4.54

3.30

–

2.33

1.58

0.88

–

–––

2.33

Table 6.3.3 13C NMR Chemical shift assignments (CDCl3, 500 MHz)
C(1)

C(2)

C(3) C(1’) C(2’) C(1”) C(a)

C(d)

C(e)

Ca

Cb

Cw

3

58.2

74.4

67.3

57.4

59.9

–

25.2

–

–

–

–

8
9

57.9
57.5

74.4
69.4

67.6
67.2

53.5
57.5

62.2

–

25.1
24.8

173.7
172.9

34.2
36.4

24.8
32.0

14.0
14.2

174.2

34.7

25.8

14.5

63.3
63.4
aConfirmed by D O shake; *(CD3OD, 400MHz)
2
10*

66.9

67.4

65.2

58.6

51.1

C(b) C(c)
34.9 23.9
110.2
36.6 24.1
109.7 36.5 34.9
112.8 36.4 34.2
––––––
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6.3.3. NMR Spectra
1

HNMR of 3-(Bis(2-hydroxyethyl)amino)propane-1,2-diol (3.47)
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HNMR of 2,2'-(((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethan-1-ol) (3.48)
O
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3.48
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CNMR of 2,2'-(((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethan-1-ol)
(3.48)
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1

HNMR of 2,2'-(((((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethane-2,1diyl))bis(oxy))bis (isoindoline-1,3-dione) (3.49)
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13

CNMR of 2,2'-(((((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethane-2,1diyl))bis(oxy))bis (isoindoline-1,3-dione) (3.49)
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HNMR of N-((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)-2-((1,3-dioxoisoindolin-2yl)oxy)-N-(2-((1,3-dioxoisoindolin-2-yl)oxy)ethyl)-N-methylpropan-1-ammonium iodide
(3.45a)
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13

CNMR of N-((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)-2-((1,3-dioxoisoindolin-2yl)oxy)-N-(2-((1,3-dioxoisoindolin-2-yl)oxy)ethyl)-N-methylpropan-1-ammonium iodide
(3.45a)
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1

HNMR of N-((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)-N-methyl-2-((((E)tetradecylidene)amino)oxy)-N-(2-((((E)-tetradecylidene)amino)oxy)ethyl)propan-1ammonium iodide (3.51)
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13

CNMR of N-((1,4-Dioxaspiro[4.5]decan-2-yl)methyl)-N-methyl-2-((((E)tetradecylidene)amino)oxy)-N-(2-((((E)-tetradecylidene)amino)oxy)ethyl)propan-1ammonium iodide (3.51)
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HNMR of 2,3-Dihydroxy-N-methyl-N-(2-((((E)-tetradecylidene)amino)oxy)ethyl)-N-(2((((E)-tetradecylidene)amino)oxy)ethyl)propan-1-ammonium iodide (OEL4)
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1

HNMR of 2,3-dihydroxy-N-methyl-N,N-bis(2-((((1E,9Z)-octadec-9-en-1ylidene)amino)oxy)ethyl)propan-1-aminium iodide (OEL5)

HO
HO

O

I
N

O

N
N
OEL5

1

HNMR of (((1,4-dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethane-2,1-diyl)
ditetradecanoate (3.53a)
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13

CNMR of (((1,4-dioxaspiro[4.5]decan-2-yl)methyl)azanediyl)bis(ethane-2,1-diyl)
ditetradecanoate (3.53a)
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HNMR of N-((1,4-dioxaspiro[4.5]decan-2-yl)methyl)-N-methyl-2-(tetradecanoyloxy)-N(2-(tetradecanoyloxy)ethyl)ethan-1-aminium iodide (3.53b)
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13

CNMR of N-((1,4-dioxaspiro[4.5]decan-2-yl)methyl)-N-methyl-2-(tetradecanoyloxy)N-(2-(tetradecanoyloxy)ethyl)ethan-1-aminium iodide (3.53b)
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1

HNMR of 2,3-dihydroxy-N-methyl-N,N-bis(2-(tetradecanoyloxy)ethyl)propan-1aminium iodide (DMDEG) 3.54
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CNMR of 2,3-dihydroxy-N-methyl-N,N-bis(2-(tetradecanoyloxy)ethyl)propan-1aminium iodide (DMDEG) 3.54
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6.4.1.5 Non-specific (nc-1) control DsiRNA Sequences
6.4.2 Cryo-EM grid preparation and image acquisition
6.4.3 Preparation of RNA-Lipid Vesicle Complexes (OEL-RNA-NPs)
6.4.3.1 Optimization of Vesicle/Nucleic Acid Binding Ratios
6.4.3.2 Preparation of OEL vesicle-DsiRNA complexes for Gene Silencing and
Animal Studies
6.4.1

Materials and methods

6.4.1.1 Materials
Phospholipids were procured from Avanti Polar Lipids Inc. (Alabaster, AL). Human breast
cancer cell line MDA-MB-231, human lung cancer cell line (A549) and luciferase
expressing A549 cells (A549-luc2) cells were purchased from ATCC (Manassas, VA,
USA). Green fluorescent protein expressing MDA-MB-231 cells (MDA-MB-231-eGFP)
were procured from Cell Biolabs Inc. (San Diego, CA, USA). Nuclease protease free water
was purchased from Quality Biological Inc. (Gaithersburg, MD). Cell titer blue reagent
and luciferase assay kit were obtained from Promega Corp. (Madison, WI, USA). Cell
culture reagents and media were purchased from Invitrogen (Grand Island, NY, USA). The
sequences for the sense and anti-sense RNA strands for the Dicer substrate of RNAs
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(DsiRNAs), and fluorescently labeled RNA sequences were purchased from Integrated
DNA Technologies, Inc. (Coralville, Iowa, USA).
MDA-MB-231 (human breast cancer) cells either stably expressing enhanced green
fluorescent protein (GFP) or non-GFP cells were maintained in a Dulbecco’s modified
Eagle’s medium (DMEM) 10% (v/v) heat-inactivated FBS (fetal bovine serum), 100
i.u./mL penicillin and 100 μg/mL streptomycin under a humidified 5% CO2 incubator at
37 °C. On the basis of the experimental requirements, either GFP-expressing or non-GFP
MDA-MB-231 cells were used.

6.4.1.2 Methods
6.4.1.2.1

Making liposomes

Materials
-

Glass tubes with caps

-

Plastic falcon tubes with caps (5mL)

-

Lipid

-

crimper, and decapper

-

Nitrogen gas/desiccator

-

Nuclease-free water

-

Water Bath

-

Dry ice

-

Sonicator

-

Parafilm

-

Vortex
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Lipid Film Preparation & Desiccation
1. Calculate the amount of lipids necessary for your films according to the molar ratio
of the formulation you plan on using. (Use the Excel liposome composition sheet)
2. Label glass tubes with caps with each lipid formulation you intend on making.
Under a fume hood, pipette the necessary amount of lipid (or lipids and other
components) to each tube. (Because the lipids are in chloroform, pipette the lipids
quickly so the tip does not dissolve)
3. Evaporate the solvent with a stream relatively slowly under the hood, rotating the
tube to create a uniform film at the bottom of the tube. Add nitrogen until the film
is completely dry. (Make sure the nitrogen stream is not too strong, it will cause
the lipid solution to splatter)
4. Cover the tubes in aluminum foil and place them in a desiccator for 24 hours with
the caps loosely placed on the tubes. This will ensure that the films are dry.
Reconstitution and Sonication
1. Remove the tubes from the desiccator, add the appropriate amount of nuclease-free
water to each tube. Parafilm each sample and vortex briefly.
2. Place each sample in a 50°C water bath for five minutes. Vortex again and return
the samples to the water bath for another 15 minutes. Vortex a final time. (If the
sample aggregates, you can keep the tube in the water bath for a longer period of
time)
3. Transfer the samples to plastic falcon tubes, parafilming each tube. Begin a freezethaw cycle using the dry ice and 50° water bath. Start by placing the samples in the

245

dry ice for five minutes, the transfer them to the water bath for five minutes. Repeat
these four more times.
4. Clean the sonicator probe using ethanol solution, then sonicate for one minute in
HBS buffer.
5. Sonicate each sample. To sonicate, clamp the sample so the probe is immersed in
the lipid solution without touching the sides of the tube. Place a beaker of ice around
the tube to make sure the sample does not overheat. Make sure the settings on the
sonicator read as follows: Mode: time (min/sec) & pulse Settings: on – 1:00, off –
1:00, amplitude – 30, exp. Time – 0:09. Each sample will take nine minutes to
sonicate.
6. Conduct necessary characterizations on each sample of liposome.

6.4.1.2.2

Sizing samples and zeta potential using the nanosizer

Materials
-

1.5mL disposable microcuvettes

-

Liposome sample

-

Buffer (HBS)

-

Malvern Zetasizer

General Protocol
1. Open the Zetasizer software on the computer and turn on the Zetasizer.
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2. Create a new measurement file. Select “measure” from the above menu and click
“manual.” In the pop-up box, name the sample and make sure the temperature is
set for 25° with an equilibration time of 20 seconds.
3. Take a microcuvette, being careful not to smudge the clear sides to be read by the
nanosizer. Pipette 5μL of the liposome sample (less if there is a fluorescent
substance). Add 400μL of HBS buffer (pH 7.4, mixing well with the pipette. Avoid
producing air bubbles, as they affect the results of the sizing. For zeta potential,
dilute the sample (liposomes and liposome-complexed DsiRNA) in 10 mM NaCl.
Using the zeta-cuvettes and a total volume of 1 mL, the values were calculated from
the electrophoretic mobility using Smoluchowski approximation.
4. Insert the cuvette into the nanosizer and start the measurement. Each
measurement should take about 12-15 readings, taking three measurements total
(in triplicate in an automatic mode at 25 °C equipped with a 633 nm laser and a
back-scattering detector).

6.4.1.2.3

Making glycerol carrier for agarose gels

Materials:
•

Glycerol

•

10 x TBE

•

MilliQ Water

1. Take a 1.5 ml Eppendorf tube and add 400 ul MilliQ water and 100 ul of 10 x TBE
2. Locate the stock glycerol bottle and another 1.5 ml Eppendorf
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3. Pipette an approximate amount of glycerol into the Eppendorf (0.6 ml – 1 ml is
fine). Take care that only the pipette tip comes in contact with the glycerol.
*Glycerol is very viscous and will cling to the sides of the tip*
4. Discard used pipette tip used to draw stock glycerol.
5. Use a fresh pipette tip and carefully pipette 500 ul of glycerol from the aliquoted
Eppendorf. Slowly draw the glycerol up. Make sure to wait 5-10 seconds for the
glycerol to rise to an accurate volume
6. Pipette glycerol into the MilliQ and TBE solution. Go slow because the glycerol
will cause the solution to shoot up.
7. Pipette to mix
8. Close Eppendorf and vortex hard several times.
9. Any leftover stock glycerol can be stored at room temperature.

6.4.1.2.4 Making an agarose gel (Small)
Materials:
• 0.75 g Agarose
•

2.5 ml 10X TBE

•

47.5 ml water

•

1 X TBE buffer solution

•

Beaker (250 ml)

•

Graduated cylinder (50 ml)

•

Gel rig

•

Two small combs

•

Microwave
248

Procedures:
1. In a 250 beaker, weigh out 0.75g of agarose
2. In a 50 ml graduated cylinder, pour 2.5 ml 0f 10XTBE. Add dstilled water to the
50 ml mark. Pour this 50ml into the beaker of agarose
3. Microwave for approximately 45 seconds. If agarose has not completely dissolved,
microwave for another 10-15 seconds
4. Swirl *CAUTION: It will be hot, and the liquid will splash up when in contact with
hot glass. Use a paper towel to handle*
5. Repeat steps 4 & 5 until the shimmering specks of agarose solubilize and the
solution is generally clear
6. Cool flask off until it is touchable sans paper towel. The flask will still be very
warm.
7. Pour agarose mixture slowly into an assembly gel mold. When pouring, the gel
plate should be perpendicular to the path of the current (sealed tight against the wal
on either side) and both combs should be in grooves.
8. Once the gel has polymerized (it turns opaque), pour some 1 X TBE on top.
Carefully, remove both combs.
9. Remove the top plastic piece with the gel and turn it sideways so the wells are on
the side with the negative electrode. Pour 1 X TBE into the gel ring up to the “Fill
Line”. Placing the greet sheet below the rig will help to better visualize molecules
while loading
10. For loading the gel:
a. Cut out a piece of parafilm
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b. Pipet 2uL drops of agarose loading buffer/1 uL of glycerol onto the
parafilm.
c. Add 3 uL of each sample to a drop of agarose loading buffer/glyceroland
pipet up and down to mix.
d. Load each sample onto the agarose gel (skip a well inbetween if possible)
e. Attached the connection (negative end near the wells, positive end away
from the wells), and run at 120 volts for 20 minutes
f. Detach theconnection and take out the center potion with the gel
g.
6.4.1.2.5.

Scan the gel using typhoon scanner
RNA duplex assembly

Materials:
•

RNA Sense (sequence below)

•

RNA Antisense (sequence below)

•

10 x Tris borate Buffer (Stock pre-made pH 8.26)

•

MgCl2 – 1M

•

KCl – 1M (Stock pre-made)

•

Nuclease free water

•

Sterile Eppendorf tubes

Alexa546-labeled RNA/DNA Sequences:
Sense: 5’-/5Phos/ACC CUG AAG UUC AUC UGC ACC ACCG -3’
Antisense: 5’-Alex546N/CGG TGG TGC AGA TGA ACT TCA GGG TCA -3’
Anti-eGFP DsiRNA Sequences
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Sense: 5’-/5Phos/ACC CUG AAG UUC AUC UGC ACC ACCG-3’
Antisense: 5’-CGG UGG UGC AGA UGA ACU UCA GGG UCA-3’
Anti-Luc DsiRNA Sequences
Sense: 5’- /5Phos/rGrGrA rCrGrA rGrGrA rCrGrA rGrGrA rCrUrU rCrArU rC 3’
Antisense: 5’- rGrArU rGrArA rGrUrG rCrUrC rGrUrC rCrUrC rGrUrC rCrUrU
-3’
Non-specific (nc-1) control DsiRNA Sequences
Sense: 5’-/5Phos/CGUUAAUCGCGUAUAAUACGCGUAU-3’
Antisense: 5’-AUACGCGUAUUAUACGCGAUUAACGAC-3’

Protocol:
Everything done sterile
1. Turn on 94˚C and 45˚C heat block on ahead of time
2. Ensure that there is water in the heat block
3. Prepare half of the 5x Assembly Buffer protocol (500 µL)
5x Assembly Buffer Protocol-Already Halved
250 µL 10 x TB
5 µL
MgCl2
125 µL KCl
120 µL Nuclease free water
Pipette individual amounts into a sterile Eppendorf
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4. Spin RNA sense and antisense stocks (solid) briefly in centrifuge to ensure
everything is aggregated
5. Solubilize both RNA sense and antisense at 100 µM IN WATER
Use concentration table with correct coefficients and concentrations to determine
amounts of RNA sense, antisense, water and assembly buffer to add for the
desired volume and concentration of duplex. To determine EXACT concentration
of original stock solutions, use nanodrop and multiply A260 reading by the
coefficient on the label. DO NOT ADD ASSEMBLY BUFFER UNTIL AFTER
PLACED ON THE 45 HEATING BLOCK.
6. Mix until homogenous through gentle flicking (Do not vortex)
7. Re-spin briefly in centrifuge
8. Place Eppendorf tube in the 94˚C heat block for 2 minutes
9. Transfer to 45˚C for about ten minutes
10. Add 20 µL assembly buffer quickly
11. Return to 45˚C heat block for an additional 10 minutes
12. Remove from heat block and allow to cool for half an hour (ensure that tubes are
covered due to light sensitivity if using a fluorescently labeled strand)
13. Store at -20˚C

6.4.2. Cryo-EM grid preparation and image acquisition
To prepare frozen hydrated grids for cryo-EM analysis, vitrification was performed using
Vitrobot Mark IV (Thermo Fisher Scientific) operated at 4 oC and 98% relative humidity.
3 µl of sample (concentrations of liposome and liposome-DS siRNA complex were 10
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mg/ml and 6 mg/ml respectively) were applied to Quantifoil R 0.6/1 200 mesh copper grids
(Quantifoil Micro Tools GmbH, Jena, Germany). Then, after a wait time of 5 seconds, the
grids were blotted for 2 seconds and plunged into liquid ethane. The vitrified grids were
preserved under liquid nitrogen until imaging. Images were collected from frozen hydrated
samples at liquid nitrogen temperature using a Titan Krios TEM operated at 300 kV and
equipped with a Gatan K2 direct electron detector (Gatan, Inc., Pleasanton, CA). Images
were acquired in counted mode using Serial EM software54 at a nominal defocus of -2 µm
and a nominal magnification of 18,000´, resulting in a pixel size of 1.358 Å. Images were
collected as dose-fractionated movies with 40 frames per movie and a total dose of 50 e/Å2. Frame alignment was done on-the-fly in SerialEM using the IMOD alignframes
plugin.
6.4.3. Preparation of OEL liposome-DsiRNA complexes for gene silencing and
animal studies
Based on the gel-binding data (above), ratios of 5 nmol DsiRNA/µmol vesicle lipid were
used for eGFP and luciferase gene silencing studies. For in vitro cell culture assays and
animal studies, lipid vesicles were prepared at 1 mg/mL and 10 mg/mL respectively.
For eGFP silencing studies, MDA-MB-231-eGFP cells were plated on 12-well plates at a
density of 30,000 cells/well one day prior to the experiments. Lipid vesicles complexed
with anti eGFP-DsiRNA duplexes (OEL-RNA-NPs or DMDEG-RNA-NPs) were prepared
prior to conducting the studies and were used within 30-60 minutes. Media was removed,
and 0.5 ml of corresponding OEL-RNA-NPs were added to the wells in triplicate.
Incubations were continued for 4-6 hours at 37 oC and media was replaced with fresh
medium (1 mL/well). Incubations were continued for 48-72 hours and eGFP silencing was
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measured by FACS. Cells only (without binding to the Vesicle-RNA-NPs) or cells
incubated with the lipofectamine bound DsiRNA were used as controls in our assays.
For luciferase down regulation, A549-luc2 cells were plated on 96-well clusters at a density
of 5x103 per well one day prior to transfections. Typically, 3 µL vesicles (10 mg/mL) were
incubated with 2 µL anti-luc DsiRNA duplexes (10 µM) for 30 minutes at room
temperature and the samples were diluted to a final concentration of 10 nM in culture
medium. Media were removed from the wells and diluted complexes (50 µL per well) were
added to the wells in quadruplicate. Control wells contained media only or scrambled
DsiRNA duplexes. Luciferase expression was assayed post 48- and 72-hours incubations
using the luciferase assay kit (Promega) in a luminometer.
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6.5. Experimental procedures for Chapter 5
6.5.1. Synthesis procedure and analytical data of compounds and intermediates
6.5.2. NMR chemical shift assignments
6.5.3. NMR spectra
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6.5.1. Synthesis Procedure and Analytical Data
3-(dimethylamino)propane-1,2-diyl ditetradecanoate (5.2a)
N

O
O
O
O

5.2a

To an oven-dried round bottom flask, was added 3-(Dimethylamino)propane-1,2-diol (0.24
g, 2.0 mmol) and Dimethyl pyridine( 0.012, 0.1 mmol). The mixture was dissolved in dry
dichloromethane (0.2M). 1.08 g of myristoyl chloride (4.4 mmol) was subsequently added
before the dropwise addition of triethylamine (0.44 g, 4.4 mmol) at 0 oC. The reaction
mixture turned orange after the addition of triethylamine. The reaction mixture was allowed
to warm to room temperature and stirred for 12 h. The resultant suspension was filtered to
remove the solid by-product and the filtrate was concentrated by rotary evaporation to
afford the crude product. The crude product was purified by silica column chromatography
(CH2Cl2: MeOH 9:1) to afford 5.2a (1.05 g, 97%) as a light yellow viscous liquid; TLC,
Rf 0.35, (CH3OH: CH2Cl2 (1:9), p-Anisaldehyde stain); FT-IR 2921, 2852, 1740, 1465,
1166 cm-1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 7.0 Hz, 6H); 1.27 (m, 38H), 1.60 (m,
4H); 2.55 (s, 6H); 2.29 (m, 4H); 2.44 (m, 2H);4.08 (m, 1H); 4.35(d, J = 12 Hz, 1H); 5.19
(m, 1H); 13C NMR (500 MHz, CDCl3) δ14.7, 23.0, 25.3 (2 signals), 29.4, 29.5, 29.6, 29.7,
29.8, 30.0, 32.3, 34.5, 34.8, 46.3, 59.7, 64.2, 69.5, 173.5, 173.8. HRMS m/z calcd
[C33H66O4N] + [M + H]+: 540.4986 , observed 540.4988.
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3-(dimethylamino)propane-1,2-diyl dioleate (5.2b)
N

O
O
O
O

5.2b

To an oven-dried round bottom flask, was added 3-(Dimethylamino)propane-1,2-diol (0.59
g, 5.0 mmol) and Dimethyl pyridine( 0.030, 0.25 mmol). The mixture was dissolved in dry
dichloromethane (0.2M). 3.31 g of oleoyl chloride (11.0 mmol) was subsequently added
before the dropwise addition of triethylamine (1.11 g, 11.0 mmol) at 0 oC. The reaction
mixture turned orange after the addition of triethylamine. The reaction mixture was allowed
to warm to room temperature and stirred for 12 h. The resultant suspension was filtered to
remove the solid by-product and the filtrate was concentrated by rotary evaporation to
afford the crude product. The crude product was purified by silica column chromatography
(CH2Cl2: MeOH 9:1) to afford 5.2b (3.15 g, 97%) as a light yellow viscous liquid; TLC,
Rf 0.35, (CH3OH: CH2Cl2 (1:9), p-Anisaldehyde stain); 1H NMR (500 MHz, CDCl3) δ
0.87 (t, J = 7.0 Hz, 6H); 1.28 (d, J = 16 Hz, 42H), 1.59 (m, 4H); 2.01 (m, 8H); 2.27 (s,
6H); 2.29 (m, 4H);2.46 (m, 2H); 4.08 (q, J = 6.5 Hz, 1H); 4.35 (dd, J = 3Hz, 1H); 5.19 (m,
1H), 5.33 (m, 4H); 13C NMR (500 MHz, CDCl3) δ14.0, 22.7, 24.9 (2 signals), 27.1, 27.2,
29.0, 29.1, 29.2, 29.3, 29.5, 29.7, 29.8, 31.9, 34.1, 34.3, 45.8, 59.3, 63.8, 69.0, 129.6, 129.9,
173.0, 173.2. HRMS m/z calcd [C41H78O4N] + [M + H]+: 648.5925, observed 648.5926.
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N,N-dimethyl-2,3-bis(tetradecanoyloxy)-N-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan2-yl)methyl)propan-1-aminium bromide (5.3a)
O
B
O

Br
N

O
O
O

5.3a

O

A pressure tube was charged with a solution of lipid 5.2a (1.05 g, 1.95 mmol) in CH2Cl2
(2.0 mL). To the solution was added 2-(Bromomethyl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane (0.516 g, 2.0 mmol). The tube was sealed and then heated at 50 °C for 8 h.
On cooling, the tube was opened, the excess solvent was evaporated using a nitrogen
stream in a closed fume hood. The residue was purified by silica column chromatography
(CH2Cl2:CH3OH 9:1) to yield lipid 5.3a (1.32 g, 89%) as a light yellow solid; TLC, Rf 0.42
(CH3OH: CH2Cl2 (1:9), p-Anisaldehyde stain); FT-IR 2984, 1737, 1372, 1233, 1043 cm1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 7.0 Hz, 6H); 1.28 (m, 52H), 1.59 (m, 4H);
2.33 (m, 4H); 3.26 (d, J = 16 Hz, 1H); 3.45 (d, J = 17 Hz, 1H); 3.60 (d, J = 18.5 Hz, 6H);
3.98 (m, 1H); 4.12 (m, 1H); 4.52 (dd, J = 3.5, 3.0 Hz, 1H);4.66 (d, J = 14 Hz, 1H); 5.60
(m, 1H);

13

C NMR (500 MHz, CDCl3) δ14.2, 22.8, 24.5, 24.7, 24.9, 25.2, 29.2 (2 signals),

29.5, 29.6, 29.8, 32.0 ,34.0, 34.3, 54.8, 55.3, 63.4, 65.3, 66.0, 85.9, 173.0, 173.2; 11BNMR
(400 MHz, CDCl3) δ 31.21; HRMS m/z calcd [C40H79O6NB]
observed 680.5999.
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+

[M +H]+: 680.6002 ,

N,N-dimethyl-2,3-bis(oleoyloxy)-N-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)methyl)propan-1-aminium bromide (5.3b)

O

O
B

Br
N

O
O
O
O

5.3b

A pressure tube was charged with a solution of lipid 5.2b (2.11 g, 3.26 mmol) in CH2Cl2
(2.0 mL). To the solution was added 2-(Bromomethyl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane (0.86 g, 3.91 mmol). The tube was sealed and then heated at 50 °C for 8 h.
On cooling, the tube was opened, the solvent was evaporated using a nitrogen stream in a
closed fume hood. The residue was purified by silica column chromatography
(CH2Cl2:CH3OH 9:1) to yield lipid 5.3b (2.40 g, 85%) as a light yellow solid; TLC, Rf 0.48
(CH3OH: CH2Cl2 (1:9), p-Anisaldehyde stain); 1H NMR (500 MHz, CDCl3) δ 0.86 (t, J =
7.0 Hz, 6H); 1.26 (m, 52H), 1.58 (m, 4H); 1.99 (d, J = 4 Hz, 8H); 2.32 (m, 4H); 3.24 (d, J
= 16.5 Hz, 1H); 3.37 (d, J = 32 Hz, 1H); 3.59 (d, J = 18.5 Hz, 6H); 3.97 (q, J = 9 Hz 1H);
4.09 (d, J = 5 Hz, 1H);4.50 (d, J = 3 Hz, 1H); 5.31 (m, 4H); 5.59 (bs, 1H); 13C NMR (500
MHz, CDCl3) δ13.9, 22.5, 24.2, 24.4, 24.5, 24.6, 24.8, 24.9, 27.0, 27.1, 28.9, 29.0, 29.1(2
signals), 29.2, 29.4, 29.6, 31.8 ,33.7, 34.0, 54.4, 55.1, 63.3, 64.6, 65.9, 85.5, 129.5, 129.8,
172.7, 172.9; 11BNMR (400 MHz, CDCl3) δ 31.21; HRMS m/z calcd [C48H91O6NB] + [M
+H]+: 788.6934 , observed 788.6944.
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N-(boronomethyl)-N,N-dimethyl-2,3-bis(tetradecanoyloxy)propan-1aminiumbromide (DMDBH) (5.4a)
HO
B
HO

Br
N

O
O
O
O

5.4a

To an oven-dried round bottom flask, was added 5.3a (0.66 g, 0.87 mmol) and sodium
periodate (0.557g, 2.61 mmol). The mixture was dissolved in a H2O/THF mixture (1:4).
The reaction mixture was stirred at 0 oC and 2.0 M HCl added dropwise. The mixture was
allowed to warm to room temperature and allowed to stir for 12 h. After completion of the
reaction, the reaction mixture was neutralized with sat. NaHCO3 and stirred under room
temperature for 15 min before extracting with dichloromethane. The excess
dichloromethane was removed by rotary evaporation under reduced pressure to afford the
crude product. The crude product was purified via column chromatography (silica, CH2Cl2:
MeOH 9:1) to afford 5.4a (0.42 g, 71%) as a light-brown solid; TLC, Rf 0.25 (CH2Cl2:
MeOH 9:1, p-Anisaldehyde stain); FT-IR 3420, 2919, 2851, 1739, 1467 cm-1; 1H NMR
(500 MHz, CD3OD) δ 0.90 (t, J = 7.0 Hz, 6H); 1.29 (m, 38H), 1.63 (m, 4H); 2.36 (m, 4H);
2.80 (bs, 1H); 3.15 (d, J = 6.5 Hz, 6H); 3.77 (m, 1H); 4.05 (m, 1H); 4.50 (d, J = 3.5, Hz,
1H); 5.63 (m, 1H); 13C NMR (500 MHz, CD3OD) δ14.5, 23.7, 25.8, 25.9, 30.2, (2 signals),
30.4, 30.5, 30.7, 30.8 (2 signals), 33.1, 34.7, 35.1, 54.7 ,54.8, 64.6, 66.9, 67.6, 174.0, 174.5;
11

BNMR (400 MHz, CDCl3) δ 19.74; HRMS m/z calcd [C34H69O6NB] + [M + H]+:

598.5212 , observed 598.5211.
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N-(boronomethyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-1-aminium bromide
(DODBH) (5.4b)
HO
B
HO

Br
N

O
O
O
O

5.4b

To an oven-dried round bottom flask, was added 5.3b (0.72 g, 0.91 mmol) and sodium
periodate (0.586g, 2.74 mmol). The mixture was dissolved in a H2O/THF mixture (1:4).
The reaction mixture was stirred at 0 oC and 2.0 M HCl added dropwise. The mixture was
allowed to warm to room temperature and allowed to stir for 12 h. After completion of the
reaction, the reaction mixture was neutralized with sat. NaHCO3 and stirred under room
temperature for 15 min before extracting with dichloromethane. The excess
dichloromethane was removed by rotary evaporation under reduced pressure to afford the
crude product. The crude product was purified via column chromatography (silica, CH2Cl2:
MeOH 9:1) to afford 5.4b (0.50 g, 70%) as a light-brown viscous liquid; TLC, Rf 0.32
(CH2Cl2: MeOH 9:1, p-Anisaldehyde stain); 1H NMR (500 MHz, CDCl3) δ 0.89 (t, J = 7.0
Hz, 6H); 1.26 (bs, 42H), 1.61 (m, 4H); 1.96 (m, 4H); 2.34 (m, 4H); 3.32 (d, J = 15 Hz, 6H);
3.51 (d, J = 6.0 Hz, 1H); 3.66 (s, 2H); 3.73 (d, J = 6 Hz,1H); 3.90 (d, J = 14 Hz, 6H); 4.04
(m, 1H); 4.13 (t, J = 6 Hz, 6H); 4.43 (m, 1H); 4.51(t, 1H), 5.38 (s, 4H), 5.55 (bs, 1H)
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6.5.2. NMR Chemical shift assignments
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Table 6.5.1. 1H NMR Chemical shift assignments (CDCl3, 400 MHz)
C(2)

C(3)

C(4)

C(5)

C(b)

5.19

2.45

2.26

–

–

12

4.52
4.64

5.60

4.00
4.12

3.59
3.63

3.28
3.46

1.23

13

4.05
4.51

5.63

3.78

3.15
3.31

2.80

–

14

4.08
4.35

5.20

2.46

2.26

–

–

15

4.50
4.57

5.59

3.97
4.10

3.57
3.61

3.23
–
3.53

1.23

16

4.44
4.51

5.55

4.05
4.14

3.29
3.32

3.66

–

11

C(1)
4.10
4.36

C(x)

C(v)

Ca

Cb

Cw

2.29

1.60

0.88

1.59

0.87

1.63

0.90

2.29

1.60

0.87

2.31

1.58

0.86

2.34

1.61

0.89

2.29
–
2.36
2.35
–
2.40
2.01

5.34

1.99

5.32

1.96

5.38

Table 6.5.2. 13C NMR Chemical shift assignments (CDCl3, 500 MHz)
C(1)

C(2)

C(3)

C(5) C(a)

11

64.2

69.5

59.7

12

65.3

66.1

63.4

55.3 86.0

13

54.8

66.9

64.6

67.6

–

–

14

63.8

69.0

59.3

–

–

–

15

63.3

65.9

64.6

55.1

85.5

24.2

–

–

C(b)
–
24.9
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C(i)
173.5
173.8
173.0
173.2
174.0
174.5
173.0
173.2
172.7
172.9

C(x)

27.2
27.1

C(v)

129.6
129.9
129.5
129.9

Ca

Cb

Cw

34.7

25.3

14.5

34.3

25.2

14.2

35.1

25.9

14.5

34.3

24.9

14.1

34.0

24.8

14.0

6.5.3. NMR Spectra
1

HNMR of 3-(dimethylamino)propane-1,2-diyl ditetradecanoate (5.2a)

N

O
O
O

5.2a

O

13

CNMR of 3-(dimethylamino)propane-1,2-diyl ditetradecanoate (5.2a)

N

O
O
O
O

5.2a
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1

HNMR of 3-(dimethylamino)propane-1,2-diyl dioleate (5.2b)
O

N

O
O
5.2b

O

13

CNMR of 3-(dimethylamino)propane-1,2-diyl dioleate (5.2b)

N

O
O
O
O

5.2b

265

1

HNMR
of
N,N-dimethyl-2,3-bis(tetradecanoyloxy)-N-((4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)methyl)propan-1-aminium bromide (5.3a)
O
B
O

Br
N

O
O
O
O

5.3a

13

CNMR
of
N,N-dimethyl-2,3-bis(tetradecanoyloxy)-N-((4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)methyl)propan-1-aminium bromide (5.3a)

O
B
O

Br
N

O
O
O
O

5.3a

266

1

HNMR of N,N-dimethyl-2,3-bis(oleoyloxy)-N-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan2-yl)methyl)propan-1-aminium bromide (5.3b)

O

O
B

Br
N

O
O
O
O

5.3b

13

CNMR of N,N-dimethyl-2,3-bis(oleoyloxy)-N-((4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)methyl)propan-1-aminium bromide (5.3b)

O

O
B

Br
N

O
O
O
O

5.3b

267

1

HNMR of N-(boronomethyl)-N,N-dimethyl-2,3-bis(tetradecanoyloxy)propan-1aminiumbromide (DMDBH) (5.4a)
HO
B
HO

Br
N

O
O
O

DMDBH
O

13

CNMR of N-(boronomethyl)-N,N-dimethyl-2,3-bis(tetradecanoyloxy)propan-1aminiumbromide (DMDBH) (5.4a)

HO
B
HO

Br
N

O
O
O

DMDBH
O
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1

HNMR of N-(boronomethyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-1-aminium
bromide (DODBH) (5.4b)
HO
B
HO

Br
N

O
O
O
O

DODBH
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